A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Phase: PHASE1
Conditions: High Grade Sarcoma, Metastatic Leiomyosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Myxofibrosarcoma, Recurrent Leiomyosarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Synovial Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma
Sponsor: National Cancer Institute (NCI)

 
1 
 
Update #09 
 
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY 
________________________________________________________________ 
PROTOCOL UPDATE TO ALLIANCE A091304 
________________________________________________________________ 
 
A PHASE I/RANDOMIZED PHASE II STUDY OF MLN0128 (TAK-228) VS. PAZOPANIB IN PATIENTS 
WITH LOCALLY ADVANCED/UNRESECTABLE AND/OR METASTATIC SARCOMA 
 
 
 
 
 
X Update: 
 
  
Status Change: 
 
 
 
 
 
 
Eligibility changes 
 
 
Pre-Activation 
 
 
 
 
 
 
Therapy / Dose Modifications / Study Calendar changes 
 
 
Activation 
 
 
 
 
 
 
Informed Consent changes 
 
 
Closure 
 
 
 
 
 
X Scientific / Statistical Considerations changes 
 
 
Suspension / temporary closure 
 
 
 
 
 
 
Data Submission / Forms changes 
 
 
Reactivation 
 
 
 
 
 
X Editorial / Administrative changes 
 
 
 
 
 
 
 
 
X Other: Updated Pazopanib CAEPR 
 
 
 
 
The CAEPR and Risk List changes included in this update to A091304 have been made in response to 
the NCI Request for Amendment from Dr. Fernanda Arnaldez. A revised CAEPR for pazopanib with 
new risks has been added to the protocol. Therefore, the model consent form has been revised to 
incorporate these new risks, consistent with the NCI Model Consent Template instructions. There are 
no changes to the risk/benefit ratio. 
 
Expedited review is allowed. IRB approval (or disapproval) is required within 90 days. Please follow 
your IRB of record guidelines. 
 
UPDATES TO THE PROTOCOL: 
Cover Page 
Kristin Poe has replaced Jenna Baker as the Data Manger. All contact information has been updated. 
 
Phase II Schema - Effective with Update #05 
Footnote *** has been added beneath the table. It reads “Note: Effective 12/21/2018, patients will no 
longer be able to crossover to MLN0218 (TAK-228).” A reference to footnote *** has been added in the 
RE-REGISTER box. 
 
Section 4.6 [Re-Registration at the Time of Progression (Step 2, if applicable) (Phase II only)] 
A note has been added as a new first paragraph that reads: “Note: Effective 12/21/2018, patients will no 
longer be able to crossover to MLN0128 (TAK-228).” 
 

 
2 
 
Section 9.4.1 (Comprehensive Adverse Events and Potential Risks List [CAEPR] for Pazopanib 
[GW786034, NSC 737754]) 
-This section has been revised to include the updated pazopanib CAEPR (Version 2.8, January 31, 2019) 
provided by CTEP. Changes from Version 2.7 to Version 2.8 include the following: 
• Added New Risk: 
o 
Also Reported on Pazopanib Trials But With Insufficient Evidence for Attribution: Muscle 
cramp. 
• Deleted Risk: 
o 
Also Reported on Pazopanib Trials But With Insufficient Evidence for Attribution: Acute 
coronary syndrome; Musculoskeletal and connective tissue disorder - Other (muscle spasms). 
• Provided Further Clarification: 
o 
Eye disorders - Other (eye/retinal hemorrhage) (CTCAE 4.0 language) is now reported as Eye 
disorders - Other (eye hemorrhage, retinal hemorrhage). 
o 
Female genital tract fistula (CTCAE 4.0 language) is now reported as Reproductive system 
and breast disorders - Other (female genital tract fistula). 
o 
Skin and subcutaneous tissue disorders - Other (hair color change/hair depigmentation) 
(CTCAE 4.0 language) is now reported as Hair color changes. 
o 
Vascular disorders - Other (arterial thromboembolic event) (CTCAE 4.0 language) is now 
reported as Arterial thromboembolism. 
o 
Gastrointestinal disorders - Other (oropharyngeal pain), previously listed under the 
GASTROINTESTINAL DISORDERS SOC (CTCAE 4.0 language), is now reported as 
Oropharyngeal pain and is now listed under the RESPIRATORY, THORACIC AND 
MEDIASTINAL DISORDERS SOC. 
o 
Investigations - Other (blood lactate dehydrogenase increased) (CTCAE 4.0 language) is now 
reported as Blood lactate dehydrogenase increased. 
 
- The following were erroneously retained with the previous updated pazopanib CAEPR (Version 2.7, 
June 2, 2017), but they have been removed with Update #09:  
• 
Also Reported on Pazopanib Trials But With Insufficient Evidence for Attribution: Cardiac 
disorders – Other (Torsades de Pointes); Eye disorders – Other (eye/retinal hemorrhage) 
Infection; Ejection fraction decreased; Intracranial hemorrhage; Hematuria; Vaginal 
hemorrhage. 
 
Section 13.3.2 (Statistical Design) 
The second sentence has been modified for accuracy. 
 
Section 13.3.4 (Analysis Plan) 
Two new sentences have been added to the end of the first bullet to provide more detail about the futility 
analysis. They begin “More specifically, the decision…” and “If P is greater than…,” respectively.  
 
 
UPDATES TO THE PHASE I MODEL CONSENT: 
No changes have been made to the Phase I MCF.  
 
UPDATES TO THE PHASE II MODEL CONSENT: 
 
What possible risks can I expect from taking part in this study? 
Based on the updated CAEPR described above, the following changes have been made to the NCI 
condensed risk profile for pazopanib: 
• 
Added New Risk: 

 
3 
 
o Rare: Blood clot in artery which may cause swelling, pain, shortness of breath or change 
of color in extremity.  
• 
Deleted Risk: 
o Rare: Bleeding of the eye which may cause blurred vision with a chance of blindness. 
• 
Provided Further Clarification: 
o High blood pressure which may cause blurred vision (under Common) is now reported as 
High blood pressure which may cause headaches, dizziness, blurred vision (under 
Common). 
o Bleeding from multiple sites including the nose or vagina (under Occasional) is now 
reported as Bleeding from multiple sites including the nose or vagina which may cause 
blurred vision with a chance of blindness (under Occasional). 
o Anemia, kidney problems which may require dialysis (under Rare) is now reported as 
Anemia, kidney problems which may cause tiredness, bruising, swellings, or may require 
dialysis (under Rare). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A replacement protocol document and model consent form have been issued. 
 
This protocol remains permanently closed to new patient accrual.  
____________________________________________________________ 
ATTACH TO THE FRONT OF EVERY COPY OF THIS PROTOCOL 
___________________________________________________________ 

 
Version Date: 04/03/2019 
1 
Update #09 
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY 
 
ALLIANCE A091304 
 
A PHASE I/RANDOMIZED PHASE II STUDY OF MLN0128 (TAK-228) VS. PAZOPANIB IN PATIENTS 
WITH LOCALLY ADVANCED/UNRESECTABLE AND/OR METASTATIC SARCOMA 
 
NCI-supplied agent: MLN0128 (TAK-228) (NSC #768435, IND #121931); IND holder: CTEP 
Commercial agent: Pazopanib (IND Exempt) 
 
ClinicalTrials.gov Identifier: NCT02601209 
 
Study Chair 
William D. Tap, MD 
Memorial Sloan-Kettering Cancer Center 
300 E. 66th Street, 10th Floor, Suite 1001 
New York, NY  10065 
Tel: 646-888-4156 Fax: 646-888-4252 
tapw@mskcc.org 
 
Community Oncology Co-chair 
Study Pathologist 
Anthony Jaslowski, M.D. 
Fabrizio Remotti, MD 
Green Bay Oncology 
Columbia University 
Tel: 920-884-3135 
Tel: 212-305-6719 
tjaslowski@gboncology.com 
fr116@cumc.columbia.edu 
 
Experimental Therapeutics Committee Co-Chair 
Experimental Therapeutics Committee Co-Chair 
Pamela Munster, M.D. 
Gary K. Schwartz, M.D. 
415 502-3598 
212-305-2055 
Pmunster@medicine.ucsf.edu 
schwartzg@columbia.edu 
 
Primary Statistician 
Michelle R. Mahoney, MS 
Tel: 507-266-4456   
mahoneym@mayo.edu 
 
Protocol Coordinator 
Data Manager 
Krista Garbacz 
Kristin Poe 
Tel: 773-702-9269 Fax: 312-345-0117 
Tel: 507-538-1610 Fax: 507-284-1902 
kgarbacz@uchicago.edu 
poe.kristin@mayo.edu 
 
Participating Organizations:  
ALLIANCE / Alliance for Clinical Trials in Oncology (lead) 
ECOG-ACRIN / ECOG-ACRIN Cancer Research Group 
NRG / NRG Oncology 
SWOG / SWOG 
 

Version Date: 04/03/2019 
2 
Update #09 
 
Study Resources: 
Expedited Adverse Event Reporting 
http://eapps-ctep.nci.nih.gov/ctepaers/ 
 Medidata Rave iMedidata portal 
https://login.imedidata.com 
OPEN (Oncology Patient Enrollment 
Network) 
https://open.ctsu.org 
Biospecimen Management System 
http://bioms.allianceforclinicaltrialsinoncology.org 
 
Protocol Contacts: 
 
A091304 Nursing Contact 
Lisa Kottschade, RN, MSN, CNP 
Mayo Clinic 
Tel: 507-538-7888  
kottschade.lisa@mayo.edu 
A091304 Pharmacy Contact 
Heidi Finnes, PharmD, BCOP 
Mayo Clinic 
Tel: 507-538-7066  
finnes.heidi@mayo.edu 
Alliance Biorepository at Ohio State 
The Ohio State University 
Innovation Centre 
2001 Polaris Parkway, Columbus, OH 43240 
Tel: 614-293-7073  Fax: 614-293-7967 
path.calgb@osumc.edu 
 
Protocol-related questions may be directed as follows: 
Questions 
Contact (via email) 
Questions regarding patient eligibility, treatment, 
and dose modification: 
Study Chair, Nursing Contact, Protocol 
Coordinator, and (where applicable) Data 
Manager 
Questions related to data submission, RAVE or 
patient follow-up: 
Data Manager  
Questions regarding the protocol document and 
model informed consent: 
Protocol Coordinator 
Questions related to IRB review 
Alliance Regulatory Inbox 
regulatory@allianceNCTN.org 
Questions regarding CTEP-AERS reporting: 
Pharmacovigilance Inbox 
pharmacovigilance@alliancenctn.org 
Questions regarding specimens/specimen 
submissions: 
appropriate Alliance Biorepository  
 
 

Alliance A091304 
Version Date: 04/03/2019 
3 
Update #09 
CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT INFORMATION 
CONTACT INFORMATION 
 
For regulatory requirements: 
For patient enrollments: 
For study data submission: 
Regulatory documentation must 
be submitted to the CTSU via 
the Regulatory Submission 
Portal. 
 
Regulatory Submission Portal: 
(Sign in at www.ctsu.org,            
and select the Regulatory 
Submission sub-tab under the 
Regulatory tab.)  
 
Institutions with patients 
waiting that are unable to use 
the Portal should alert the 
CTSU Regulatory Office 
immediately at 1-866-651-2878 
to receive further instruction 
and support. 
 
Contact  the CTSU Regulatory 
Help Desk at 1-866-651-2878 
for regulatory assistance. 
Please refer to the patient 
enrollment section of the protocol 
for instructions on using the 
Oncology Patient Enrollment 
Network (OPEN) which can be 
accessed at 
https://www.ctsu.org/OPEN_SYS
TEM/ or https://OPEN.ctsu.org. 
 
Contact the CTSU Help Desk 
with any OPEN-related questions 
at ctsucontact@westat.com. 
 
 
Data collection for this study 
will be done exclusively through 
Medidata Rave.  Please see the 
data submission section of the 
protocol for further instructions.  
 
The most current version of the study protocol and all supporting documents must be downloaded 
from the protocol-specific Web page of the CTSU Member Web site located at https://www.ctsu.org.  
Access to the CTSU members’ website is managed through the Cancer Therapy and Evaluation Program 
- Identity and Access Management (CTEP-IAM) registration system and requires user log on with 
CTEP-IAM username and password. Include this statement if applicable: Permission to view and 
download this protocol and its supporting documents is restricted and is based on person and site roster 
assignment housed in the CTSU RSS.   
 
For clinical questions (i.e. patient eligibility or treatment-related) contact the Study PI of the 
Lead Protocol Organization 
For non-clinical questions (i.e. unrelated to patient eligibility, treatment, or clinical data 
submission) contact the CTSU Help Desk by phone or e-mail:  
CTSU General Information Line – 1-888-823-5923, or ctsucontact@westat.com.  All calls and 
correspondence will be triaged to the appropriate CTSU representative.  
The CTSU Website is located at https://www.ctsu.org. 
 
 
 
 

Alliance A091304 
Version Date: 04/03/2019 
4 
Update #09 
A PHASE I/RANDOMIZED PHASE II STUDY OF MLN0128 (TAK-228) VS. PAZOPANIB IN PATIENTS 
WITH LOCALLY ADVANCED/UNRESECTABLE AND/OR METASTATIC SARCOMA 
 
Pre-Registration Eligibility Criteria (see Section 3.2) 
Central pathology review submission (See §3.2.1) 
Eligibility Criteria (see Section 3.3) 
Documentation of disease subtypes listed in Section 3.3.1 
by central review 
Locally advanced or metastatic disease 
Measurable disease and/or nonmeasureable as defined in 
Section 11.0 
Prior treatment: Progression on at least one prior systemic 
chemotherapy for advanced, unresectable or metastatic 
disease. See Section 3.3.4 for additional information and 
exclusions. 
Not pregnant and not nursing. 
Age ≥ 18 years 
ECOG Performance Status ≤ 1 
Patients may not have any history of the diseases, conditions or disorders described in Section 3.3.8. 
Concomitant medications: concomitant treatment with strong inhibitors of CYP3A4 inhibitors must 
discontinue the drug for 14 days prior to registration. Chronic concomitant treatment with strong 
CYP3A4 inducers is not allowed. 
Phase I Schema 
SLOT RESERVATION 
 
PRE-REGISTRATION 
 
Confirmation 
of Locally 
Advanced/ 
Unresectable 
and/or 
Metastatic 
Sarcoma 
(UPS, MFH, MFS, 
HGNOS, LMS, 
SS, 
MPNST) 
 
REGISTRATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MLN0128 
(TAK-228) 
 
 
 
 
weekly 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Phase I portion of this study will assess safety and tolerability of the new milled formulation of 
MLN0128 (TAK-228). The Phase I portion is a standard 3+3 design which includes dose level 0, 1, 2 for 
entry and dose modifications as per protocol. Patients may remain on treatment until disease progression, 
unacceptable toxicity, or withdrawal of consent. 
 
Please Note: For the phase I portion of this study, patient enrollment will be facilitated using the Slot-
Reservation System in conjunction with the Registration system on Oncology Patient Enrollment 
Network (OPEN). Prior to discussing protocol entry with the patient, all site staff must use the CTSU 
OPEN Slot Reservation System to insure that a slot on the protocol is available to the patient. Once a slot 
reservation confirmation is obtained, site staff may then proceed to pre-register the patient for central 
pathology review. Once eligibility has been confirmed centrally, then proceed to register patient onto the 
appropriate dose level. 
Toxicity call attendance is required during the Phase I portion of the trial. See Section 7.1 for more 
information...
Required Initial Laboratory Values 
Absolute 
neutrophil 
 
count (ANC) ≥ 1,500/mm3 
Platelet Count ≥ 100,000/mm3 
Creatinine < 1.5 x ULN  
Total Bilirubin ≤ 1.5 x ULN* 
AST / ALT ≤ 3 x ULN* 
UPC ≤ 1* 
TSH WNL 
*See Section 3.3.9 

Version Date: 04/03/2019 
5 
Update #09 
 
 
Phase II Schema – Prior to Update #05 
Prior to discussing protocol entry with prospective patients, site staff must go to the A091304 study page 
on the CTSU web site to check histologic cohort status and accrual. See Section 4.4 for more information. 
 
1 Cycle = 4 weeks 
PRE-REGISTRATION 
 
Confirmation 
of Locally 
Advanced/ 
Unresectable 
and/or 
Metastatic 
Sarcoma 
(UPS, MFH, 
MFS, 
HGNOS, LMS, 
SS, 
MPNST) 
 
REGISTRATION/ 
RANDOMIZATION 
 
ARM 1 
 
 
 
 
 
 
 
MLN0128 
(TAK-228) 
 
 
 
 
 
 
 
30mg 
 
 
 
 
 
 
 
weekly 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ARM 2 
Pazopanib 
800mg p.o. 
once daily 
 
 
 
 
 
 
 
 
RE- 
REGISTER 
 
ARM 3 
 
 
 
PD* 
 
MLN0128 
(TAK-228) 
 
 
 
 
 
30mg, 
weekly 
 
* Patients who progress on Arm 2 will have the option to crossover to receive MLN0128 (TAK-228). 
Patients who opt to crossover must be re-registered to the study. Patients must initiate treatment with 
MLN0128 (TAK-228) within 28 days of the CT demonstrating progression. 
 
Treatment is to continue until disease progression or unacceptable adverse event. Patients discontinuing 
their initial treatment for reasons other than progressive disease and within 15 months of randomization 
will continue following the Study Calendar for disease assessments until progressive disease is 
documented. Upon progression, patients will be followed for survival for two years post-randomization or 
until death, whichever comes first. 
 
Please refer to the full protocol text for a complete description of the eligibility criteria and 
treatment plan. 
 
M
PD*

Alliance A091304 
Version Date: 04/03/2019 
6 
Update #09 
Phase II Schema – Effective with Update #05 
Prior to discussing protocol entry with prospective patients, site staff must go to the A091304 study page 
on the CTSU web site to check histologic cohort status and accrual. See Section 4.4 for more information. 
 
1 Cycle = 4 weeks 
PRE-REGISTRATION 
 
Confirmation 
of Locally 
Advanced/ 
Unresectable 
and/or 
Metastatic 
Sarcoma 
(UPS, MFH, 
MFS, 
HGNOS, LMS, 
SS, 
MPNST) 
 
REGISTRATION/ 
RANDOMIZATION 
 
ARM 5 
 
 
 
 
 
 
 
MLN0128 
(TAK-228) 
 
 
 
 
 
 
 
30mg 
 
 
 
 
 
 
 
weekly 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ARM 6 
Pazopanib 
400mg** 
p.o. 
once daily 
 
 
 
 
 
 
 
 
RE- 
REGISTER
*** 
 
ARM 3 
 
 
 
PD* 
 
MLN0128 
(TAK-228) 
 
 
 
 
 
30mg, 
weekly 
 
* Patients who progress on Arm 6 will have the option to crossover to receive Arm 3 MLN0128 (TAK-
228). Patients who opt to crossover must be re-registered to the study. Patients must cross over within 6 
weeks of documented progression and need to have a CT scan within 28 days of starting MLN0128 to 
serve as a baseline. 
** Effective with Update #05 pazopanib will be started at 400mg, titrated to a dose of 800 mg per section 
7.2.  
***Note: Effective 12/21/2018, patients will no longer be able to crossover to MLN0128 (TAK-228) 
 
Treatment is to continue until disease progression or unacceptable adverse event. Patients discontinuing 
their initial treatment for reasons other than progressive disease and within 15 months of randomization 
will continue following the Study Calendar for disease assessments until progressive disease is 
documented. Upon progression, patients will be followed for survival for two years post-randomization or 
until death, whichever comes first. 
 
Please refer to the full protocol text for a complete description of the eligibility criteria and 
treatment plan. 
 
 
M
R
PD*

Alliance A091304 
Version Date: 04/03/2019 
7 
Update #09 
 
Table of Contents 
1.0 
BACKGROUND .............................................................................................................................. 9 
1.1 
Signaling in Sarcoma ...................................................................................................................... 9 
1.2 
MLN0128 (TAK-228) .................................................................................................................. 10 
1.3 
Preclinical Data in Sarcoma Models ............................................................................................ 11 
1.4 
Clinical Data ................................................................................................................................. 16 
1.5 
Pazopanib ..................................................................................................................................... 19 
1.6 
Registration Quality of Life (QOL) Measurements ..................................................................... 20 
1.7 
Impact of this Trial ....................................................................................................................... 20 
1.8 
Rationale for Pazopanib Dosing Change ...................................................................................... 20 
2.0 
OBJECTIVES ................................................................................................................................ 21 
2.1 
Primary Phase I objective ............................................................................................................. 21 
2.2 
Primary Phase II objective ........................................................................................................... 21 
2.3 
Secondary Phase I/II objectives ................................................................................................... 21 
2.4 
Exploratory Phase II objectives .................................................................................................... 21 
3.0 
PATIENT SELECTION ............................................................................................................... 22 
3.1 
On-Study Guidelines .................................................................................................................... 22 
3.2 
Pre-Registration Eligibility Criteria (Step 0) ................................................................................ 23 
3.3 
Registration Eligibility Criteria (Step 1) ...................................................................................... 23 
4.0 
PATIENT REGISTRATION ....................................................................................................... 26 
4.1 
CTEP Investigator Registration Procedures ................................................................................. 26 
4.2 
CTSU Site Registration Procedures ............................................................................................. 27 
4.3 
Phase I Enrollment Requirements ................................................................................................ 28 
4.4 
Phase II Patient Enrollment Requirements ................................................................................... 29 
4.5 
Patient Enrollment through OPEN ............................................................................................... 31 
4.6 
Re-Registration at the Time of Progression (Step 2, if applicable) (Phase II only) ..................... 31 
4.7 
Stratification Factors, Treatment Assignments and Grouping Factors ......................................... 32 
5.0 
STUDY CALENDAR .................................................................................................................... 33 
6.0 
DATA AND SPECIMEN SUBMISSION .................................................................................... 35 
6.1 
Data collection and submission .................................................................................................... 35 
6.2 
Specimen collection and submission ............................................................................................ 36 
7.0 
TREATMENT PLAN/INTERVENTION ................................................................................... 38 
7.1 
Phase I Description and Treatment Plan ...................................................................................... 38 
7.2 
Phase II Description and Treatment Plan ..................................................................................... 40 
7.3 
CYP3A4 Inhibitors ....................................................................................................................... 41 
7.4 
CYP3A4 Inducers......................................................................................................................... 41 
8.0 
DOSE AND TREATMENT MODIFICATIONS........................................................................ 42 
8.1 
Ancillary therapy, concomitant medications, and supportive care ............................................... 42 
8.2 
Dose Modifications ...................................................................................................................... 45 
9.0 
ADVERSE EVENTS ..................................................................................................................... 50 
9.1 
Routine adverse event reporting ................................................................................................... 50 
9.2 
CTCAE Routine Study Reporting Requirements ......................................................................... 50 
9.3 
Expedited Adverse event reporting (CTEP-AERS) ..................................................................... 51 
9.4 
CAEPRs ....................................................................................................................................... 53 
10.0 
DRUG INFORMATION ............................................................................................................... 62 

Alliance A091304 
Version Date: 04/03/2019 
8 
Update #09 
10.1 Pazopanib (Commercial; IND Exempt) ....................................................................................... 62 
10.2 MLN0128 (TAK-228) (Supplied) (INK128, NSC #768435, IND 121931); IND holder: CTEP 64 
11.0 
MEASUREMENT OF EFFECT .................................................................................................. 67 
11.1 Schedule of Evaluations: .............................................................................................................. 67 
11.2 Definitions of Measurable and Non-Measurable Disease ............................................................ 67 
11.3 Guidelines for Evaluation of Measurable Disease ....................................................................... 68 
11.4 Measurement of Treatment/Intervention Effect ........................................................................... 69 
11.5 Definitions of analysis variables .................................................................................................. 72 
12.0 
END OF TREATMENT/INTERVENTION ............................................................................... 72 
12.1 Duration of Treatment .................................................................................................................. 72 
12.2 Managing ineligible patients and registered patients who never receive protocol intervention ... 73 
12.3 Extraordinary Medical Circumstances ......................................................................................... 73 
13.0 
STATISTICAL CONSIDERATIONS AND METHODOLOGY ............................................. 74 
13.1 Study Design ................................................................................................................................ 74 
13.2 Statistical Design and Analysis for the Primary Endpoint (Phase I) ............................................ 75 
13.3 Statistical Design and Analysis for the Primary Endpoint (Phase II) ........................................... 76 
13.4 Sample Size, Accrual Time, and Study Duration (Phase I and II) ............................................... 77 
13.5  Primary Endpoint Completion Time Estimation (For clinicaltrials.gov reporting) ..................... 79 
13.6 Supplementary Analysis Plans (Phase I and II) ........................................................................... 79 
13.7 Study Monitoring ......................................................................................................................... 81 
13.8  Study Reporting ............................................................................................................................ 82 
13.9 Descriptive Factors ....................................................................................................................... 83 
13.10 Inclusion of Women and Minorities ............................................................................................. 83 
14.0 
CORRELATIVE AND COMPANION STUDIES ..................................................................... 85 
14.1 Tissue Specimens for Banking ..................................................................................................... 85 
15.0 
GENERAL REGULATORY CONSIDERATIONS AND CREDENTIALING ...................... 86 
16.0 
REFERENCES .............................................................................................................................. 87 
APPENDIX I 
REGISTRATION FATIGUE/UNISCALE ASSESSMENTS ................................. 89 
APPENDIX II MEDICATION DIARIES .............................................................................................. 90 
APPENDIX III  CRADA .......................................................................................................................... 93 
APPENDIX IV: PATIENT DRUG INFORMATION HANDOUT AND WALLET CARD ............. 95 

Alliance A091304 
Version Date: 04/03/2019 
9 
Update #09 
1.0 
BACKGROUND 
Sarcoma is a heterogeneous group of malignancies that are of mesenchymal and neural origin. There 
are approximately 60-80 specific subtypes of bone and soft tissue sarcoma [1]. Sarcomas are 
relatively rare neoplasms with an approximate incidence of 30 per million or about 13,000 cases 
diagnosed in the United States each year [2]. Sarcomas can arise in individuals of all ages; they 
represent approximately 1 percent of adult and 15 percent of pediatric malignancies. Surgery is the 
only treatment for adult patients that can be offered with curative intent. Chemotherapy, and more so 
radiation, are useful adjuncts in localized disease, but neither has shown to contribute to a survival 
benefit. When curative surgery cannot be delivered or when patients present with locally advanced 
or metastatic disease, survival rates in sarcoma plummet drastically despite the use of standard 
cytotoxics with estimated five-year survival rates of approximately 20% [3].  
Historically, sarcomas have been broken down into two specific subgroups; those with simple 
karyotypes that are often defined by reciprocal or simple translocations and/or specific gene 
amplifications (e.g. Ewing’s sarcoma, synovial sarcoma, GIST) and those with complex karyotypes 
with multiple chromosomal aberrations (e.g. liposarcoma, leiomyosarcoma, osteosarcoma) [4, 5].  
The introduction of large-scale molecular and genomic studies has begun to shed light on the 
numerous diseases that are generally referred to as ‘sarcomas’ [6, 7]. We now view sarcoma as a 
complex group of many individual, molecularly unique neoplasms; all of which require individual 
attention and personally designed treatment paradigms. 
1.1 
Signaling in Sarcoma 
The mTOR pathway regulates growth and maintains homeostasis in mesenchymal cells [8]. 
Under normal cellular conditions, the mTOR pathway is responsive to signals that can influence 
cell growth such as exogenous growth factors and changes in the levels of nutrition, energy, and 
oxygen. Dysregulation of the mTOR pathway can lead to uncontrolled cellular proliferation and 
the avoidance of programmed cell death.  The updated results of a Phase II trial of AP23573 
(ridaforolimus, formerly deforolimus) in patients with advanced soft tissue sarcoma (STS) has 
been published [9]. Ridaforolimus is a novel non-prodrug mTOR inhibitor (rapamycin 
analogue). The Phase II study which evaluated 212 patients with soft tissue and bone sarcomas 
met its primary endpoint by achieving a clinical benefit ratio [CBR – complete response (CR) + 
partial response (PR) + stable disease (SD) > 24 weeks] of 29%. The 6-month Progression Free 
Survival (PFS) rate in all study participants was 23%. A cohort analysis showed that the CBR 
rate was 30% in bone sarcomas, 33% in leiomyosarcomas (LMS), 30% in liposarcomas, and 
23% in all other sarcomas. Therefore, all groups except for the ‘all other STS’ group met the 
study’s primary endpoint of a CBR >25%. No CR’s were achieved and four patients (2.0%) 
achieved a PR. The median OS rate of the entire cohort was 40 weeks. In a subset analysis 
presented at ASCO, the median OS of those participants who achieved a CBR was 67.6 weeks 
[10]. The investigators concluded that a CBR may be a surrogate marker for OS. These results 
prompted the initiation of the SUCEED trial (Sarcoma Multi-Center Clinical Evaluation of the 
Efficacy of Deforolimus), a double-blinded, placebo-controlled trial in patients with metastatic 
sarcoma who had a favorable response to chemotherapy. The SUCCEED trial evaluated the 
efficacy of maintenance ridaforolimus with a primary PFS endpoint. The SUCCEED trial had 
achieved its primary endpoint with an approximate 3.1 week improvement in median PFS over 
placebo. Ridaforolimus was not granted FDA approval based on these data. 
In general, the activity of ridaforolimus in sarcoma is encouraging. Evaluation and noted 
responses as defined by a CBR do suggest activity of the mTOR pathway in the pathogenesis 
and propagation of sarcoma. However, lack of true response as defined by conventional size 
based overall response rates suggest that inhibition of mTORC1 is not sufficient to drastically 
impact a patient’s clinical outcome. This is most likely due to incomplete blockade of the 
PI3K/AKT/mTOR pathway and/or upregulation of survival/bypass pathways that accelerate the 

Alliance A091304 
Version Date: 04/03/2019 
10 
Update #09 
cellular growth of tumors [11, 12]. For example, blockade of mTORC1 alone paradoxically 
activates AKT through various feedback mechanisms including upregulation of the Insulin 
Growth Factor 1 Receptor (IGF1R) [13]. This is of critical interest in sarcoma as the Insulin 
Growth Factor Pathway (IGF) has also been implicated in the pathogenesis of these tumors [14-
16].  
Several phase II studies evaluating inhibition of the IGF pathway in sarcoma have been reported 
[17, 18]. The first trial evaluated AMG-479, an antibody to IGF1R, in patients with 
relapsed/recurrent Ewing’s Sarcoma Family of Tumor (ESFT) [17]. This included patients with 
Ewing’s sarcoma (ES), primitive neuroectodermal tumors (PNET), Askin’s tumor and 
desmoplastic small round cell tumors (DSRCT). The trial reported on 35 patients, two had a PR 
and 4 had SD>24 weeks. This led to an overall response rate (ORR, CR+PR) of 6% and a CBR 
of 17%. Of note, the median PFS was 7.9 weeks in ES and 19 weeks in DSRCTs. A second trial 
reported on the activity of R1507, an antibody to IGF1R, in another Phase II trial in patients 
with ESFT [18]. This trial reported on 109 patients, with an ORR of 10%, a median duration of 
tumor response of 29 weeks and a median overall survival rate of 7.6 mos.  Although these trials 
showed significant activity in a few patients, the overall response rate was discouraging and 
suggests that resistance may be mediated by downstream effectors not associated with or not 
properly targeted by inhibitors of the IGF1R pathway.  
Much like the use of mTOR inhibitors in sarcoma, preclinical and clinical work is ongoing in 
order to determine the subset of patients who respond to IGF1R inhibition and why. In addition, 
as the mTOR and IGF pathway are closely related, evaluation of combined mTOR/IGF1R 
inhibition has also been performed in an effort to overcome mechanisms of resistance and 
provide more comprehensive pathway inhibition. A large multicenter study evaluating the 
combination of everolimus (mTOR inhibitor) and cixutumumab (IGF1R inhibitor) in patients 
with locally advanced, metastatic, recurrent soft tissue or bone sarcoma (NCT01016015) was 
reported [18]. Overall, the trial was positive, meeting predefined 12-week PFS endpoints in three 
cohorts of patients that included IGF1R+ (IHC) soft tissue sarcomas (12 wk. PFS 31%), IGF1R+ 
(IHC) bone sarcomas (12 wk. PFS 35%) and IGF1R- (IHC) bone and soft tissue sarcomas (12 
wk. PFS 39%). These results were encouraging and exceeded prior PFS rates noted with single 
agent IGF1R or mTOR inhibitors in sarcoma [17-19]. However, Overall Response Rate by 
RECIST was once again only 5% [20].  
1.2 
MLN0128 (TAK-228) 
MLN0128 (TAK-228) (Millennium/Takeda) is a selective and highly potent ATP competitor of 
both mTORC1 and mTORC2 [21].MLN0128 (TAK-228) has been shown in preclinical breast 
models (in vitro and in vivo) to overcome resistance to anti-HER2 agents that are mediated by 
secondary upregulation of the PI3K/AKT pathway [22]. As a preclinical tool, MLN0128 (TAK-
228) provides an opportunity to investigate efficacy of dual mTORC1/mTORC2 inhibition in 
sarcoma as compared to combined IGF1R/mTOR inhibition and allows for further pathway 
evaluation to determine which mediators of the PI3K/AKT/mTOR axis drive tumor growth 
despite inhibition of mTOR and AKT. As a clinical tool, MLN0128 (TAK-228) competitively 
inhibits both mTORC1 and mTORC2 with high affinity. This should avoid primary and 
overcome secondary drug resistance that develops from blockade of Receptor Tyrosine Kinases 
(RTKs) that mediate signaling through the PI3K/mTOR pathway and selective mTORC1 
inhibitors alone.  
Mechanism of Action 
MLN0128 (TAK228) selectively and potently inhibited mTOR kinase, demonstrating 50% 
inhibition at the concentration of 1.1 nM (IC50). Relative to mTOR, MLN0128 (TAK228) was 

Alliance A091304 
Version Date: 04/03/2019 
11 
Update #09 
>100-fold less potent as an inhibitor of Class I (PI3 kinase isoforms α, β, γ, δ (Table 1), class II 
(PI3KC2α and PI3K2Cβ), and Class III (VPS34) PI3K family members, as well as PI3Kα and 
PI3Kβ. 
MLN0128 (TAK228) (1 mcM) also inhibited (>80%) biochemical activity of five kinases 
(mTOR, DNA-PK, PDGFRα, Flt3, and CK1 epsilon kinases) out of a panel of 222 protein 
kinases.  MLN0128 (TAK228) inhibited ligand binding of 10 receptor and intracellular protein 
kinases including (ACVR1, BMPR1B, CSF1R, CSNK1D, CSNK1E, DDR1, MEK1, MEK2 
PDGFRβ, and RIPK2) out of a panel of 402 distinct kinases. MLN0128 (TAK228) displayed 
cellular inhibition of TORC1 and TORC2 pathways with IC50 less than 10 nM. 
In Vivo Studies: 
Pharmacokinetic (PK) studies of MLN0128 (TAK228) have been investigated in a number of 
animal models, including mice, rats, dogs, and monkeys.   
Drug Metabolism and Pharmacokinetics: TAK-228 was rapidly absorbed after PO 
administration to mice, rats, dogs, and monkeys, with high oral bioavailability.  TAK-228 
displayed dose-proportional plasma exposures, a moderate propensity to cross the blood-brain 
barrier, and was modestly bound (70.5%) to human plasma proteins.  TAK-228 did not inhibit 
P-glycoprotein, but did inhibit breast cancer-resistance protein (BCRP), organic cation 
transporter (OCT)1 and OCT2. 
The main isozymes responsible for phase 1 metabolism appear to be cytochrome P450 (CYP) 
2C9, 2C19, and 3A4. TAK-228 did not induce CYP1A2, 2B6, and 3A4 activity and expression 
at concentrations up to 10 
M. TAK-228 displayed low potential for inhibition and is not a 
time-dependent inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5. 
Toxicology: Adverse events of TAK-228 in rats and monkeys included body weight loss, 
decreased activity, increased glucose and insulin levels, alterations in white blood cells, bone 
marrow and lymphoid depletion, thymic necrosis, oligospermia, testes degeneration/atrophy, 
nonglandular 
stomach 
epithelial 
degeneration/ulceration/hyperplasia, 
pancreatic 
islet 
degeneration and fibrosis, lens fiber degeneration with cataract correlate, adrenal cortex 
hypertrophy, pituitary atrophy secondary to body weight loss, liver hepatocellular vacuolation, 
retinal dysplasia with or without optic nerve atrophy, and alveolar histiocytosis.  TAK-228 was 
negative for genotoxicity in an in vitro bacterial mutagenesis (Ames) assay, an in vivo rat 
micronucleus assay, and an in vivo rat comet assay.  TAK-228 was negative for phototoxicity 
in the 3T3 fibroblast assay. 
Safety Pharmacology: TAK-228 has a low potential to affect the human ether-a-go-go related 
gene (hERG) potassium ion channel and did not affect cardiovascular (CV) parameters in vivo 
in telemeterized monkeys. 
1.3 
Preclinical Data in Sarcoma Models 
Data from in vitro and in vivo sarcoma models from the laboratory of PI GK Schwartz confirm 
that both primary and acquired resistance to single agent mTORC1 inhibitors in sarcoma is 
potentially mediated by upregulation of aberrant pAKT signaling (Figure 1; MPNST and ST88 
[MPNST], LS141 [Liposarcoma]). 
Dual IGF1R and mTORC1 inhibition suppresses total PI3K/AKT/mTOR signaling and 
overcomes drug resistance as mediated by aberrant pAKT as encountered with the single agents 
respectively (Figure 2; MXF8000 myxofibrosarcoma). This, in part, is due to the IGF1R 
inhibitors ability to abrogate the increase in pAKT signaling that is caused by mTORC1 
inhibition alone. In addition, proliferation assays show at least additive effects on proliferation 
for the combination as opposed to either single agent alone. 

Alliance A091304 
Version Date: 04/03/2019 
12 
Update #09 
 
This data led to the now completed Phase II trial of everolimus and cixutumumab that was 
described above. Pre and post-treatment biopsies performed at Memorial Sloan Kettering Cancer 
Center (MSKC) on this study demonstrated inhibition of pIGF1R, pAKT, and pS6. However, in 
spite of this, patients with apparent pathway inhibition still progressed on drug, suggesting 
continued input to this pathway from an effector(s) not captured in assays performed on tissue 
samples taken from the study participants.  
Follow-up work done at MSKCC on the sarcoma cell lines including a myxofibrosarcoma 
(MXF8000) cell line that was derived from a patient who rapidly progressed on the clinical trial 
suggest that dual mTORC1/IGF1R inhibition does not cause complete and sustained 
PI3K/AKT/mTOR pathway inhibition as 4EBP1 signaling is shown to be maintained through 
exposure to the combination (Figure 3). 
 
Ideally, a stronger and more direct inhibitor of this axis is required to achieve predicted clinical 
results.MLN0128 (TAK-228) is a selective and highly potent ATP competitor/inhibitor of both 
mTORC1 and mTORC2 [21]. Direct inhibition of mTORC1 and mTORC2 provides a unique 

Alliance A091304 
Version Date: 04/03/2019 
13 
Update #09 
opportunity to target the PI3K/AKT/mTOR pathway in sarcoma while suppressing de novo and 
secondary resistance generated through AKT activation and has the potential of providing more 
sustained pathway inhibition. In addition, it affords the ability to target PI3K/AKT/mTOR 
signaling at a single critical point, decreasing the likelihood of aberrant input from the numerous 
effectors involved in the signaling cascade of this complex pathway.  
A growth response curve of MLN0128 (TAK-228) was generated against a large panel of well-
characterized sarcoma cell lines. A representative panel of growth inhibition achieved with a 6-
day proliferation assay is depicted (Figure 4, CHP100 [Ewing’s Sarcoma], SaSO2 
[osteosarcoma]). As noted, the concentration that achieved 50% growth inhibition in all of the 
cell lines was less than 50nm of drug. This confirms activity of the PI3K/AKT/mTOR pathway 
in these sarcoma cell lines and the significant activity of MLN0128 (TAK-228), a selective 
mTORC1/mTORC2 inhibitor in sarcoma. 
 
Comparative experiments in a large panel of sarcoma cell lines were also performed with the 
use of a single agent mTORC1 inhibitor (rapamycin), single agent IGF1R inhibitor (A12), 
combined mTORC1/IGF1R inhibitors and MLN0128 (TAK-228). Representative results at 3 
and 6 days are depicted (Figure 5; DDLS (Liposarcoma). In each cell line, it is clear that single 
agent MLN0128 (TAK-228) has superior activity than mTORC1, IGF1R and dual 
mTORC1/IGF1R inhibition. 

Alliance A091304 
Version Date: 04/03/2019 
14 
Update #09 
 
To investigate the molecular effects of MLN0128 (TAK-228) in the sarcoma cell lines, western 
blot analysis of protein lysates obtained before and after exposure to MLN0128 (TAK-228) were 
performed (Figure 6). Unlike single agent and combined mTORC1 (rapamycin) and IGF1R 
(A12) inhibition, dual mTORC1/mTORC2 (MLN0128 (TAK-228)) causes complete blockade 
of the PI3K/AKT/mTOR pathway as noted by complete inhibition of pAKT, pS6K, pS6 and 
p4EBP1. 
 
In addition, as indicated by the presence of cleaved PARP, exposure of the sarcoma cell lines to 
MLN0128 (TAK-228) causes cellular disassembly and apoptosis (Figure 7).  

Alliance A091304 
Version Date: 04/03/2019 
15 
Update #09 
 
Efficacy of MLN0128 (TAK-228) has also been confirmed in xenograft models (Figure 8). With 
lysates confirming total blockage of the PI3K/AKT/mTOR pathway as found in the sarcoma cell 
lines (Figure 9).  Taken together, all of these data strongly support the clinical application of 
MLN0128 (TAK-228) across sarcoma subtypes. 
 

Alliance A091304 
Version Date: 04/03/2019 
16 
Update #09 
 
1.4 
Clinical Data 
MLN0128 (TAK-228) (Millennium/Takeda) is a selective and highly potent ATP competitor of 
both mTORC1 and mTORC2 [21].MLN0128 (TAK-228) is currently in clinical development. 
At the time of writing this protocol, MLN0128 (TAK-228) was being tested in two phase I 
studies as a single agent, one in solid tumors and the other in multiple myeloma and 
Waldenstroms macroglobulinemia, and in one Phase I study in combination with paclitaxel +/- 
trastuzumab (Investigator’s Brochure, Edition 7). As of December 2013, 248 patients have 
received MLN0128 (TAK-228) on these three trials. The single agent experience with the Phase 
I Solid Tumor and the Phase I hematology trials are listed (Table 1). 
Phase I Solid 
Tumors 
QD schedule 
2mg (3pts), 4mg 
(7pts), 6mg (13pts), 
7mg (8pts) 
MTD – 6mg 
RP2D 5mg 
 
QW schedule 
7mg (3 pts.), 10mg 
(3 pts.), 15mg (3 
pts.), 20 mg (3 pts.), 
30 mg (3 pts.), 40 
mg (15 pts.) 
MTD – 40mg 
RP2D 30mg 
 
QD x 3d QW 
6mg (3 pts.), 9mg 
(8 pts.), 12mg (6 
pts.), 16 mg (12 
pts.), 20 mg (4pts),  
MTD – 16mg 
 
 
QD x 5d QW 
7mg (6 pts.), 10mg 
(13 pts.), 13mg (3 
pts.) 
MTD – 10mg 
 

Alliance A091304 
Version Date: 04/03/2019 
17 
Update #09 
 
Expansion QD 
schedule 
5mg (16 pts.) 
 
 
 
Expansion QW 
schedule 
40 mg (27 pts.), 30 
mg (7 pts.) 
 
 
Phase I MM and 
WM (Heme) 
QD schedule 
2mg (5pts), 4mg 
(7pts), 6mg (6pts), 
7mg (8pts) 
 
 
 
QD x 3d QW 
9mg (6pts), 12mg 
(7pts) 
 
 
Safety:  
As of 09 December 2014, a total of 335 patients had received ≥ 1 dose of study drug across 
studies. A total of 18 deaths that occurred within 30 days of the last study drug dose had been 
reported to the clinical database as of the data cutoff; of these events, 1 (cardiac arrest; Study 
INK128-001) was considered related to TAK-228.  At least 1 treatment-emergent SAE, 
regardless of causality, had been reported in 125/335 patients (37%). Across the studies and 
regardless of causality or dosing regimen, the most common TEAEs included nausea, fatigue, 
hyperglycemia, vomiting, diarrhea, stomatitis, and decreased appetite. 
To date, MLN0128 (TAK-228) appears well tolerated with the report of most toxicities as 
reversible grade 1 and 2. In the solid tumor phase I study, 41% of patients experienced treatment-
emergent serious adverse events (TESAE). The most common was mucosal inflammation (4%), 
asthenia, and pneumonia (3% each), and abdominal pain, stomatitis, and renal failure (2% each). 
98% of 142 treated patients had a treatment-emergent adverse event (TEAE). Hyperglycemia 
was recorded in 65% of patients, nausea in 63% of patients and vomiting in 54% of patients. 
Most TEAEs were grade 1 or 2 and easily manageable with supportive care. Grade 3 or greater 
TEAE were recorded in 6% of patients with the most frequent (regardless of causality) were 
hyperglycemia 6%, asthenia 8%, anemia 7%, and hypophosphatemia and lymphopenia 6%.  
Due to the cardiac death on study INK128-001, study C31002, a phase 1 single-arm study to 
evaluate the effect of a single dose of 40 mg TAK-228 on the QT/QTc interval was initiated in 
patients with advanced solid tumors.  After completing the per-protocol PK/ECG/cardiac 
contractility monitoring, the patients  continued TAK-228 30 mg QW with continued cardiac 
monitoring.  The study results showed that treatment with TAK-228 was not associated with 
clinically meaningful effects on the overall elecrocardiographic safety profile, and that 
ECHO/MUGA at screening was not required.  
Pharmacokinetics: MLN0128 (TAK-228) has been tested as a single agent in several doses and 
schedules as outlined above. It appears to exhibit fast absorption [Tmax] 1-4 hours after dosing, 
dose linear pharmacokinetics with a mean plasma half-life (t1/2) of approximately 8 hours, an 
apparent total body clearance of approximately of 20L/hr., and does not appear to accumulate 
in plasma when dosed as frequently as once daily. MLN0128 (TAK-228) exposures also 
increase linearly with dose and the pharmacokinetics are consistent across the various dose 
levels. 
Both daily and weekly dosing schedules are being considered for Phase II trials. However, the 
weekly dosing schedule is now believed to be superior (see below). 
Reporting on clinical responses is not yet available through the IB. Millennium Pharmaceutical 
has provided a graphic of best responses on their Phase I solid tumor trial. To our knowledge, 
only one patient with sarcoma has been treated with MLN0128 (TAK-228). This was a patient 
with liposarcoma who progressed on the 10mg QDx5 dose and schedule. Of all of the patients 

Alliance A091304 
Version Date: 04/03/2019 
18 
Update #09 
treated, only two patients with Renal Cell Carcinoma have achieved a partial response. Both of 
these patients were on the Q week dosing schedule at 15 and 40mg, respectively. Millennium 
Pharmaceuticals believes that these data underscore that MLN0128 (TAK-228) should be used 
in a weekly dosing schedule.  Preclinical data suggests that higher/intermittent dosing of 
MLN0128 (TAK-228) may be superior in sarcoma than daily dosing (Figure A). As of 
November, 2014, MLN0128 (TAK-228) capsule was reconfigured to contain a milled active 
pharmaceutical ingredient (API). The milled API may result in faster absorption with possibly 
higher maximum concentration (Cmax), which could result in a different safety profile 
compared to the current unmilled API. For this reason, a Phase Ib component is included in this 
protocol utilizing a Qweek dosing and a standard 3+3 design. The Phase I component will be 
used to confirm safety of the new formulation prior to entering into the randomized Phase II 
portion of the trial. Please see Sections 7 and 8 for treatment plan and dose modification details.  
Figure A 
 
The new capsule API requires administration in fasting conditions. MLN0128 (TAK-228) 
milled API should be administered once weekly. It is recommended that each dose is given 
orally with 8 ounces (240 mL) of water. MLN0128 (TAK-228) should be administered on an 
empty stomach. The patients should be instructed to refrain from eating and drinking (except for 
water and prescribed medications) for 2 hours before and 1 hour after each dose. 
Development of a Milled Formulation of TAK-228 
In order to allow more predictable absorption of TAK-228 after oral administration and to allow 
scale-up manufacturing of TAK-228 capsules, Millenium/Takeda developed a new milled 
formulation of the agent.  The physical milling step during the granulation process controls 
particle size distribution of TAK-228.  In order to observe whether this milling step altered the 
safety and PK profile of TAK-228, the company performed in vivo studies with PK analysis of 

Alliance A091304 
Version Date: 04/03/2019 
19 
Update #09 
milled TAK-228.  These studies indicated that the milled formulation may result in faster 
absorption with possibly higher maximum concentration (Cmax), which could result in a 
different safety profile, compared to the previous unmilled API capsules. 
Takeda developed new TAK-228 capsules containing milled active pharmaceutical ingredient 
(API) for clinical studies in 1 mg, 3 mg, and 5 mg strengths.  Patients receiving the milled 
formulation were added onto ongoing studies C31001 and C31002, as well as a new study 
MLN0128-1004, with various treatment cohorts including daily and weekly administration of 
milled TAK-228 
The recommended dose of milled TAK-228 was evaluated in 17 patients of MLN0128-1004, 
with PK, safety, and tolerability assessed.  Six patients were given a 4 mg QD dose of milled 
TAK-228 and 3 patients had observed DLT (rash, appetite loss and fatigue).  A dose of 3 mg 
QD was given to 11 patients with only 1 DLT (decreased platelets) observed.  The 3 mg QD 
dose of TAK-228 was declared the RP2D, and was generally well tolerated and demonstrating 
objective responses in patients.   
The significant difference in tolerability observed in the comparison of the MTDs between 
unmilled and milled TAK-228 when administered QD may be possibly explained due to the 
effect of food on the safety/tolerability of unmilled TAK-228 in study IND128-001.  The 
GastroPlusTM simulation performed under fasting conditions on the trial demonstrated that 
unmilled and milled TAK-228 administration result in comparable exposures to TAK-228; 
whereas in the fed state, milled TAK-228 resulted in higher Cmax (1.5- to 2-fold higher) and 
earlier Tmax than unmilled TAK-228 with comparable AUCs.  Consequently, a dose of 3 mg QD 
was chosen as the RP2D of milled TAK-228 dose in empty stomach conditions.   
The RP2D for milled TAK-228 on a weekly schedule was determined to be 30 mg, the same 
weekly RP2D as seen for the older unmilled formulation.  Six patients treated at 30 mg weekly 
with the milled formulation did not demonstrate any DLT, but the agent was not escalated 
further.  No DLT had been demonstrated for milled TAK-228 at the prior 20 mg QW dose as 
well.  
TAK-228-1004, a phase I, open label study to evaluate the safety, tolerability, and 
pharmacokinetics of TAK-228 in combination with paclitaxel in adult patients with advanced 
non-hematological malignancies-), with the new milled API was used to determine the 
recommended phase 2 dose (RP2D) for TAK-228 QD×3days per week in combination with 
paclitaxel.  The RP2D of milled TAK-228, given 3 consecutive days weekly, in combination 
with weekly paclitaxel at 80 mg/m2, was 6 mg.  
1.5 
Pazopanib 
In a key multicenter, placebo-controlled Phase 3 trial, pazopanib at a dose of 800 mg daily 
demonstrated a significant benefit in progression-free survival for patients with metastatic soft 
tissue sarcomas that had progressed on at least one prior therapy[22]. Median PFS (with 95% 
confidence interval) was 4.6 months (3.7 – 4.8) versus 1.8 months for placebo (0.9-1.8); Hazard 
Ratio 0.31 (0.24 – 0.40)[22]. Overall survival was not significantly improved, with a median OS 
of 12.5 vs 10.7 months, HR 0.86, 95% CI 0.67 – 1.11. The trial was not powered to detect a 3-
month difference of median OS. Of note, adipocytic STS was excluded, as were embryonal 
rhabdomyosarcoma, osteosarcoma, chondrosarcoma, Ewing’s sarcoma, gastrointestinal stromal 
tumor, dermatofibrosarcoma protuberans, and inflammatory myofibroblastic sarcomas. Based 
on this trial, the FDA granted approval for pazopanib to treat non-adipogenic metastatic soft 
tissue sarcomas in the second-line setting. 
Although median dose intensity on this trial was 96%, it is notable that 49% of patients required 
a dose interruption, and 39% required a dose reduction [22]. The most common adverse events 
were fatigue, diarrhea, nausea, weight loss, and hypertension. Venous thromboembolic events 

Alliance A091304 
Version Date: 04/03/2019 
20 
Update #09 
occurred in 5% of the study population who received pazopanib. A drop in Left Ventricular 
Ejection Fraction occurred in a similar number of patients, the majority of which were 
asymptomatic. Dose reductions were mainly caused by hypertension, fatigue, diarrhea, 
hand/foot syndrome, and elevation of AST/ALT. Grade 3 fatigue occurred in 13% of patients; 
other Grade 3 toxicities were hypertension and gastrointestinal in nature. 
1.6 
Registration Quality of Life (QOL) Measurements 
QOL measurements of fatigue and overall perception of QOL are routinely included in Alliance 
studies and will be assessed upon registration in this study.  Evidence has arisen indicating that 
baseline single-item assessments of fatigue and overall QOL are strong prognostic indicators for 
survival in cancer patients, independent of performance status. This evidence was derived from 
two separate meta-analyses recently presented at ASCO, the first involving 23 NCCTG and 
Mayo Clinic Cancer Center oncology clinical trials, the second involving 43 clinical trials. 
Routine inclusion of these measures should be considered similar to that of including 
performance status, either as stratification or prognostic covariates. It will take approximately 
one minute to complete this measure [23]. 
1.7 
Impact of this Trial 
Pazopanib represents the first oral multikinase inhibitor that has a specific FDA-approved 
indication for the treatment of non-GIST soft tissue sarcomas. This trial aims to compare 
TORC1/TORC2 inhibition with MLN0128 (TAK-228) against this regimen with established 
efficacy. Should this trial demonstrate a significant benefit in PFS, it would suggest a pivotal 
Phase III  trial would be warranted to assess its benefit over the current standard. 
1.8 
Rationale for Pazopanib Dosing Change 
On August 4, 2017, the protocol was suspended due to the DSMB stopping rules as outlined in 
section 13.7.1.2 of the old protocol. Five of the first 12 patients on the control arma (pazopanib) 
experienced a grade 3 or higher adverse event. All of these events were carefully reviewed by 
the study team and were felt to be expected toxicities of the pazopanib. The study team felt that 
the starting dose of pazopanib was too high, accounting for these toxicities, and not reflective of 
the starting dose used in routine clincial practice. For this reason, the protocol was amended to 
allow for pazopanib to be initiated at 400mg qd, with plans to titrate to tolerable doses as outlined 
in section 7.2. 
 
 

Alliance A091304 
Version Date: 04/03/2019 
21 
Update #09 
2.0 
OBJECTIVES  
2.1 
Primary Phase I objective 
To determine the safety and maximum tolerable dose of MLN0128 (TAK-228) within this 
patient population. 
2.2 
Primary Phase II objective  
To determine the differences in progression-free survival (PFS) in patients with sarcoma who 
receive MLN0128 (TAK-228) as compared to pazopanib. 
2.3 
Secondary Phase I/II objectives 
2.3.1 To evaluate adverse events. 
2.3.2 To evaluate Overall Response Rate (ORR), Clinical Benefit Rate (CBR), and Duration of 
Response (DOR). 
2.3.3 To evaluate Time to Progression (TTP) and Overall Survival (OS). 
2.4 
Exploratory Phase II objectives 
2.4.1 To evaluate PFS and secondary endpoints within patients crossing over to MLN0128 (TAK-
228), upon disease progression during treatment with pazopanib. 
2.4.2 To evaluate the 4 month CBR observed within patients treated with MLN0128 (TAK-228) 
and grouped by histologically defined Cohorts. 

Alliance A091304 
Version Date: 04/03/2019 
22 
Update #09 
3.0 
PATIENT SELECTION 
For questions regarding eligibility criteria, see the Study Resources page. Please note that the Study 
Chair cannot grant waivers to eligibility requirements.  
Prior to discussing protocol entry with prospective patients, site staff must go to the A091304 study 
page on the CTSU web site to check cohort status and accrual. Please note that Cohort 3 is limited to 
25 patients and as of Update #05, this applies to Arms 5 and 6. If a patient is eligible (from local 
pathology review) for Cohort 3, and 18 or more patients have accrued to Cohort 3 (post-Update #05), 
contact the Alliance Registration Office at random01@mayo.edu or 507-284-4130 (during regular 
business hours 8:00-4:30 CT) to be sure that there is an available spot for the patient. If the 
Registration Office has confirmed that a spot is available, site staff may then proceed to consent and 
pre-register the patient.  
3.1 
On-Study Guidelines 
This clinical trial can fulfill its objectives only if patients appropriate for this trial are enrolled. 
All relevant medical and other considerations should be taken into account when deciding 
whether this protocol is appropriate for a particular patient. Physicians should consider the risks 
and benefits of any therapy, and therefore only enroll patients for whom this treatment is 
appropriate.  
Although they will not be considered formal eligibility (exclusion) criteria, physicians should 
recognize that the following may seriously increase the risk to the patient entering this protocol: 
• 
Psychiatric illness which would prevent the patient from giving informed consent. 
• 
Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes 
mellitus or cardiac disease which, in the opinion of the treating physician, would make this 
protocol unreasonably hazardous for the patient. No ischemic myocardial or cerebrovascular 
event, class III or IV heart failure, placement of pacemaker, or pulmonary embolism within 
six months of receiving first dose of MLN0128 (TAK-228).   
• 
Patients with a “currently active” second malignancy other than non-melanoma skin 
cancers. Patients are not considered to have a “currently active” malignancy if they have 
completed therapy and are free of disease for ≥ 3 years. 
• 
Patients who cannot swallow oral formulations of the agent(s). 
In addition: 
• 
Women and men of reproductive potential are advised to use 2 acceptable methods of birth 
control (one of which must include a condom as a barrier method of contraception) due to 
the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth 
control include abstinence, oral contraceptives, implantable hormonal contraceptives or 
double barrier method (diaphragm plus condom). The methods should be continued for three 
months  for females and 4 months for males after completing study drug. Men must agree 
not to donate sperm during the course of this study or within 4 months after receiving their 
last dose of study drug. 
• 
Drugs that prolong the QTc interval should be avoided if possible. Pazopanib can prolong 
the QTc interval. Drugs that are generally accepted to have a risk of causing Torsades de 
Pointes should be discontinued or replaced with drugs that do not carry this risk, if at all 
possible. Patients who receive potential QTc-prolonging medications should be monitored 
closely. 
 
 

Alliance A091304 
Version Date: 04/03/2019 
23 
Update #09 
3.2 
Pre-Registration Eligibility Criteria (Step 0) 
Use the spaces provided to confirm a patient’s eligibility by indicating Yes or No as appropriate. 
It is not required to complete or submit the following pages. 
When calculating days of tests and measurements, the day a test or measurement is done is 
considered Day 0. Therefore, if a test were done on a Monday, the Monday four weeks later 
would be considered Day 28. 
A female of childbearing potential is a sexually mature female who: 1) has not undergone a 
hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 
12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive 
months). 
___ 
3.2.1 
Central pathology review submission  
Patients must have slides available for submission to central pathology review. This review is 
mandatory prior to registration to confirm eligibility and proper cohort assignment. See Section 
6.2 for details on slide submission. 
Sarcoma of the following histologic subtypes by local pathology review may be submitted for 
central pathology review**: 
• 
HISTOLOGIC COHORT 1: Undifferentiated Pleomorphic Sarcoma (Includes: Malignant 
Fibrous Histiocytoma, Myxofibrosarcoma, High Grade Sarcoma NOS). 
• 
HISTOLOGIC COHORT 2: Leiomyosarcoma (Either Uterine or Extra-Uterine). 
• 
HISTOLOGIC COHORT 3: Other (Either Malignant Peripheral Nerve Sheath Tumor or 
Synovial Sarcoma). During the Phase II portion of the study, enrollment will be limited to 
maximum of 25 patients in this cohort. This applies to those assigned to Arms 5 and 6, as 
of Update #05. 
 
** Note that the Phase I is limited to the histologic subtypes listed above. Since patients 
will be enrolling onto Dose cohorts during the Phase I, they will not enroll onto specific 
Histologic Cohorts, although the histologic subtype informed will be collected during 
patient enrollment. 
3.3 
Registration Eligibility Criteria (Step 1) 
___  
3.3.1 Documentation of Disease: 
 
Histologic Documentation: Eligible patients must have histopathologically confirmed 
sarcoma of one of the subtypes listed in Section 3.2.1, by central review. 
 
 
Locally advanced or metastatic disease. Locally advanced disease is defined as disease 
not amenable to local therapy such as surgery and/or radiation. 
___ 
3.3.2 
Measurable disease as defined in Section 11.0. 
___ 
3.3.3 Prior Treatment  
___ 
• 
Progression on at least one prior systemic chemotherapy for advanced, unresectable or 
metastatic disease. Prior adjuvant or neoadjuvant therapy is not included as prior 
systemic chemotherapy unless treatment occurred within the 6 months prior to study 
enrollment. 
 
___ 
• 
There is no limit to the number of prior lines of treatment a patient has received. 

Alliance A091304 
Version Date: 04/03/2019 
24 
Update #09 
 
___ 
• 
No treatment with biological therapy, immunotherapy, chemotherapy, investigational 
agent for malignancy, or radiation ≤ 28 days before study registration. No treatment 
with nitrosourea or mitomycin ≤ 42 days before study registration. 
 
___ 
• 
No treatment with radiation therapy ≤ 28 days before study registration. 
 
___ 
• 
Patients should have resolution of any toxic effects of prior therapy (except alopecia) to 
NCI CTCAE, Version 4.0, grade 1 or less. 
 
___ 
• 
Prior treatment with pazopanib or any PI3K, mTOR, AKT, or dual PI3K/mTOR 
complex (TORC1/TORC2) inhibitors will be prohibited. 
___ 
3.3.4 Not pregnant and not nursing, because this study involves an investigational agent whose 
genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are 
unknown and  an agent that has known genotoxic, mutagenic and teratogenic effects. 
Therefore, for women of childbearing potential only, a negative pregnancy test done ≤ 7 
days prior to registration is required. 
___ 
3.3.5 Age ≥ 18 years  
 
___ 
3.3.6 ECOG Performance Status ≤ 1 
___ 
3.3.7 Patient history: patients who have any of the following are NOT eligible: 
___ 
• 
CNS: Symptomatic, untreated, or uncontrolled brain metastases present 
___ 
• 
Heme: Active bleeding or bleeding diathesis 
___ 
• 
GI: 
- 
Abdominal fistula, GI perforation, or intra-abdominal abscess within 28 days prior 
to registration 
- 
Acute GI bleed within 28 days of registration 
___ 
• 
Diabetes Mellitus: Patients with diabetes mellitus with inadequate control, based on 
either a glycosylated hemoglobin (Hgb A1c) of >7.0 or fasting blood glucose above or 
equal to 130 mg/dL. 
___ 
• 
Cardiac and Vascular Disorders: 
- 
History of congenital long QT syndrome or torsades de pointes 
- 
Any arrhythmia that is currently not rate-controlled (rate between 60 and 100) 
- 
Prolongation of corrected QT interval via Friderica’s formula (QTcF) >480 msec  
- 
Ongoing unstable angina 
- 
Symptomatic peripheral vascular disease 
- 
Arterial thrombosis within 28 days of registration including TIA, CVA, MI. 
- 
Patients with DVT or PE must be on a stable dose of anticoagulation for 14 days 
prior to registration 
- 
Uncontrolled hypertension, defined as BP > 140/90 
- 
MUGA with EF, 50% or echo with low EF 
- 
Class III or IV CHF within 28 days of registration  
___ 
3.3.8 
Concomitant Medications: 
• 
Chronic concomitant treatment with proton pump inhibitors must discontinue the 
drug for 7 days prior to registration on the study. 

Alliance A091304 
Version Date: 04/03/2019 
25 
Update #09 
___ 
• 
Chronic concomitant treatment with strong inhibitors of CYP3A4 inhibitors must 
discontinue the drug for 14 days prior to registration on the study. See Section 7.3 for 
more information. 
___ 
• 
Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients 
must discontinue the drug 14 days prior to the start of study treatment. See Section 7.4 
for more information.  
 
___ 
3.3.9 Required Initial Laboratory Values:  
Absolute Neutrophil Count (ANC) 
≥ 1,500/mm3 
Platelet Count 
≥ 100,000/mm3 
Creatinine 
≤ 1.5 x upper limit of normal (ULN) 
Total Bilirubin 
≤ 1.5 x upper limit of normal (ULN)* 
AST / ALT  
≤ 3 x upper limit of normal (ULN)** 
UPC 
≤ 1*** 
TSH 
WNL**** 
*  
Unless patient has Gilbert disease 
** 
If liver metastases, ≤ 5 x upper limit of normal (ULN) 
*** 
If UPC ≥ 1, then a 24-hour urine protein must be assessed. Eligible patients must 
have a 24-hour urine protein value < 1 g/L  
**** 
Supplementation is acceptable to achieve a TSH WNL. In patients with abnormal 
TSH however if the Free T4 is normal and patient is clinically euthyroid, patient 
is eligible. 
 

Version Date: 04/03/2019 
26 
Update #09 
 
4.0 
PATIENT REGISTRATION 
4.1 
CTEP Investigator Registration Procedures 
Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy 
require all individuals contributing to NCI-sponsored trials to register and to renew their 
registration annually.  To register, all individuals must obtain a Cancer Therapy Evaluation 
Program 
(CTEP) 
Identity 
and 
Access 
Management 
(IAM) 
account 
(https://ctepcore.nci.nih.gov/iam).  In addition, persons with a registration type of Investigator 
(IVR), Non-Physician Investigator (NPIVR), or Associate Plus (AP) (i.e., clinical site staff 
requiring write access to OPEN, RAVE, or TRIAD or acting as a primary site contact) must 
complete their annual registration using CTEP’s web-based Registration and Credential 
Repository (RCR) (https://ctepcore.nci.nih.gov/rcr).  Documentation requirements per 
registration type are outlined in the table below. 
 
Documentation Required 
IVR 
NPIVR 
AP 
A 
FDA Form 1572 
 
 
Financial Disclosure Form 
 
 
 
NCI Biosketch (education, training, employment, 
license, and certification) 
 
 
 
HSP/GCP training 
 
 
 
Agent Shipment Form (if applicable) 
 
CV (optional) 
 
 
 
 
An active CTEP-IAM user account and appropriate RCR registration is required to access all 
CTEP and CTSU (Cancer Trials Support Unit) websites and applications.  In addition, IVRs and 
NPIVRs must list all clinical practice sites and IRBs covering their practice sites on the FDA 
Form 1572 in RCR to allow the following: 
• 
Added to a site roster 
• 
Assigned the treating, credit, consenting, or drug shipment (IVR only) tasks in OPEN 
• 
Act as the site-protocol PI on the IRB approval 
• 
Assigned the Clinical Investigator (CI) role on the Delegation of Tasks Log (DTL). 
Additional 
information 
can 
be 
found 
on 
the 
CTEP 
website 
at 
< 
https://ctep.cancer.gov/investigatorResources/default.htm >. For questions, please contact the 
RCR Help Desk by email at < RCRHelpDesk@nih.gov mailto:>. 
 

Alliance A091304 
Version Date: 04/03/2019 
27 
Update #09 
4.2 
CTSU Site Registration Procedures 
This study is supported by the NCI Cancer Trials Support Unit (CTSU). 
IRB Approval:   
Each investigator or group of investigators at a clinical site must obtain IRB approval for this 
protocol and submit IRB approval and supporting documentation to the CTSU Regulatory 
Office before they can be approved to enroll patients.  Assignment of site registration status in 
the CTSU Regulatory Support System (RSS) uses extensive data to make a determination of 
whether a site has fulfilled all regulatory criteria including but not limited to the following: 
• 
An active Federal Wide Assurance (FWA) number 
• 
An active roster affiliation with the Lead Network or a participating organization 
• 
A valid IRB approval 
• 
Compliance with all protocol specific requirements. 
In addition, the site-protocol Principal Investigator (PI) must meet the following criteria: 
• 
Active registration status 
• 
The IRB number of the site IRB of record listed on their Form FDA 1572 
• 
An active status on a participating roster at the registering site. 
Sites participating on the NCI CIRB initiative that are approved by the CIRB for this study are 
not required to submit IRB approval documentation to the CTSU Regulatory Office. For sites 
using the CIRB, IRB approval information is received from the CIRB and applied to the RSS in 
an automated process. Signatory Institutions must submit a Study Specific Worksheet for Local 
Context (SSW) to the CIRB via IRB Manager to indicate their intent to open the study locally.  
The CIRB’s approval of the SSW is then communicated to the CTSU Regulatory Office.  In 
order for the SSW approval to be processed, the Signatory Institution must inform the CTSU 
which CIRB-approved institutions aligned with the Signatory Institution are participating in the 
study. 
4.2.1 Downloading Site Registration Documents 
Site registration forms may be downloaded from the A091304 protocol page located on the 
CTSU members’ website.  
• 
Go to https://www.ctsu.org and log in to the members’ area using your CTEP-
IAM username and password 
• 
Click on the Protocols tab in the upper left of your screen 
• 
Either enter the protocol # in the search field at the top of the protocol tree, or 
• 
Click on the By Lead Organization folder to expand 
• 
Click on the Alliance link to expand, then select trial protocol # A091304 
• 
Click on LPO Documents, select the Site Registration documents link, and 
download and complete the forms provided.  
4.2.2 Requirements for A091304 Site Registration 
• 
IRB approval (For sites not participating via the NCI CIRB; local IRB documentation, 
an IRB-signed CTSU IRB Certification Form, Protocol of Human Subjects Assurance 
Identification/IRB Certification/Declaration of Exemption Form, or combination is 
accepted)  
NOTE: Per NCI policy all institutions that participate on protocols with a radiation 
therapy component must participate in the Radiological Physics Center (RPC) 

Alliance A091304 
Version Date: 04/03/2019 
28 
Update #09 
monitoring program.  If this form has been previously submitted to CTSU it does not 
need to be resubmitted unless updates have occurred at the RT facility. 
4.2.3 Submitting Regulatory Documents 
Submit required forms and documents to the CTSU Regulatory Office via the 
Regulatory Submission Portal, where they will be entered and tracked in the CTSU 
RSS. 
Regulatory Submission Portal: www.ctsu.org  (members’ area) → Regulatory Tab 
→ Regulatory Submission 
 
When applicable original documents should be mailed to: 
CTSU Regulatory Office 
      
1818 Market Street, Suite 3000 
       
Philadelphia, PA 19103 
4.2.4 Checking Your Site’s Registration Status 
You can verify your site registration status on the members’ section of the CTSU website  
• 
Go to https://www.ctsu.org and log in to the members’ area using your CTEP-IAM 
username and password 
• 
Click on the Regulatory tab 
• 
Click on the Site Registration tab 
• 
Enter your 5-character CTEP Institution Code and click on Go 
Note: The status given only reflects compliance with IRB documentation and institutional 
compliance with protocol-specific requirements  outlined by the Lead Network. It does not 
reflect compliance with protocol requirements for individuals participating on the protocol 
or the enrolling investigator’s status with the NCI or their affiliated networks. 
4.3 
Phase I Enrollment Requirements 
4.3.1 Pre-Registration Requirements (Step 0) 
• 
Informed consent: the patient must be aware of the neoplastic nature of his/her disease 
and willingly consent after being informed of the procedure to be followed, the 
experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, 
and discomforts. Current human protection committee approval of this protocol and a 
consent form is required prior to patient consent and registration. 
• 
Slot reservation: patient enrollment will be facilitated using the Slot-Reservation 
System in conjunction with the Registration system on Oncology Patient Enrollment 
Network (OPEN). Prior to discussing protocol entry with the patient, all site staff must 
use the CTSU OPEN Slot Reservation System to insure that a slot on the protocol is 
available to the patient. Once a slot reservation confirmation is obtained, site staff may 
then proceed to pre-register the patient. Once a patient is pre-registered, specimens 
should be submitted for central pathology review. 
• 
Central pathology review submission: Patients who have 1) met pre-registration 
eligibility criteria, 2) been consented, and 3) have received a slot reservation 
confirmation, will be pre-registered using the OPEN registration system (see Section 
4.5) in order to submit specimens for central pathology review. Once the patient is pre-
registered, the sarcoma tissue slides from diagnostic biopsy should be sent to: 
 

Alliance A091304 
Version Date: 04/03/2019 
29 
Update #09 
Dr. Fabrizio Remotti 
Department of Pathology VC14-215 
Columbia University Medical Center 
630 W 168th St, New York, NY 10032 
along with a completed “Central Pathology Review Form”, per Section 6.2.2. Failure to 
submit this form with the specimens will delay turnaround time for central pathology 
review. The specimen will be centrally reviewed to confirm study eligibility. The tissue 
slides will not be returned.  
4.3.2 Registration Requirements (Step 1) 
• 
Confirmation of eligibility by central pathology review: Sites will be notified via e-
mail within 5 business days of receipt, whether or not the patient is eligible based on the 
central pathology review. The results section of “Central Pathology Review Form” will 
be completed by the pathologist, scanned and sent via e-mail to the Responsible CRA 
listed on the form. The form will indicate whether or not the patient is eligible, and if a 
discrepancy was found in central vs. local pathology review. If the central review 
disagrees with local review, then the following may occur: 
• 
Complete discordance: the patient is ineligible for the trial. The treating physician 
should inform the patient and determine next steps.  
• 
Partial discordance: the patient is eligible as they have one of the histologic subtypes 
allowed on the trial. However, the subtype that they have is discordant between the 
local and central review. The patient should be informed of the discordance. 
After receiving the results form via e-mail, the institution must forward the form to the 
Alliance Patient Registration office at random01@mayo.edu in order to register the patient. 
Once the form is forwarded to the Alliance Patient Registration Office and the Registration 
Eligibility Criteria have been met, the patient can be registered using the OPEN system per 
Section 4.5. Registration must occur within 21 days of specimen submission. The same 
patient ID number obtained at pre-registration from the OPEN system should be used to 
register 
the 
patient. 
Please 
contact 
Alliance 
Patient 
Registration 
office 
at 
random01@mayo.edu or 507-284-4130 if registration problems occur. Dose Cohort 
assignment will be made at registration. If the patient is ineligible you will need to contact 
the registration/randomization office to release the slot.   
• 
Once a patient is enrolled on the phase I portion of the study and assigned a dose cohort, 
one representative from the institution must participate in a bi-weekly conference call. 
Institutions with a patient enrolled who do not participate in the bi-weekly conference 
call will be denied future registrations to this study. These calls will be used to review 
adverse events, discuss dose limiting toxicity, and address any questions that arise over 
the course of the Phase I. These calls can be attended by the Principal Investigator, a 
Co-Investigator or the Study Coordinator responsible for A091304 at that site.  
4.4 
Phase II Patient Enrollment Requirements  
4.4.1 Pre-Registration Requirements (Step 0) 
• 
Cohort Status and Accrual: Prior to discussing protocol entry with prospective 
patients, site staff must go to the A091304 study page on the CTSU web site to check 
cohort status and accrual. Please note that Histologic Cohort 3 is limited to 25 patients 
and for enrollment associated with Update #05 (Arms 5 and 6). Sites will be notified 
when the accrual goal has been met for Cohort 3. If the patient has been pre-registered 
when the accrual has goal has been met for Cohort 3 the patient will be allowed to 

Alliance A091304 
Version Date: 04/03/2019 
30 
Update #09 
proceed to registration. If a patient has been consented but not pre-registgered when the 
accrual goal has been met for Cohort 3 the patient will not be allowed to register to the 
study. 
• 
Informed consent: the patient must be aware of the neoplastic nature of his/her disease 
and willingly consent after being informed of the procedure to be followed, the 
experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, 
and discomforts. Current human protection committee approval of this protocol and a 
consent form is required prior to patient consent and registration. 
• 
Central pathology review submission: Patients who meet the pre-registration 
eligibility criteria (and who have been consented) will be pre-registered using the OPEN 
registration system (see Section 4.5) in order to submit specimens for central pathology 
review. Once patient is consented and pre-registered, all representative H&E and IHC 
slides used locally for diagnosis (Include slides representative of stains for the sarcoma 
subtype involved) should be sent to:  
Dr. Fabrizio Remotti 
Department of Pathology VC14-215 
Columbia University Medical Center 
630 W 168th St, New York, NY 10032 
Tel: 212-342-0419 
along with a completed “Central Pathology Review Form”, per Section 6.2.2. Failure 
to submit this form with the specimens will delay turnaround time for central 
pathology review. The specimen will be centrally reviewed to confirm study eligibility 
and histologic cohort assignment. The tissue slides may not be returned.  
• 
Protected Health Information: H & E slides will be sent directly to the Department of 
Pathology of Columbia University Medical Center. These slides will be labeled with 
patient initials, study ID and collection date. 
 
4.4.2 Patient Registration Requirements (Step 1) 
• 
Confirmation of eligibility by central pathology review: Sites will be notified via e-
mail within 5 business days of receipt, whether or not the patient is eligible based on the 
central pathology review. The results section of “Central Pathology Review Form” will 
be completed by the pathologist, scanned and sent via e-mail to the Responsible CRA 
listed on the form. The form will indicate whether or not the patient is eligible, and if a 
discrepancy was found in central vs. local pathology review. If the central review 
disagrees with local review, then the following may occur: 
• 
Complete discordance: the patient is ineligible for the trial. The treating physician 
should inform the patient and determine next steps.  
• 
Partial discordance: the patient is eligible as they have one of the histologic subtypes 
allowed on the trial. However, the subtype that they have is discordant between the 
local and central review. The patient should be informed of the discordance. 
After receiving the results form via e-mail, the institution must forward the form to the 
Alliance Patient Registration office at random01@mayo.edu in order to register the 
patient. Once the form is forwarded to the Alliance Patient Registration Office and the 
Registration and Randomization Eligibility Criteria have been met, the patient can be 
registered using the OPEN system per Section 4.5. Registration must occur within 21 
days of specimen submission. The same patient ID number obtained at pre-registration 
from the OPEN system should be used to register the patient. Please contact Alliance 

Alliance A091304 
Version Date: 04/03/2019 
31 
Update #09 
Patient Registration office at random01@mayo.edu or 507-284-4130 if registration 
problems occur. Please note: If your patient was registered to the wrong histologic 
cohort due to a discrepancy between the local and central pathology read the patient will 
be allowed to register to histologic cohort 3 regardless of the number of patients 
registered to the cohort.    
4.5 
Patient Enrollment through OPEN 
Patient enrollment will be facilitated using the Oncology Patient Enrollment Network (OPEN).  
OPEN is a web-based registration system available on a 24/7 basis.  To access OPEN, the site 
user must have an active CTEP-IAM account (check at < https://ctepcore.nci.nih.gov/iam >) and 
a 'Registrar' role on either the LPO or participating organization roster.  Registrars must hold a 
minimum of an AP registration type.   
All site staff will use OPEN to enroll patients to this study.  It is integrated with the CTSU 
Enterprise System for regulatory and roster data and, upon enrollment, initializes the patient in 
the Rave database.}.  OPEN can be accessed at https://open.ctsu.org or from the OPEN tab on 
the CTSU members’ side of the website at https://www.ctsu.org.  To assign an IVR or NPIVR 
as the treating, crediting, consenting, drug shipment (IVR only), or investigator receiving a 
transfer in OPEN, the IVR or NPIVR must list on their Form FDA 1572 in RCR the IRB number 
used on the site’s IRB approval.    
Prior to accessing OPEN, site staff should verify the following: 
• 
All eligibility criteria have been met within the protocol stated timeframes.  
• 
All patients have signed an appropriate consent form and HIPAA authorization form (if 
applicable). 
Note: The OPEN system will provide the site with a printable confirmation of registration and 
treatment information. Please print this confirmation for your records. 
Further instructional information is provided on the OPEN tab of the CTSU members’ side of 
the CTSU website at https://www.ctsu.org or at https://open.ctsu.org.  For any additional 
questions contact the CTSU Help Desk at 1-888-823-5923 or ctsucontact@westat.com. 
Phase I patient enrollment: For the phase I portion of the study, patient enrollment will be 
facilitated using the Slot-Reservation System in conjunction with the Registration system in 
OPEN. Prior to discussing protocol entry with the patient, all site staff must use the CTSU OPEN 
Slot Reservation System to insure that a slot on the protocol is available to the patient. See 
Section 4.4.1 for more information. 
4.6 
Re-Registration at the Time of Progression (Step 2, if applicable) (Phase II only) 
Note: Effective 12/21/2018, patients will no longer be able to crossover to MLN0128 (TAK-
228) 
Upon progression on pazopanib, patients may elect to crossover to MLN0128 (TAK-228). 
Women of child-bearing potential must have a negative pregnancy test within 7 days prior 
to re-registration.  
Re-registration procedures: Only for patients originally assigned to Pazopanib:  
• 
For a patient on pazopanib, once they are deemed by their local physician to have 
progressive disease as per section 11.4.3, they may cross-over to receive MLN0128 
(TAK-228).   
• 
Follow OPEN enrollment procedures as detailed in Section 4.5 to register patient to 
crossover 

Alliance A091304 
Version Date: 04/03/2019 
32 
Update #09 
The OPEN system will provide the registering site with a printable confirmation of re-
registration. Please print the confirmation for your records. Further instructional information is 
provided on the CTSU members’ website OPEN tab, or within the OPEN URL. For any 
additional 
questions, 
contact 
the 
CTSU 
Help 
Desk 
at 
1-888-823-5923, 
or 
ctsucontact@westat.com.  
Once the patient has been re-registered and crossed over to MLN0128 (TAK-228), the 
initial shipment of MLN0128 (TAK-228) will arrive within 7-10 days. Patients must cross 
over within 6 weeks of documented progression and need to have a CT scan within 28 days 
of starting MLN0128 to serve as a baseline. 
4.7 
Stratification Factors, Treatment Assignments and Grouping Factors  
4.7.1 Phase I 
Patients will be directly assigned to a “Dose Cohort” at registration for MLN0128 (TAK-
228) treatment.  The dose cohorts are defined as follows: 
• 
Dose Level -1: 15 mg MLN0128 (TAK-228) weekly 
• 
Dose Level 0: 20 mg MLN0128 (TAK-228) weekly 
• 
Dose Level 1: 25 mg MLN0128 (TAK-228) weekly 
• 
Dose Level 2: 30 mg MLN0128 (TAK-228) weekly 
All patients will be characterized and grouped by histology as follows: 
• 
Histologic Subtype 1: Undifferentiated Pleomorphic Sarcoma (Includes: Malignant 
Fibrous Histiocytoma, Myxofibrosarcoma, and High Grade Sarcoma NOS),  
• 
Histologic Subtype 2: Leiomyosarcoma (Either: Uterine or Extra-Uterine), and 
• 
Histologic Subtype 3: Other (Either: Malignant Peripheral Nerve Sheath Tumor or 
Synovial Sarcoma)]. 
4.7.2 Phase II 
As of protocol Update #05, the balancing of treatment arms will re-start for patients  enrolled 
to Arms 5 and 6. 
Stratification factors used at the time of patient randomization will include the number of 
prior systemic anticancer therapies for this cancer (1-2, >2) and the sarcoma histologic 
subtype [Histologic Cohort 1: Undifferentiated Pleomorphic Sarcoma (Includes: Malignant 
Fibrous Histiocytoma, Myxofibrosarcoma, and High Grade Sarcoma NOS), Histologic 
Cohort 2: Leiomyosarcoma (Either: Uterine or Extra-Uterine), Histologic Cohort 3: Other 
(Either: Malignant Peripheral Nerve Sheath Tumor or Synovial Sarcoma)]. 

Alliance A091304 
Version Date: 04/03/2019 
33 
Update #09 
5.0 
STUDY CALENDAR 
Laboratory and clinical parameters during treatment are to be followed using individual institutional 
guidelines and the best clinical judgment of the responsible physician. It is expected that patients on 
this study will be cared for by physicians experienced in the treatment and supportive care of patients 
on this trial.  
Pre-Study Testing Intervals  
• 
To be completed ≤ 16 DAYS before registration: All laboratory studies, history and physical. 
• 
To be completed ≤ 28 DAYS before registration: Any scan which is utilized for tumor 
measurement per protocol. 
• 
To be completed ≤ 42 DAYS before registration: Any baseline exams used for screening, or 
ultrasound of uninvolved organs which is not utilized for tumor measurement. 
 
Prior to 
Registration* 
Days 1 and 15 of 
cycles 1 and 2, 
then Day 1 of 
cycles 3 and 
on*† 
Post treatment 
follow up** 
At PD, 
withdrawal, or 
removal*** 
Tests & Observations 
 
 
 
 
History and physical, weight, 
PS 
X 
X 
X 
 
Height 
X 
 
 
 
Pulse, Blood Pressure 
X 
X 
 
 
ECG Ψ 
X 
X 
 
 
Adverse Event Assessment Ω 
X 
X 
X 
 
Patient Medication Diary Φ 
 
X 
X 
 
TTE/MUGA π 
X 
 
 
 
Registration Fatigue/Uniscale 
Assessment # 
X 
 
 
 
Laboratory Studies 
 
 
 
 
Complete Blood Count, 
Differential, Platelets 
X 
X 
 
 
Chemistry (Serum Creatinine, 
AST, ALT, Alk. Phos., Bili) 
X 
X 
 
 
Fasting glucose 
X 
X(1) 
 
 
Hemoglobin A1c 
 
X(2) 
 
 
TSH 
X 
A 
 
 
Serum or Urine HCG 
X(3) 
 
 
 
UPC ratio/urine protein 
X 
A 
 
 
Staging 
 
 
 
 
Central Pathology review for 
eligibility 
X(4) 
 
 
 
CT/MRI chest/abd/pelvis 
X (5) 
B 
B 
X 
Correlative studies: For patients who consent to participate 
Tissue sample 
Archival tissue for banking, see Section 6.2 
* 
Labs completed prior to registration may be used for day 1 of cycle 1 tests if obtained ≤ 16 days 
prior to treatment. For subsequent cycles, labs, tests and observations may be obtained +/- 3 

Alliance A091304 
Version Date: 04/03/2019 
34 
Update #09 
days from scheduled day of assessment. Radiographic windows are +/- 7 days from scheduled 
day of assessment.   
** 
Physical examination, adverse event assessment, and medication diary are required 4 weeks (+/- 
7 days) after the end of treatment. 
*** Patients discontinuing less than 15 months post-registration for reasons other than progressive 
disease will have staging scans every 8 weeks (+/- 7 days) until they have reached 15 months 
post-registration or until documented progression, whichever occurs first. Thereafter, survival 
information is required every 6 months for 2 years post-registration. For patients who 
discontinue treatment for progressive disease, survival information is required every 6 months 
for 2 years post-registration. See also Section 12. For crossover patients after completion of open 
label MLN0128 (TAK-228), only survival information is required every 6 month for 2 years the 
date of randomization onto the study. 
† 
Follow this column for crossover patients during therapy. 
Ψ 
ECG at baseline then day 1 of every other cycle, starting with day 1 cycle 3, +/- 3 days. QTc 
should be calculated using Friderica formula (see Section 3.3.7). 
Ω 
Solicited AEs are to be collected starting at baseline. Routine AEs are to be collected starting 
after registration. See Section 9.1 for expedited reporting of SAEs. 
Φ 
Medication diary should be completed by the patient throughout treatment, and should be 
collected at day 1 of every cycle starting with day 1 cycle 2. Completion of the medication diary 
is mandatory effective with Update #05.  
π 
Baseline echo or MUGA is recommended for patients at risk of cardiac dysfunction, at the 
discretion of the treating physician.  
# 
To be completed after pre-registration and prior to registration, see Appendix I. 
1 
Glucose needs to be fasting only in patients randomized to MLN0128 (TAK-228). 
2 
Glycosylated hemoglobin should be checked every 3 cycles in patients receiving MLN0128 
(TAK-228) only, starting with day 1 cycle 3. 
3 
For women of childbearing potential (see Section 3.2). Must be done ≤ 7 days prior to 
registration, and must be repeated in crossover patients within 7 days of re-registration. 
4 
See Sections 4.4 and 6.2. 
5 
Baseline scans can include either: 1) a CT, spiral CT, or MRI, or 2) an FDG-PET scan and 
diagnostic CT performed with both IV and oral contrast, and the CT acquired with 5 mm or less 
slice thickness (per Section 11.0). Supporting documentation is to be submitted, per Section 
6.1.1. 
A 
Patients randomized in Phase II to receive pazopanib should have TSH and UPC every other 
cycle starting with day 1 cycle 3. 
B 
Every 8 weeks (e.g. prior to Cycle 3 Day 1) for 1 year, then every 12 weeks until evidence of 
progression. Scans may be done within +/- 7 days of a scheduled time point. Patients initiating 
crossover will restart their scanning intervals as every 8 weeks from date of crossover for 6 
assessments, followed by every 12 weeks thereafter. Response assessment should include 
assessment of all sites of disease and use the same imaging method as was used at baseline. 
 

Alliance A091304 
Version Date: 04/03/2019 
35 
Update #09 
6.0 
DATA AND SPECIMEN SUBMISSION  
6.1 
Data collection and submission 
Data collection for this study will be done exclusively through the Medidata Rave clinical data 
management system. Access to the trial in Rave is granted through the iMedidata application to 
all persons with the appropriate roles assigned in Regulatory Support System (RSS). To access 
Rave via iMedidata, the site user must have an active CTEP-IAM account (check at 
https://eapps-ctep.nci.nih.gov/iam/index.jsp) and the appropriate Rave role (Rave CRA, Read-
Only, Site Investigator) on either the LPO or participating organization roster at the enrolling 
site. To the hold Rave CRA role or CRA Lab Admin role, the user must hold a minimum of an 
AP registration type.  To hold the Rave Site Investigator role, the individual must be registered 
as an NPIVR or IVR.  Associates can hold read-only roles in Rave.   
Upon initial site registration approval for the study in RSS, all persons with Rave roles assigned 
on the appropriate roster will be sent a study invitation e-mail from iMedidata. To accept the 
invitation, site users must log into the Select Login (https://login.imedidata.com/selectlogin) 
using their CTEP-IAM user name and password, and click on the “accept” link in the upper 
right-corner of the iMedidata page. Please note, site users will not be able to access the study in 
Rave until all required Medidata and study specific trainings are completed. Trainings will be 
in the form of electronic learnings (eLearnings), and can be accessed by clicking on the link in 
the upper right pane of the iMedidata screen. 
Users who have not previously activated their iMedidata/Rave account at the time of initial site 
registration approval for the study in RSS will also receive a separate invitation from iMedidata 
to activate their account. Account activation instructions are located on the CTSU website, Rave 
tab under the Rave resource materials (Medidata Account Activation and Study Invitation 
Acceptance). Additional information on iMedidata/Rave is available on the CTSU members’ 
website under the Rave tab at www.ctsu.org/RAVE/ or by contacting the CTSU Help Desk at 
1-888-823-5923 or by e-mail at ctsucontact@westat.com.   
A Schedule of Forms is available on the Alliance study webpage, within the Case Report Forms 
section. The Schedule of Forms is also available on the CTSU site within the study-specific 
Education and Promotion folder, and is named Time & Events. 
6.1.1 Supporting documentation 
This study requires supporting documentation for diagnosis and progression. Supporting 
documentation will include pathology report, radiology report, and clinic note. These must 
be de-identified and uploaded into iMedidata Rave at registration and progression. 
Additionally, the “Central Pathology Review Form” confirming eligibility and histologic 
subtype and histologic cohort assignment must be uploaded via iMedidata Rave on the 
Screening form.  
Effective with Update #05 the Patient Medication Diaries will be required for all patients. 
The medication diaries will need to be updloaded into iMedidata Rave.  

Alliance A091304 
Version Date: 04/03/2019 
36 
Update #09 
6.2 
Specimen collection and submission  
For all patients pre-registered to Phase I or Phase II component of Alliance A091304:  Real-
time histopathology review will be conducted in patients with sarcoma of the following 
subtypes**: 
• 
HISTOLOGIC COHORT 1: Undifferentiated Pleomorphic Sarcoma (Malignant Fibrous 
Histiocytoma, Myxofibrosarcoma, High Grade Sarcoma NOS). 
• 
HISTOLOGIC COHORT 2: Leiomyosarcoma (Uterine and Extra-Uterine). 
• 
HISTOLOGIC COHORT 3: Other (Malignant Peripheral Nerve Sheath Tumor and 
Synovial Sarcoma). NOTE: During the Phase II portion of the study, enrollment will be 
limited to maximum of 25 patients in this cohort. This applies to those assigned to Arms 
5 and 6, as of Update #05. 
 
** Note that the Phase I is limited to the histologic subtypes listed above. Since patients 
will be enrolling onto Dose Cohorts during the Phase I, they will not enroll onto specific 
Histologic Cohorts, although the histologic subtype informed will be collected during 
patient enrollment. 
 
 
≤ 3 days from pre-
registration 
Submit to: 
Mandatory for all patients pre-registered to A091304: 
All representative H&E and 
IHC slides used locally for 
diagnosis (Includinge slides 
representative of stains for the 
sarcoma subtype involved.) 
X 
Columbia 
(Dr. Remotti) 
For patients pre-registered to A091304**: 
Archival FFPE tumor block 
OR 20 unstained tissue slides* 
(4-5 microns thickness, if site 
does not have 20 slides, please 
send as many as possible, up to 
20) 
X 
OSU 
* Slides are acceptable but tumor block is preferred. 
**For patients who consent to biobanking for future research: All participating institutions must 
ask patients for their consent to store samples for future research, although patient participation 
is optional. Rationale and methods for the scientific components of banking are described in 
Section 14.0. For patients who consent to participate, a portion of the archival FFPE tumor block 
OR tissue slides will be stored for future research. Please see section 6.2.1 for BIOMS 
instructions.  
6.2.1 Specimen submission using the Alliance Biospecimen Management System  
USE OF THE ALLIANCE BIOSPECIMEN MANAGEMENT SYSTEM (BioMS) IS 
MANDATORY AND ALL SPECIMENS MUST BE LOGGED AND SHIPPED VIA THIS 
SYSTEM.  
BioMS is a web-based system for logging and tracking all biospecimens collected on 
Alliance trials. Authorized individuals may access BioMS at the following URL:  
http://bioms.allianceforclinicaltrialsinoncology.org using most standard web browsers 

Alliance A091304 
Version Date: 04/03/2019 
37 
Update #09 
(Safari, Firefox, Internet Explorer). For information on using the BioMS system, please refer 
to the ‘Help’ links on the BioMS webpage to access the on-line user manual, FAQs, and 
training videos.  To report technical problems, such as login issues or application errors, 
please contact: 1-855-55-BIOMS or Bioms@alliancenctn.org.  For assistance in using the 
application or questions or problems related to specific specimen logging, please contact: 1-
855-55-BIOMS or Bioms@alliancenctn.org. 
After logging collected specimens in BioMS, the system will create a shipping manifest.  
This shipping manifest must be printed and placed in the shipment container with the 
specimens. 
All submitted H&E, IHC slides and tumor blocks must be labeled with the protocol 
number (A091304), Alliance patient number, patient’s initials and date and type of 
specimen collected. If you are submitting unstained slides as block alternative, please make 
sure each each slide is labeled with the specimen surgical pathology number and block 
number either via your institution’s standard method for labeling clinical slides or using a 
permanent marker. Please DO NOT use sticky labels.  
A copy of the Shipment Packing Slip produced by BioMS must be printed and placed in the 
shipment with the specimens to both Dr. Remotti’s office and the Alliance biorepository at 
Ohio State University.  
Instructions for the collection of samples are included below. Please be sure to use a method 
of shipping that is secure and traceable. Extreme heat precautions should be taken when 
necessary.  
Shipment on Monday through Thursday by overnight service to assure receipt is 
encouraged. Do not ship specimens on Fridays or Saturdays. 
All representative H&E and IHC slides used locally for diagnosis for pathology review 
including slides representative of stains for the sarcoma subtype involved should be sent to:  
Dr. Fabrizio Remotti 
Department of Pathology VC14-2015 
Columbia University Medical Center 
630 W 168th St, New York, NY 10032 
Tel: 212-342-0419 
Tumor blocks (or up to 20 unstained slides) should be sent to the following address: 
Alliance Biorepository at Ohio State University 
Department of Pathology 
Polaris Innovation Centre 
2001 Polaris Parkway 
Columbus, OH  43240 
Tel: 614-293-7073  Fax: 614-293-7967 
6.2.2 Collection and processing of tissue 
When shipping blocks and /or FFPE slides, it is important to avoid extreme heat. If 
environmental conditions indicate, specimens may be shipped in containers containing cold 
packs. The diagnostic slides must be appropriately packed to prevent damage (e.g. slides 
should be placed in appropriate slide container) and placed in an individual plastic bag. It is 
also important that blocks are shipped in appropriately padded and secure containers to 
avoid physical damage.  Do not wrap blocks or slides in tissue or paper toweling that is in 
direct contact with the paraffin. 

Alliance A091304 
Version Date: 04/03/2019 
38 
Update #09 
The Alliance has instituted special considerations for the small percentage of institutions 
whose policy prohibits long-term storage of blocks, and the smaller percentage of 
institutions whose policies prohibit release of any block. For those instituations, please 
submit 20 unstainded slides (thickness of 4-5 microns) as block alternatives (if the istituton 
does not have 20 slides, please send as many as possible, up to 20). 
The goal of the Alliance is to provide investigators with quality histology sections for their 
research while maintaining the integrity of the tissue. All slides/blocks may be returned with 
written request by the site. 
A de-identified surgical pathology report should be sent with all specimens. Usually, this is 
generated by obscuring all PHI (names and dates) with white-out or a black magic marker, 
labeling each page of the report with the Alliance patient ID, and photocopying the report. 
Central Pathology Review 
Consistent and accurate histologic grading is important for this study. All representative 
H&E and IHC slides including slides representative of stains for the sarcoma subtype 
involved from the diagnostic biopsy must be submitted to Dr. Remotti. Please be aware that 
those slides will not be returned. If slides used locally for diagnosis can’t not be released, 
please make a separate set of slides for this study. The submission should be taken from the 
highest grade area as identified by your local pathologist/investigator. 
In addition to the pathology report, the institution must complete and submit the 
“Central Pathology Review Form” with slides to Dr. Remotti. Failure to submit this 
form with the specimens will delay turnaround time for central pathology review. The 
top portion of the form must be completed by typing and cannot be handwritten. For Alliance 
members, the form may be found on the A091304 study page on the Alliance website under 
the “Supplemental Materials” tab. For non-Alliance institutions, the form can be found 
under “Miscellaneous” documents section of the CTSU A091304 study page 
(www.ctsu.org). 
Tissue Banking 
A FFPE tumor block OR up to 20 unstained tissue slides (thickness of 4-5 microns) of the 
patient’s locally advanced/unresectable and/or metastatic sarcoma of selected subtypes 
diagnosis should be retrieved from the surgical pathology department. Blocks which contain 
minimal amounts of tissue specimen or that are very thin should not be submitted unless the 
block is the only representative tissue for the case.  
7.0 
TREATMENT PLAN/INTERVENTION 
Protocol treatment is to begin ≤ 10 days of registration. For questions regarding treatment, please see 
the study contacts page.  
Administration ≤ +/- 1 day of schedule will not be considered a protocol violation. In addition, 
patients are permitted to have a new cycle of therapy delayed up to 7 days for major life events (e.g., 
serious illness in a family member, major holiday, vacation that cannot be rescheduled) without this 
being considered a protocol violation. Documentation to justify this delay should be provided. 
7.1 
Phase I Description and Treatment Plan 
The Phase I portion of this study will assess safety and tolerability of the new milled dosage of 
MLN0128 (TAK-228). Protocol therapy will consist of MLN0128 (TAK-228) administered 
weekly on days 1, 8, 15, and 22 over a 28 day cycle. MLN0128 (TAK-228) should be taken on 
an empty stomach. A patient medication diary will be used to assess adherence to therapy. 
Patients may remain on treatment until disease progression, unacceptable toxicity, or withdrawal 
of consent. 

Alliance A091304 
Version Date: 04/03/2019 
39 
Update #09 
7.1.1 Phase I- Determination of Maximum Tolerated Dose (MTD) 
Dose Levels 
All patients on the phase I portion of the study will receive MLN0128 (TAK-228). This will 
be a dose-escalation scheme to determine the MTD of MLN0128 (TAK-228). Patients will 
be placed in one of the dose cohorts of MLN0128 (TAK-228) listed below, using a 
conventional 3+3 design. Only the first cycle will be used to determine dose limiting 
toxicity. 
The dose of MLN0128 (TAK-228) will be dictated by the dose cohort to which a patient is 
assigned. Patients will be assigned to a new dose cohort only after it has been determined 
that the MTD has not been exceeded in the previous dose cohort (see section 13.2.2 for 
details).  
 
Table 7.1.1 Phase I Dose Finding Plan 
Dose Level 
MLN0128 (TAK-228) weekly (Days 1, 8, 
15, 22) 
-1 
15mg 
*0 
20 mg 
1 
25 mg 
2 
30 mg 
* Starting dose level 
 
• 
Plan: Three to 6 patients will be treated at each dose level and observed for a 
minimum of 28 days to assess adverse events in cycle 1 before new patients are 
treated. The MTD will be determined by DLTs seen in cycle 1 of therapy (please 
refer to section 13.2.2 for details regarding definition of the MTD and criteria for 
dose level escalation and de-escalation). Please note that if the DLTs are met at dose 
level 0, then dose level -1 will be initiated.  
• 
Intrapatient dose escalation: Intra-patient escalation of dosing is allowed if it has 
been determined that the MTD has not been exceeded for the next dose level, and 
the patient has not required any dose modifications or delays as a result of adverse 
events. Intrapatient escalation will be managed during the toxicity calls, and is only 
allowed if approved by the Alliance study chair and executive officer. 
• 
Missed doses: A dose may be made up as long as it is taken within 24 hours of the 
scheduled dose. For patients who have a missed dose in excess of 24 hours, they 
will be replaced for purposes of the dose finding plan. If they miss doses during 
cycle 2 and beyond, the patients will not be replaced during the phase I portion of 
this study.  
• 
Toxicity calls: Phase I conference calls will be held every other week and are 
mandatory for all sites with a patient registered on the phase I portion of the study. 
These calls will be used to review adverse events, assess study enrollment and 
address any questions that arise over the course of the study. These calls will be 
attended by the study team (Study chair, statistician, executive officer, and protocol 
coordinator). Site staff attendance can be the Principal Investigator, a Co-

Alliance A091304 
Version Date: 04/03/2019 
40 
Update #09 
Investigator or the Study Coordinator responsible for A091304 at that site. In 
addition, a Dose Escalation conference call will be held immediately after a dose 
cohort has completed accrual and all patients have been treated for 28 days (1 cycle). 
All phase I Principal Investigators should participate in these calls. 
7.1.2 Definitions of DLT 
DLTs will be determined during cycle 1 of therapy. Adverse events will be graded per 
CTCAE, version 4.0.  
For this protocol, DLT will be defined by the following adverse events at least possibly 
related to study therapy: 
Grade 3 or higher non-hematologic adverse events, with the following exceptions: 
• 
Alopecia is not expected but is not considered a DLT 
• 
Nausea, vomiting and diarrhea  
• 
Hypokalemia, Hypomagnesemia, Hypophosphatemia 
• 
Hyperglycemia 
• 
Rash 
• 
Fatigue 
Grade 4 hematologic adverse events, with the following exceptions: 
• 
Grade 4 lymphopenia  
• 
Grade 4 neutropenia will only be considered a DLT if it lasts longer than 7 days  
• 
Grade 4 thrombocytopenia will only be considered a DLT if it lasts longer than 7 
days or is associated with a ≥grade 3 bleeding event. 
The maximum tolerated dose is the dose level where at most 1 out of 6 patients treated at 
that dose level report a DLT and the next higher dose level is such that 2 or more patients 
treated at that dose level reported a DLT. 
7.2 
Phase II Description and Treatment Plan 
Patients with locally advanced/unresectable and/or metastatic sarcoma of selected subtypes will 
be randomized in a 1:1 fashion to receive either MLN0128 (TAK-228) at 30 mg weekly  or 
pazopanib. Pazopanib will start at 400mg orally once daily and titrated to tolerance by the 
treating physician. At the day 15 visit of cycle 1 and 2, decisions will be made to escalate the 
pazopanib. For example, at Day 15 of Cycle 1, attempts will be made to escalate the patient to 
600mg once daily based. The patient will be seen again on Day 1 of Cycle 2 for a toxicity check. 
On Day 15 of Cycle 2, reassessment will be made for dose escalation to 800mg. Escalations will 
be in a stepwise fashion of 200mg. If the treating physician decides not to escalate at these times, 
they can use their clinical judgement as to the timing of any escalation or the highest pazopanib 
dose that is clinically safe for the patient to receive. The pazopanib dose will not exceed 800 mg 
orally once daily. 
Pazopanib should be taken without food at least two hours after and one hour before a meal. The 
tablets should be swallowed whole and must not be crushed or broken. The time of day the 
tablets are taken should be relatively constant. For patients receiving a medically necessary 
H2-receptor antagonist, pazopanib should be taken without food at least 2 hours before or at 
least 10 hours after a dose of the H2-receptor antagonist. Pazopanib should be administered at 
least 1 hour before or 2 hours after administration of short acting antacids. 

Alliance A091304 
Version Date: 04/03/2019 
41 
Update #09 
In patients who are randomized to pazopanib, the patient may crossover to MLN0128 (TAK-
228) at time of progression (see Section 4.7). If a patient does crossover, MLN0128 (TAK-228) 
must begin within 6 weeks of the last dose of pazopanib on study. If restaging imaging has not 
been done within 28 days before treatment with MLN0128 (TAK-228), it must be repeated.  
At the time of crossover, pregnancy test must be repeated. Other lab tests and observations will 
be performed per study calendar in Section 5.0. 
Patients will remain on treatment as long as there is no progression of disease, excessive toxicity 
requiring the patient to come off of treatment, or the patient withdraws from treatment.  
 
ARMS 1, 5 and crossover (Arm 3):  
Agent 
Dose & Route 
Frequency 
 Cycle Length (ReRx) 
MLN0128 
(TAK-228) 
30 mg PO 
Weekly 
every 4 weeks 
 
ARM 2 (patients enrolled prior to Update #05): 
Agent 
Dose & Route 
Frequency 
 Cycle Length (ReRx) 
Pazopanib 
800 mg PO 
Once daily 
every 4 weeks 
 
ARM 6 (patients enrolled after Update #05): 
Agent 
Dose & Route 
Frequency 
 Cycle Length (ReRx) 
Pazopanib 
400 mg PO to start, 
with escalations as 
outlined in section 7.2 
Once daily 
every 4 weeks 
7.3 
CYP3A4 Inhibitors 
Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this trial. 
The following drugs are EXAMPLES of strong inhibitors of CYP3A4 and are not allowed 
during treatment with pazopanib. 
• 
Indinavir 
• 
Clarithromycin 
• 
Ketoconazole 
Because lists of these agents are constantly changing, please consult and review any drugs for 
their potential to inhibit CYP3A4. Examples of resources that may be utilized include the 
product information for the individual concomitant drug in question, medical reference texts 
such as the Physicians’ Desk Reference, the FDA and/or IUPUI websites, or your local 
institution’s pharmacist. 
7.4 
CYP3A4 Inducers 
Chronic concomitant treatment with strong inducers of CYP3A4 is not allowed during on this 
trial. The following drugs are EXAMPLES of strong inducers of CYP3A4 and are not allowed 
during treatment with pazopanib. 
• 
Rifampin 
• 
Carbamazepine 
Because lists of these agents are constantly changing, please consult and review any drugs for 
their potential to induce CYP3A4. Examples of resources that may be utilized include the 

Alliance A091304 
Version Date: 04/03/2019 
42 
Update #09 
product information for the individual concomitant drug in question, medical reference texts 
such as the Physicians’ Desk Reference, the FDA and/or IUPUI websites, or your local 
institution’s pharmacist. 
8.0 
DOSE AND TREATMENT MODIFICATIONS 
8.1 
Ancillary therapy, concomitant medications, and supportive care 
8.1.1 Patients should not receive any other agent which would be considered treatment for 
the primary neoplasm or impact the primary endpoint. 
8.1.2 Patients should receive full supportive care while on this study.  This includes blood 
product support, antibiotic treatment, and treatment of other newly diagnosed or concurrent 
medical conditions.  All blood products and concomitant medications such as antidiarrheals, 
analgesics, and/or antiemetics received from the first day of study treatment administration 
until 30 days after the final dose will be recorded in the medical records. 
8.1.3 Treatment with hormones or other chemotherapeutic agents may not be administered 
except for steroids given for adrenal failure; hormones administered for non-disease-related 
conditions (e.g., insulin for diabetes); and intermittent use of dexamethasone as an 
antiemetic in solid tumor protocols. 
8.1.4 Antiemetics may be used at the discretion of the attending physician. If severe emesis or 
mucositis prevents the patient from taking scheduled doses, that dose will be skipped. If 
emesis occurs after study medication ingestion, the dose will not be readministered, and 
patients should resume dosing at the next scheduled time with the prescribed dosage. Patients 
should record the occurrence of the emesis in their dosing diaries. Under no circumstance 
should a patient repeat a dose or double-up doses. 
8.1.5 Diarrhea: This could be managed conservatively with loperamide. The recommended dose 
of loperamide is 4 mg at first onset, followed by 2 mg every 2-4 hours until diarrhea free 
(maximum 16 mg/day). 
In the event of grade 3 or 4 diarrhea, the following supportive measures are allowed:  
hydration, octreotide, and antidiarrheals.   
8.1.6 Palliative radiation therapy may not be administered. Irradiate a symptomatic lesion, or 
one that may produce disability (e.g., unstable femur) prior to study initiation, provided 
other measurable disease is present.  
Patients who require radiation therapy during protocol treatment will be removed from 
protocol therapy due to disease progression. 
8.1.7 Surgery: Patients who require surgery during protocol treatment may proceed as such, 
unless the surgery involves resection of sarcoma. Pazopanib should be held prior to and after 
surgery, for a maximum of 28 days. If the patient requires an interruption of > 28 days, then 
they will be removed from protocol therapy. 
8.1.8 Pneumonitis: Patients with suspected pneumonitis should undergo full evaluation, which 
may include CT scan, PFTs, O2 saturation, bronchoscopy. Treatment may involve steroids, 
at the discretion of the treating physician. 
8.1.9 Alliance Policy Concerning the Use of Growth Factors 
Blood products and growth factors should be utilized as clinically warranted and following 
institutional policies and recommendations.  The use of growth factors should follow 
published guidelines of the American Society of Clinical Oncology 2006 Update of 

Alliance A091304 
Version Date: 04/03/2019 
43 
Update #09 
Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based, 
Clinical Practice Guideline.  J Clin Oncol 24(19): 3187-3205, 2006. 
Epoetin (EPO): Use of epoetin in this protocol is permitted at the discretion of the treating 
physician. 
Filgrastim (G-CSF) and sargramostim (GM-CSF) 
1. Filgrastim (G-CSF)/pegfilgrastim and sargramostim (GM-CSF) treatment for patients 
on protocols that do not specify their use is discouraged. 
2. Filgrastim/pegfilgrastim and sargramostim may not be used: 
a. To avoid dose reductions, delays or to allow for dose escalations specified in the 
protocol. 
b. For the treatment of febrile neutropenia the use of CSFs should not be routinely 
instituted as an adjunct to appropriate antibiotic therapy. However, the use of CSFs 
may be indicated in patients who have prognostic factors that are predictive of 
clinical deterioration such as pneumonia, hypotension, multi-organ dysfunction 
(sepsis syndrome) or fungal infection, as per the ASCO guidelines.  Investigators 
should therefore use their own discretion in using the CSFs in this setting.  The use 
of CSF (filgrastim/pegfilgrastim or sargramostim) must be documented. 
c. If filgrastim/pegfilgrastim or sargramostim are used, they must be obtained from 
commercial sources. 
8.1.10 Hyperglycemia:  
Phase I 
Most episodes of hyperglycemia occur within the first 60 days after initiation of treatment 
with TAK-228. Patients developing hyperglycemia during the study should have their 
glucose closely monitored, at a frequency that is at the discretion of the treating physician. 
With ≥Grade 2 hyperglycemia it is recommended to treat with oral hypoglycemic agents 
and/or insulin. The investigator should consult an endocrinologist, if needed. Oral 
sulfonylureas (eg, glipizide or glyburide) should be used with caution, due to the higher risk 
of inducing hypoglycemia in patients. 
Phase II 
Management of Hyperglycemia 
On the basis of the clinical experience in TAK-228 trials, most episodes of hyperglycemia 
observed occurred within the first 60 days after initiation of treatment with TAK-228 and 
have been either Grade 1 or Grade 2, and have responded quickly to oral metformin. 
Hyperglycemia has not been dose-limiting since the institution of a standard regimen for 
early treatment of hyperglycemia.  
All patients developing hyperglycemia during the study should have their glucose closely 
monitored by study staff. The investigator may choose to continue close monitoring of 
patients who develop Grade 1 hyperglycemia (fasting glucose >ULN ≤160 mg/dL) or, 
alternatively, consider initiating treatment with an oral hypoglycemic agent, such as 
metformin. All patients with ≥Grade 2 hyperglycemia (fasting glucose >160 mg/dL) must 
be treated aggressively with oral hypoglycemic agents and/or insulin as clinically indicated. 
The investigator should consult an endocrinologist, if needed, to aid in optimizing the 
patient’s hyperglycemia treatment plan. 
It is recommended that patients with elevated fasting blood glucose be initially treated with 
a fast acting insulin sensitizer such as metformin at 500 mg orally QD, and titrate up to a 
maximum of 1000 mg orally BID as needed. Concurrent addition to metformin of DPP-4 

Alliance A091304 
Version Date: 04/03/2019 
44 
Update #09 
inhibitors (eg, sitagliptin or vildagliptin) and/or insulin should also be considered. Oral 
sulfonylureas (eg, glipizide or glyburide) should be used with caution, due to the higher risk 
of inducing hypoglycemia in patients. The dose of oral hypoglycemic agents should be 
adjusted in patients with renal insufficiency. In addition, patients should be encouraged to 
follow a low carbohydrate diet once hyperglycemia is first observed. 
If any fasting serum glucose reading performed at the site indicates hyperglycemia (>ULN 
or ≥110 mg/dL), the study staff should first confirm that the patient was fasting at the time 
of blood specimen collection (ie, nothing by mouth for at least 8 hours before collection). 
 
In-Home Daily Fasting Glucose Monitoring 
In addition to obtaining fasting glucose levels at the clinic visits as outlined in the study 
calendar (Section 5.0), all patients randomized to receive MLN0128/TAK-228 will be given 
a glucometer to monitor their daily FBG levels at home. The level should be collected daily, 
predose on dosing days, and at approximately the same time each day. The glucometer 
reimbursement form can be found under Supplemental Materials (on the Alliance web site) 
and under MISC (on the CTSTU web site).  
On Cycle 1 Day 1, the patient will be provided an in-home glucometer. Patients should be 
trained on proper use of the glucometer and instructed to collect a daily FBG level every 
morning (predose on dosing days), starting on Cycle 1 Day 2. Patients will be instructed to 
bring the glucometer with them to each study visit so that the data collected can be reviewed 
and recorded in the source documents. Investigators will be responsible for reviewing the 
home glucose monitoring logs for hyperglycemia. 
The patient will be instructed to contact their physician immediately if the value is abnormal 
(ie, ≥150 mg/dL) for further instructions on the management of their hyperglycemia. 
Hyperglycemia observed during home glucose monitoring should be confirmed in the clinic. 
If no irregularities in the fasting blood glucose level are observed during a minimum of 2 
consecutive months, then the frequency of in-home fasting blood glucose testing can be 
reduced to a minimum frequency of once weekly, depending on the investigator’s judgment 
and approval. Patients will continue to notify the investigator of fasting blood glucose levels 
that exceed 150 mg/dL and, if blood glucose levels are not well controlled, or if the patient 
requires either oral hypoglycemic agents or insulin to control blood glucose levels, then the 
frequency of in-home testing of FBG levels will be reinstated to daily. 

Alliance A091304 
Version Date: 04/03/2019 
45 
Update #09 
8.2 
Dose Modifications 
8.2.1 General Rules 
• 
If multiple adverse events are seen, administer dose based on greatest reduction required for 
any single adverse event observed. 
• 
Reductions or increases apply to treatment given in the preceding cycle and are based on 
adverse events observed since the prior dose. 
• 
MLN0128 (TAK-228) or pazopanib will not be re-escalated once reduced. 
• 
If dose reduction beyond dose level -2  for MLN0128 (TAK-228) is required or MLN0128 
(TAK-228) or pazopanib is held for 4 weeks, MLN0128 (TAK-228) or pazopanib will be 
discontinued. 
• 
Descriptors below utilize CTCAE version 4.03. AERs reporting may be required for some 
adverse events (See Section 9.0). 
• 
Dose reductions for pazopanib are based on the criteria listed in section 8.2.5. Dose 
reductions for pazopanib will be made in 200mg increments. Patients cannot be dose 
reduced below 200mg of pazopanib, therefore three dose reductions are allowed for patients 
receiving 800mg of pazopanib, two dose reductions for patients receiving 600mg, and only 
one dose reduction for patients receiving 400mg. Patients must come off study if a dose 
reduction is required at 200mg. 
8.2.2 Dose Modification Levels for Phase I 
Please note that the MLN0128 (TAK-228) starting dose in the phase I portion of the protocol 
will be dictated by the dose level to which the patient is assigned. 
Dose Level 
Drug Name 
Dose (weekly) 
Dose (weekly) 
Dose (weekly) 
Dose (weekly) 
0* 
 
MLN0128 
(TAK-228) 
15mg 
20. mg 
25 mg 
30 mg 
-1 
 
MLN0128 
(TAK-228) 
10mg 
15 mg 
20 mg 
20 mg 
-2 
 
MLN0128 
(TAK-228) 
8mg 
10 mg 
15 mg 
15 mg 
*Dose level 0 refers to the starting dose in the dose cohort to which the patient has been assigned. 
8.2.3 Dose Modification Levels for Phase II 
Arms 1, 5, and Crossover (Arm 3) 
Dose 
Level 
Drug Name 
Dose (weekly) 
 0* 
 
MLN0128 (TAK-228) 
30mg weekly 
-1 
 
MLN0128 (TAK-228) 
20mg weekly 
-2 
 
MLN0128 (TAK-228) 
15mg weekly 
*Dose level 0 refers to the starting dose. 
 
 
 
 

Alliance A091304 
Version Date: 04/03/2019 
46 
Update #09 
Arm 2 (patients enrolled prior to Update #05) 
 
Dose 
Level 
Drug Name 
Dose (daily) 
0* 
 
Pazopanib 
800mg once daily 
-1  
 
Pazopanib 
600mg once daily 
-2 
 
Pazopanib 
400mg once daily 
-3 
Pazopanib 
200mg once daily 
*Dose level 0 refers to the starting dose. 
 
Arm 6 (patients enrolled after Update #05) 
 
Dose 
Level 
Drug Name 
Dose (daily) 
+2 
 
Pazopanib 
800mg once daily 
+1 
 
Pazopanib 
600mg once daily 
0* 
 
Pazopanib 
400mg once daily 
-1 
Pazopanib  
200 mg once daily 
*Dose level 0 refers to the starting dose. 
 
8.2.4 MLN0128 (TAK-228) 
Hematologic Toxicities 
Grade ≥3 neutropenia, thrombocytopenia, or neutropenic fever: Delay MLN0128 
(TAK-228) until ≤ grade 2, then resume with one dose level reduction of MLN0128 
(TAK-228) for all subsequent doses. 
Gastrointestinal Toxicities 
• 
Grade ≥ 3 diarrhea: Delay MLN0128 (TAK-228) until diarrhea improves to ≤ 
grade 2, then resume MLN0128 (TAK-228) with one dose level reduction. 
• 
Grade ≥ 3 nausea or vomiting: Delay MLN0128 (TAK-228) until 
nausea/vomiting improves to ≤ grade 2, then resume MLN0128 (TAK-228) at same 
dose 
• 
Grade 3 stomatitis: Delay MLN0128 (TAK-228) until ≤ grade 1 then resume with 
one dose level reduced. 
• 
Grade 4 stomatitis: Discontinue MLN0128 (TAK-228)  
Skin Toxicity 
• 
Grade 3 or 4 Acneiform Rash: Delay MLN0128 (TAK-228) until grade ≤ 2, then 
restart at one dose level decreased 

Alliance A091304 
Version Date: 04/03/2019 
47 
Update #09 
• 
Grade 3 Maculopapular Rash: Delay MLN0128 (TAK-228) until grade ≤ 2, then 
restart at one dose level decreased 
Pulmonary Toxicity 
• 
Grade 2 or 3 pneumonitis: Delay MLN0128 (TAK-228) until ≤ grade 1, then 
resume MLN0128 (TAK-228) at one dose level decreased. For recurrent grade 3 
pneumonitis, discontinue TAK-228. 
• 
Grade 4 pneumonitis: Discontinue MLN0128 (TAK-228) 
Renal Toxicity 
• 
Grade 2 increased creatinine: Delay MLN0128 (TAK-228) until grade ≤ 1, then 
resume with one dose level decreased  
• 
Grade 3 and 4 increased creatinine: Discontinue MLN0128 (TAK-228) 
Metabolism 
• 
Grade 3 Hyperglycemia: Delay MLN0128 (TAK-228) until grade ≤ 2, then 
resume at same dose 
• 
Grade 4 Hyperglycemia: Discontinue MLN0128 (TAK-228) 
Cardiac Toxicity  
• 
For grade 3 ECG QTc interval prolonged, delay MLN0128 (TAK-228) until 
grade ≤ 1, then resume MLN0128 (TAK-228) with one dose level reduction 
• 
For grade 4 ECG QTc interval prolonged, discontinue MLN0128 (TAK-228) 
General Disorders 
• 
Grade 3 Edema: Delay MLN0128 (TAK-228) until ≤ grade 2, then resume at one 
dose level decreased 
Other Non-hematologic Toxicities 
For other clinically significant grade 3/4 non-hematologic toxicities likely related to 
MLN0128 (TAK-228), delay MLN0128 (TAK-228). Resume MLN0128 (TAK-228) at 
1 dose level reduced when the toxicity resolves to a clinically acceptable level (grade 
1/2). 
 
8.2.5 Pazopanib 
Hematologic toxicity  
• 
For grade 3 ANC on Day 1 of a cycle: Delay pazopanib until ≤ grade 2, then 
resume pazopanib at the previous dose level.  
• 
For grade 4 ANC on Day 1 of a cycle: Delay pazopanib until ≤ grade 2, then 
resume pazopanib with one dose level reduction.  
• 
For grade 3 or 4 ANC decreased during a cycle omit pazopanib until ANC 
improves to ≤ grade 2, then resume pazopanib with one dose level reduction.  
• 
Febrile neutropenia: Delay pazopanib until toxicity resolves and ANC ≤ grade 2, 
then resume pazopanib with one dose level reduction.  
• 
For grade 3 or 4 thrombocytopenia: Delay pazopanib until platelets ≤ grade 1, 
then resume pazopanib with one dose level reduction.  

Alliance A091304 
Version Date: 04/03/2019 
48 
Update #09 
Hepatic Toxicity  
• 
For grade 2 ALT, AST, or bilirubin, continue pazopanib, but monitor weekly 
until ALT, AST, and bilirubin return to ≤ grade 1.  
• 
For grade 3 or 4 ALT, AST, or Bilirubin, delay pazopanib. Restart treatment with 
one dose level reduction of pazopanib when AST, ALT and bilirubin improve to ≤ 
grade 1.  
• 
For grade ≥ 2 ALT/AST AND concurrent grade ≥ 2 bilirubin, discontinue 
pazopanib.  
• 
For ≥ grade 3 hepatic failure, discontinue pazopanib.  
• 
For any AST/ALT elevation occurring in a patient receiving simvastatin, 
discontinue simvastatin and follow the appropriate dose modification for pazopanib.  
Proteinuria   
• 
For UPC Ratio ≥ 2.0 and < 3.0 or urine protein ≥ 2.0 g/24 hours and < 3.0, hold 
pazopanib until proteinuria resolves to UPC < 2.0 or urine protein < 2.0 g/24 hours, 
then resume pazopanib at current dose level.  
• 
For UPC Ratio ≥ 3.0 and < 4.0 or urine protein ≥ 3.0 g/24 hours and < 4.0, hold 
pazopanib until proteinuria resolves to UPC < 2.0 or urine protein <2.0 g/24 hours. 
Once resolved, resume pazopanib with one dose level reduced.  
• 
For UPC Ratio ≥ 4.0 or Nephrotic Syndrome: Discontinue pazopanib. 
Nephrotoxicity  
• 
For grade 2 creatinine increased, delay pazopanib until toxicity resolves to ≤ 
grade 1, then resume pazopanib with one dose level reduction.  
• 
For grade 3 or 4 creatinine increased, discontinue pazopanib.  
Cardiac Toxicity  
• 
For grade 3 ECG QTc interval prolonged, delay pazopanib until grade ≤ 1, then 
resume pazopanib with one dose level reduction 
• 
For grade 4 ECG QTc interval prolonged, discontinue pazopanib 
Thrombosis  
• 
For grade 2 or 3 venous thrombosis requiring anticoagulation, delay pazopanib. 
If the planned duration of full dose anticoagulation is ≤ 2 weeks, omit pazopanib 
until anticoagulation is completed, then resume pazopanib at same dose. If the 
planned duration of full dose anticoagulation is > 2 weeks, pazopanib may be 
restarted at same dose during anticoagulation if all of the following are met:  
- 
The patient must have an in-range INR (usually between 2 and 3) on a stable 
dose of warfarin or be on a stable dose of LMWH prior to restarting 
pazopanib.  
- 
The patient must not have any pathological condition that carries a high risk 
of bleeding.  
- 
The patient must not have had any hemorrhagic events while on study.  
• 
For recurrent/worsening venous thromboembolic events after resumption of 
pazopanib, discontinue pazopanib.  
• 
For grade 4 venous thromboembolic events, discontinue pazopanib.  

Alliance A091304 
Version Date: 04/03/2019 
49 
Update #09 
• 
For arterial thromboembolic events (any grade) including cerebrovascular 
ischemia, cardiac ischemia/infarction, peripheral or visceral arterial ischemia, 
discontinue pazopanib.  
Hypertension  
• 
For persistent Grade 3 hypertension (Systolic ≥ 160 Diastolic ≥ 100): Hold 
pazopanib until grade ≤ 2, then resume pazopanib at1 dose level reduction. 
HOWEVER, if the patient requires hospitalization for management of symptomatic 
systolic BP > 180 or diastolic BP > 110, permanently discontinue pazopanib.  
• 
Grade 4 Hypertension (life-threatening consequences of hypertension): 
Permanently discontinue pazopanib.  
NOTE: Stopping or reducing the dose of pazopanib is expected to cause a decrease 
in BP. The treating physician should monitor for hypotension and adjust the number 
and dose of antihypertensive medication(s) accordingly. 
Reversible Posterior Leukoencephalopathy Syndrome (RPLS)   
For signs and symptoms suggestive of RPLS, delay pazopanib. If RPLS is 
confirmed by MRI, discontinue pazopanib. If RPLS is ruled out via MRI, the 
decision to resume pazopanib should be based on symptoms: for grade ≥ 2 RPLS 
considered ≥ possibly related to pazopanib, discontinue pazopanib.  
Hemorrhage  
• 
For grade 2 CNS or pulmonary hemorrhage, discontinue pazopanib.  
• 
For non-CNS, non-pulmonary grade 2 bleeding, delay pazopanib until resolved 
to ≤ grade 1, then resume at 1 dose level reduced. 
• 
For any grade 3 or 4 hemorrhage, discontinue pazopanib.  
Fistula, perforations, bowel obstruction or wound dehiscence  
• 
For any grade perforation of any organ, GI leak, or any fistula, discontinue 
pazopanib.  
• 
For any grade bowel obstruction requiring medical intervention, delay 
pazopanib until obstruction resolves completely, then resume pazopanib at the 
previous dose. For obstruction requiring surgery delay pazopanib until full recovery 
from surgery, then resume pazopanib at the previous dose. Also see Section 8.1.7 
• 
For wound dehiscence requiring medical or surgical intervention discontinue 
pazopanib.  
Thyroid Dysfunction  
For grade 3 or 4 hyper-or hypothyroidism, discontinue pazopanib.  
Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura  
For any grade of hemolytic uremic syndrome (thrombotic microangiopathy) or 
thrombotic thrombocytopenic purpura, discontinue pazopanib.  
Other Non-Hematologic Grade 3 or 4 Toxicity  
For other grade 3 or 4 non-hematologic toxicity not described above, (excluding 
nausea, vomiting, and diarrhea; unless refractory to anti-emetics and/or anti-
diarrheals) and considered at least possibly related to treatment, delay pazopanib 
treatment until toxicity improves to ≤ grade 1, then resume treatment with one dose 
level reduction. 

Alliance A091304 
Version Date: 04/03/2019 
50 
Update #09 
9.0 
ADVERSE EVENTS 
The prompt reporting of adverse events is the responsibility of each investigator engaged in clinical 
research, as required by Federal Regulations. Adverse events must be described and graded using the 
terminology and grading categories defined in the NCI’s Common Terminology Criteria for Adverse 
Events (CTCAE), Version 4.0. However, CTCAE v5.0 must be used for serious AE reporting 
through 
CTEP-AERS 
as 
of 
April 
1, 
2018. 
The 
CTCAE 
is 
available 
at 
ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
Attribution 
to 
protocol 
treatment for each adverse event must be determined by the investigator and reported on the required 
forms, using the codes provided. 
9.1 
Routine adverse event reporting 
Adverse event data collection and reporting, which are required as part of every clinical trial are 
done to ensure the safety of patients enrolled in the studies as well as those who will enroll in 
future studies using similar agents. Adverse events are reported in a routine manner at scheduled 
times according to the study calendar in Section 5.0. For this trial, “Adverse Events: Baseline” 
and “Adverse Events: Solicited” will be used for routine AE reporting in Rave. 
Solicited Adverse Events: The following adverse events are considered "expected" and their 
presence/absence should be solicited, and severity graded, at baseline and for each cycle of 
treatment. 
 
CTCAE v4.0 Term 
CTCAE v4.0 System Organ Class (SOC) 
Rash maculo-papular 
Skin and subcutaneous tissue disorders 
Hyperglycemia 
Metabolism and nutrition disorders 
Anorexia 
Metabolism and nutrition disorders 
Diarrhea 
Gastrointestinal disorders 
Mucositis oral 
Gastrointestinal disorders 
Fatigue 
General Disorders and Administration 
Site Conditions 
Neutrophil count decreased 
Blood and Lymphatic System Disorders 
Platelet count decreased 
Blood and Lymphatic System Disorders 
Electrocardiogram QT corrected interval 
prolonged 
Cardiac Disorders 
Hypertension 
Vascular Disorders 
9.2 
CTCAE Routine Study Reporting Requirements  
In addition to the solicited adverse events listed in Section 9.1, the following table outlines the 
combinations of time points, grades and attributions of AEs that require routine reporting to the 
Alliance Statistics and Data Center. Questions about routine reporting should be directed to the 
Data Manager. 
*Combinations of CTCAE Grade & Attribution Required for Routine AE Data 
Submission on Case Report Forms (CRFs) 

Alliance A091304 
Version Date: 04/03/2019 
51 
Update #09 
 
Attribution 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Grade 5 
Unrelated 
 
 
a 
a 
a 
Unlikely 
 
 
a 
a 
a 
Possible 
a 
a 
a, b 
a, b 
a, b 
Probable 
a 
a 
a, b 
a, b 
a, b 
Definite 
a 
a 
a, b 
a, b 
a, b 
a) Adverse Events: Other CRF - Applies to AEs occurring between registration and 
within 30 days of the patient’s last treatment date, or as part of the Clinical Follow-Up 
Phase. 
b) Adverse Events: Late CRF - Applies to AEs occurring greater than 30 days after the 
patient’s last treatment date and applies to Grade 3-5 events considered at least possibly 
related to study treatment. 
9.3 
Expedited Adverse event reporting (CTEP-AERS) 
Investigators are required by Federal Regulations to report serious adverse events as defined in 
the table below. Alliance investigators are required to notify the Investigational Drug Branch 
(IDB), the Alliance Central Protocol Operations Program, the Study Chair, and their Institutional 
Review Board if a patient has a reportable serious adverse event. The descriptions and grading 
scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) 
version 5.0 will be utilized for AE reporting beginning April 1, 2018. All appropriate treatment 
areas should have access to a copy of the CTCAE version 5.0. A copy of the CTCAE version 
5.0 
can 
be 
downloaded 
from 
the 
CTEP 
web 
site 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
All 
reactions 
determined to be “reportable” in an expedited manner must be reported using the Cancer 
Therapy Evaluation Program Adverse Event Reporting System (CTEP-AERS). 
Note:  All deaths on study require both routine and expedited reporting regardless of 
causality.  Attribution to treatment or other cause should be provided. 
9.3.1 Late Phase 2 and Phase 3 Studies:  Expedited Reporting Requirements for Adverse Events 
that Occur on Studies under an IND/IDE ≤ 30 Days of the Last Administration of the 
Investigational Agent/Intervention 1, 2 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312) 
NOTE:  Investigators MUST immediately report to the sponsor (NCI) ANY Serious Adverse Events, 
whether or not they are considered related to the investigational agent(s)/intervention (21 CFR 
312.64) 
 An adverse event is considered serious if it results in ANY of the following outcomes:   
1) Death 
2) A life-threatening adverse event  
3) An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization 
for ≥ 24 hours  
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based upon medical judgment, they may jeopardize 
the patient or subject and may require medical or surgical intervention to prevent one of the 

Alliance A091304 
Version Date: 04/03/2019 
52 
Update #09 
outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6). 
ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the 
NCI via CTEP-AERS within the timeframes detailed in the table below. 
Hospitalization 
• 
Grade 1 
Timeframes 
• 
Grade 2 
Timeframes 
• 
Grade 3 
Timeframes 
• 
Grade 4 & 5 
Timeframes 
Resulting in 
Hospitalization ≥ 24 hrs 
10 Calendar Days 
24-Hour; 
5 Calendar Days 
Not resulting in 
Hospitalization ≥ 24 hrs 
Not required 
10 Calendar 
Days 
NOTE:  Protocol specific exceptions to expedited reporting of serious adverse events are found in 
the Specific Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR 
Expedited AE reporting timelines are defined as: 
o “24-Hour; 5 Calendar Days” - The AE must initially be reported via CTEP-AERS ≤ 24 hours 
of learning of the AE, followed by a complete expedited report ≤ 5 calendar days of the 
initial 24-hour report. 
o “10 Calendar Days” - A complete expedited report on the AE must be submitted ≤ 10 
calendar days of learning of the AE. 
1 Serious adverse events that occur more than 30 days after the last administration of investigational 
agent/intervention and have an attribution of possible, probable, or definite require reporting as 
follows:  
Expedited 24-hour notification followed by complete report ≤ 5 calendar days for: 
• 
All Grade 4, and Grade 5 AEs  
Expedited 10 calendar day reports for: 
• 
Grade 2 adverse events resulting in hospitalization or prolongation of hospitalization  
• 
Grade 3 adverse events 
2 For studies using PET or SPECT IND agents, the AE reporting period is limited to 10 radioactive 
half lives, rounded UP to the nearest whole day, after the agent/intervention was last administered.  
Footnote “1” above applies after this reporting period. 
 
• 
Expedited AE reporting timelines defined: 
➢ “24 hours; 5 calendar days” – The investigator must initially report the AE via CTEP-AERS 
≤ 24 hours of learning of the event followed by a complete CTEP-AERS report ≤ 5 calendar 
days of the initial 24-hour report. 
➢ “10 calendar days” - A complete CTEP-AERS report on the AE must be submitted ≤ 10 
calendar days of the investigator learning of the event.  
• 
Any medical event equivalent to CTCAE grade 3, 4, or 5 that precipitates hospitalization (or 
prolongation of existing hospitalization) must be reported regardless of attribution and 
designation as expected or unexpected with the exception of any events identified as protocol-
specific expedited adverse event reporting exclusions (see below). 
• 
Any event that results in persistent or significant disabilities/incapacities, congenital anomalies, 
or birth defects must be reported via CTEP-AERS if the event occurs following treatment with 
an agent under a CTEP IND. 

Alliance A091304 
Version Date: 04/03/2019 
53 
Update #09 
• 
Use the NCI protocol number and the protocol-specific patient ID provided during trial 
registration on all reports. 
Additional Instructions or Exclusion to CTEP-AERS Expedited Reporting Requirements for 
Phase 2 and 3 Trials Utilizing an Agent Under a CTEP IND or non-CTEP IND: 
• 
All adverse events reported via CTEP-AERS (i.e., serious adverse events) should also be 
forwarded to your local IRB. 
• 
Alliance A091304 uses a drug under a CTEP IND. The reporting requirements for investigational 
agents under a CTEP IND should be followed for all agents (any arm) in this trial. 
• 
Grade 3/4 hematosuppression and hospitalization resulting from such do not require CTEP-
AERS, but should be submitted as part of study results. All other grade 3, 4, or 5 adverse events 
that precipitate hospitalization or prolong an existing hospitalization must be reported via CTEP-
AERS. 
• 
The AML/MDS Secondary Reporting form is no longer available on the CTEP website.  In lieu 
of this form, AML/MDS events are now to be reported. 
• 
Treatment expected adverse events include those listed in the package insert and in the CAEPR 
for pazopanib. Note that the ASAEL column of the CAEPR has been replaced with the Specific 
Protocol Exceptions to Expedited Reporting (SPEER) column. The SPEER includes “expected” 
severity grades in addition to event terms. Events listed in the SPEER only require expedited 
reporting if the severity grade is above the grade noted in SPEER. 
• 
CTEP-AERS reports should be submitted electronically. 
• 
When submitting CTEP-AERS reports for “Pregnancy”, “Pregnancy loss”, or “Neonatal loss”, 
the Pregnancy Information Form should be completed and submitted, along with any additional 
medical information (form is available on the CTEP website at http://ctep.cancer.gov/). The 
potential risk of exposure of the fetus to the investigational agent(s) or chemotherapy agent(s) 
should be documented in the “Description of Event” section of the CTEP-AERS report. 
• 
Death due to progressive disease should be reported as Grade 5 “Disease progression” 
in the system organ class (SOC) “General disorders and administration site conditions.” 
Evidence that the death was a manifestation of underlying disease (e.g., radiological 
changes suggesting tumor growth or progression: clinical deterioration associated with 
a disease process) should be submitted.  
• 
Any death occurring within 30 days of the last dose, regardless of attribution to the 
investigational agent/intervention requires expedited reporting within 24 hours. 
• 
Any death occurring greater than 30 days after the last dose of the investigational 
agent/intervention requires expedited reporting within 24 hours only if it is possibly, probably, 
or definitely related to the investigational agent/intervention. 
• 
Pregnancy loss is defined in CTCAE as “Death in utero.” Any Pregnancy loss should be 
reported expeditiously, as Grade 4 “Pregnancy loss” under the Pregnancy, puerperium and 
perinatal conditions SOC. A Pregnancy loss should NOT be reported as a Grade 5 event under 
the Pregnancy, puerperium and perinatal conditions SOC, as currently CTEP-AERS recognizes 
this event as a patient death. 
• 
A neonatal death should be reported expeditiously as Grade 4, “Death neonatal” under the 
General disorders and administration SOC. 
 
9.4 
CAEPRs  
9.4.1 Comprehensive Adverse Events and Potential Risks list (CAEPR) for Pazopanib 
(GW786034, NSC 737754) 

Alliance A091304 
Version Date: 04/03/2019 
54 
Update #09 
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list 
of reported and/or potential adverse events (AE) associated with an agent using a uniform 
presentation of events by body system. In addition to the comprehensive list, a subset, the 
Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate 
column and is identified with bold and italicized text. This subset of AEs (SPEER) is a list 
of events that are protocol specific exceptions to expedited reporting to NCI (except as noted 
below).  Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf 
for further clarification. Frequency is provided based on 2383 patients. Below is the CAEPR 
for Pazopanib (GW786034) 
NOTE: Report AEs on the SPEER ONLY IF they exceed the grade noted in parentheses 
next to the AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple 
investigational agents and has an AE listed on different SPEERs, use the lower of the grades 
to determine if expedited reporting is required. 
Version 2.8, January 31, 20191 
 
 Adverse Events with Possible  
 Relationship to Pazopanib (GW786034) 
 (CTCAE 5.0 Term) 
[n= 2383] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
  
BLOOD AND LYMPHATIC SYSTEM DISORDERS 
  
 
Anemia 
 
 Anemia (Gr 3) 
 
 
Hemolytic uremic syndrome2 
  
 
 
Thrombotic thrombocytopenic 
purpura 
  
CARDIAC DISORDERS 
  
 
 
Cardiac disorders - Other 
(Torsades de Pointes) 
  
 
 
Heart failure 
  
 
 
Left ventricular systolic 
dysfunction 
  
 
 
Myocardial infarction 
  
 
Sinus bradycardia 
 
  
ENDOCRINE DISORDERS 
  
 
Hypothyroidism 
 
  
EYE DISORDERS 
  
 
 
Eye disorders - Other (eye 
hemorrhage, retinal 
hemorrhage) 
  
GASTROINTESTINAL DISORDERS 
  
 
Abdominal pain 
 
 Abdominal pain (Gr 3) 
 
Constipation 
 
 Constipation (Gr 2) 
Diarrhea 
 
 
 Diarrhea (Gr 3) 
 
Dyspepsia 
 
  
 
 
Gastrointestinal fistula3 
 Gastrointestinal fistula3 (Gr 2) 
 
 
Gastrointestinal hemorrhage4 
  
 
 
Gastrointestinal perforation5 
 Gastrointestinal perforation5 (Gr 2) 
 
Mucositis oral 
 
  
Nausea 
 
 
 Nausea (Gr 3) 
Vomiting 
 
 
 Vomiting (Gr 3) 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS 
  

Alliance A091304 
Version Date: 04/03/2019 
55 
Update #09 
 
 Adverse Events with Possible  
 Relationship to Pazopanib (GW786034) 
 (CTCAE 5.0 Term) 
[n= 2383] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
  
 
Edema limbs 
 
  
Fatigue 
 
 
 Fatigue (Gr 3) 
 
Fever 
 
  
HEPATOBILIARY DISORDERS 
  
 
 
Hepatic failure 
  
INFECTIONS AND INFESTATIONS 
  
 
 
Infection6 
  
INVESTIGATIONS 
  
 
Activated partial thromboplastin 
time prolonged 
 
  
Alanine aminotransferase increased  
 
 Alanine aminotransferase increased 
(Gr 4) 
 
Alkaline phosphatase increased 
 
 Alkaline phosphatase increased (Gr 
3) 
Aspartate aminotransferase 
increased 
 
 
 Aspartate aminotransferase 
increased (Gr 3) 
Blood bilirubin increased 
 
 
 Blood bilirubin increased 
(Gr 3) 
 
Creatinine increased 
 
 Creatinine increased (Gr 2) 
 
 
Ejection fraction decreased 
  
 
 
Electrocardiogram QT corrected 
interval prolonged 
  
Lymphocyte count decreased 
 
 
 Lymphocyte count decreased (Gr 4) 
Neutrophil count decreased 
 
 
 Neutrophil count decreased (Gr 4) 
Platelet count decreased 
 
 
 Platelet count decreased  
(Gr 4) 
 
Weight loss 
 
 Weight loss (Gr 2) 
White blood cell decreased 
 
 
 White blood cell decreased (Gr 3) 
METABOLISM AND NUTRITION DISORDERS 
  
Anorexia 
 
 
 Anorexia (Gr 2) 
 
Dehydration 
 
 Dehydration (Gr 3) 
 
Hypercalcemia 
 
  
Hyperglycemia 
 
 
 Hyperglycemia (Gr 2) 
 
Hyperkalemia 
 
 Hyperkalemia (Gr 2) 
 
Hypermagnesemia 
 
  
 
Hypernatremia 
 
  
 
Hypoalbuminemia 
 
 Hypoalbuminemia (Gr 2) 
 
Hypocalcemia 
 
 Hypocalcemia (Gr 3) 
 
Hypoglycemia 
 
 Hypoglycemia (Gr 2) 
 
Hypokalemia 
 
  
 
Hypomagnesemia 
 
  
Hyponatremia 
 
 
 Hyponatremia (Gr 3) 
 
Hypophosphatemia 
 
 Hypophosphatemia (Gr 3) 
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS 
  
 
Arthralgia 
 
 Arthralgia (Gr 2) 
 
Back pain 
 
  
 
Myalgia 
 
 Myalgia (Gr 2) 
 
Pain in extremity 
 
  

Alliance A091304 
Version Date: 04/03/2019 
56 
Update #09 
 
 Adverse Events with Possible  
 Relationship to Pazopanib (GW786034) 
 (CTCAE 5.0 Term) 
[n= 2383] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
  
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)   
 
Tumor pain 
 
  
NERVOUS SYSTEM DISORDERS 
  
 
Dizziness 
 
 Dizziness (Gr 2) 
 
Dysgeusia 
 
 Dysgeusia (Gr 2) 
 
Headache 
 
 Headache (Gr 2) 
 
 
Intracranial hemorrhage 
  
 
 
Reversible posterior 
leukoencephalopathy syndrome 
  
RENAL AND URINARY DISORDERS 
  
 
 
Acute kidney injury 
  
 
 
Hematuria 
  
 
Proteinuria 
 
 Proteinuria (Gr 2) 
 
 
Urinary fistula 
 Urinary fistula (Gr 2) 
REPRODUCTIVE SYSTEM AND BREAST DISORDERS 
  
 
 
Reproductive system and breast 
disorders - Other (female 
genital tract fistula) 
 Reproductive system and breast 
disorders - Other (female genital 
tract fistula) (Gr 2) 
 
 
Uterine fistula 
 Uterine fistula (Gr 2) 
 
 
Vaginal fistula 
 Vaginal fistula (Gr 2) 
 
 
Vaginal hemorrhage 
  
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS 
  
 
Cough 
 
  
 
Dyspnea 
 
  
 
Respiratory hemorrhage7 
 
 Respiratory hemorrhage7 (Gr 2) 
 
 
Respiratory, thoracic and 
mediastinal disorders - Other 
(interstitial lung disease)8  
  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS 
  
 
Alopecia 
 
 Alopecia (Gr 2) 
Hair color changes 
 
 
 Hair color changes (Gr 2) 
 
Palmar-plantar erythrodysesthesia 
syndrome 
 
  
 
Rash maculo-papular 
 
 Rash maculo-papular (Gr 2) 
 
Skin hypopigmentation 
 
 Skin hypopigmentation (Gr 2) 
VASCULAR DISORDERS 
  
 
 
Arterial thromboembolism9 
  
Hypertension 
 
 
 Hypertension (Gr 3) 
 
 
Thromboembolic event9 
  
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision.  The current version can be obtained by 
contactingPIO@CTEP.NCI.NIH.GOV. Your name, the name of the investigator, the protocol and the 
agent should be included in the e-mail.  
 
2Thrombotic microangiopathy (TMA) which includes both Hemolytic uremic syndrome (HUS) and 
Thrombotic thrombocytopenic purpura (TTP) has been reported in clinical trials of GW786034. 

Alliance A091304 
Version Date: 04/03/2019 
57 
Update #09 
 
3Gastrointestinal fistula includes Anal fistula, Colonic fistula, Duodenal fistula, Enterovesical fistula, 
Esophageal fistula, Gastric fistula, Gastrointestinal fistula, Ileal fistula, Jejunal fistula, Oral cavity fistula, 
Pancreatic fistula, Rectal fistula, and Salivary gland fistula under the GASTROINTESTINAL 
DISORDERS SOC.  
 
4Gastrointestinal hemorrhage includes Anal hemorrhage, Cecal hemorrhage, Colonic hemorrhage, 
Duodenal hemorrhage, Esophageal hemorrhage, Esophageal varices hemorrhage, Gastric hemorrhage, 
Hemorrhoidal hemorrhage, Ileal hemorrhage, Intra-abdominal hemorrhage, Jejunal hemorrhage, Lower 
gastrointestinal hemorrhage, Oral hemorrhage, Pancreatic hemorrhage, Rectal hemorrhage, 
Retroperitoneal hemorrhage, and Upper gastrointestinal hemorrhage under the GASTROINTESTINAL 
DISORDERS SOC.  
 
5Gastrointestinal perforation includes Colonic perforation, Duodenal perforation, Esophageal perforation, 
Gastric perforation, Ileal perforation, Jejunal perforation, Rectal perforation, and Small intestinal 
perforation under the GASTROINTESTINAL DISORDERS SOC.  
 
6Infection includes all 75 sites of infection under the INFECTIONS AND INFESTATIONS SOC. 
 
7Respiratory hemorrhage includes Bronchopulmonary hemorrhage, Epistaxis, Laryngeal hemorrhage, 
Mediastinal hemorrhage, Pharyngeal hemorrhage, and Pleural hemorrhage under the RESPIRATORY, 
THORACIC AND MEDIASTINAL DISORDERS SOC.  
 
8Interstitial lung disease may include, Adult respiratory distress syndrome, Pneumonitis, Pulmonary 
fibrosis, Respiratory, thoracic and mediastinal disorders - Other (Acute respiratory distress syndrome), 
Respiratory, thoracic and mediastinal disorders - Other (Aveolitis), Respiratory, thoracic and mediastinal 
disorders - Other (Bronchiolitis obliterans), Respiratory, thoracic and mediastinal disorders - Other 
(Interstitial fibrosis), Respiratory, thoracic and mediastinal disorders - Other (Interstitial pneumonia), 
Respiratory, thoracic and mediastinal disorders - Other (Interstitial pneumonitis), Respiratory, thoracic 
and mediastinal disorders - Other (Organizing pneumonia), Respiratory, thoracic and mediastinal 
disorders - Other (Pulmonary infiltrates), Respiratory, thoracic and mediastinal disorders - Other (Toxic 
pneumonitis). 
 
9These events can result in life-threatening pulmonary, cardiac, cerebral, and other complications. 
 
Adverse events reported on pazopanib (GW786034) trials, but for which there is insufficient 
evidence to suggest that there was a reasonable possibility that pazopanib (GW786034) caused the 
adverse event:  
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS - Febrile neutropenia; Hemolysis 
CARDIAC DISORDERS - Atrial fibrillation; Cardiac disorders - Other (sinus arrest); Cardiac disorders 
- Other (supraventricular extrasystoles); Cardiac disorders - Other (Takotsubo [Broken Heart Syndrome]); 
Chest pain - cardiac; Pericardial effusion; Supraventricular tachycardia 
ENDOCRINE DISORDERS - Adrenal insufficiency 
EYE DISORDERS - Blurred vision; Dry eye; Eye disorders - Other (asthenopia); Eye disorders - Other 
(foreign body sensation in eyes); Eye pain; Floaters; Glaucoma; Photophobia; Retinal tear 
GASTROINTESTINAL DISORDERS - Abdominal distension; Dry mouth; Duodenal obstruction; 
Dysphagia; Esophagitis; Flatulence; Gastroesophageal reflux disease; Gastrointestinal disorders - Other 
(hyperactive bowel); Gastrointestinal disorders - Other (pneumatosis intestinalis); Gastrointestinal pain; 
Oral pain; Pancreatitis; Periodontal disease; Proctitis; Small intestinal obstruction 

Alliance A091304 
Version Date: 04/03/2019 
58 
Update #09 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - Chills; Edema face; 
Malaise; Non-cardiac chest pain; Pain 
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - Bruising 
INVESTIGATIONS - Blood lactate dehydrogenase increased; Cardiac troponin T increased; Cholesterol 
high; GGT increased; INR increased; Investigations - Other (blood TSH increased); Lipase increased; 
Serum amylase increased; Weight gain 
METABOLISM AND NUTRITION DISORDERS - Hypertriglyceridemia 
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - Bone pain; Chest wall pain; 
Generalized muscle weakness; Head soft tissue necrosis; Muscle cramp; Muscle weakness lower limb; 
Muscle weakness upper limb; Neck pain 
NERVOUS SYSTEM DISORDERS - Extrapyramidal disorder; Ischemia cerebrovascular; Memory 
impairment; Paresthesia; Peripheral sensory neuropathy; Stroke; Syncope; Transient ischemic attacks 
PSYCHIATRIC DISORDERS - Agitation; Anxiety; Confusion; Depression; Insomnia; Suicide attempt 
RENAL AND URINARY DISORDERS - Urinary frequency 
REPRODUCTIVE SYSTEM AND BREAST DISORDERS - Irregular menstruation; Reproductive 
system and breast disorders - Other (vaginal necrosis); Vaginal discharge 
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - Laryngeal edema; 
Oropharyngeal pain; Pharyngolaryngeal pain; Pleural effusion; Pleuritic pain; Pneumothorax; Postnasal 
drip; Sore throat; Voice alteration 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Dry skin; Hyperhidrosis; Pruritus; Purpura; 
Skin hyperpigmentation; Skin ulceration 
VASCULAR DISORDERS - Flushing; Hot flashes; Hypotension; Vasculitis 
 
Note: Pazopanib (GW786034) in combination with other agents could cause an exacerbation of any 
adverse event currently known to be caused by the other agent, or the combination may result in events 
never previously associated with either agent. 
 
9.4.2 Comprehensive Adverse Events and Potential Risk list (CAEPR) For MLN0128 (TAK-
228) (INK128, NSC 768435) 
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list 
of reported and/or potential adverse events (AE) associated with an agent using a uniform 
presentation of events by body system. In addition to the comprehensive list, a subset, the 
Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate 
column and is identified with bold and italicized text. This subset of AEs (SPEER) is a list 
of events that are protocol specific exceptions to expedited reporting to NCI (except as noted 
below).  Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf 
for further clarification. Frequency is provided based on 311 patients. Below is the CAEPR 
for MLN0128 (TAK228).  
NOTE: Report AEs on the SPEER ONLY IF they exceed the grade noted in parentheses 
next to the AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple 
investigational agents and has an AE listed on different SPEERs, use the lower of the grades 
to determine if expedited reporting is required. 

Alliance A091304 
Version Date: 04/03/2019 
59 
Update #09 
Version 2.2, April 26, 20161 
 
 Adverse Events with Possible  
 Relationship to MLN0128 (TAK228) 
 (CTCAE 4.0 Term) 
[n= 311] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
 
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS 
  
 
Anemia 
 
 Anemia (Gr 2) 
CARDIAC DISORDERS 
  
 
 
Cardiac arrest 
  
 
 
Ventricular fibrillation 
  
GASTROINTESTINAL DISORDERS 
  
 
Abdominal pain 
 
 Abdominal pain (Gr 2) 
 
Constipation 
 
 Constipation (Gr 2) 
Diarrhea 
 
 
 Diarrhea (Gr 2) 
 
Dry mouth 
 
 Dry mouth (Gr 2) 
Mucositis oral 
 
 
 Mucositis oral (Gr 2) 
Nausea 
 
 
 Nausea (Gr 2) 
Vomiting 
 
 
 Vomiting (Gr 2) 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS 
  
 
Edema limbs 
 
  
Fatigue 
 
 
 Fatigue (Gr 2) 
 
Fever 
 
 Fever (Gr 2) 
 
General disorders and 
administration site 
conditions - Other (mucosal 
inflammation) 
 
 General disorders and 
administration site conditions - 
Other (mucosal inflammation) 
(Gr 2) 
INFECTIONS AND INFESTATIONS 
  
 
Urinary tract infection 
 
 Urinary tract infection (Gr 2) 
INVESTIGATIONS 
  
 
Creatinine increased 
 
 Creatinine increased (Gr 2) 
 
 
Electrocardiogram QT 
corrected interval 
prolonged 
  
 
Platelet count decreased 
 
 Platelet count decreased (Gr 2) 
 
Weight loss 
 
 Weight loss (Gr 2) 
METABOLISM AND NUTRITION DISORDERS 
  
Anorexia 
 
 
 Anorexia (Gr 2) 
 
Dehydration 
 
 Dehydration (Gr 2) 
Hyperglycemia 
 
 
 Hyperglycemia (Gr 2) 
 
Hypokalemia 
 
 Hypokalemia (Gr 2) 
 
Hypomagnesemia 
 
 Hypomagnesemia (Gr 2) 
 
Hypophosphatemia 
 
 Hypophosphatemia (Gr 2) 
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS 
  
 
Arthralgia 
 
  

Alliance A091304 
Version Date: 04/03/2019 
60 
Update #09 
 
 Adverse Events with Possible  
 Relationship to MLN0128 (TAK228) 
 (CTCAE 4.0 Term) 
[n= 311] 
 
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
 
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
 
 
Back pain 
 
 Back pain (Gr 2) 
 
Pain in extremity 
 
  
NERVOUS SYSTEM DISORDERS 
  
 
Dizziness 
 
 Dizziness (Gr 2) 
 
Dysgeusia 
 
 Dysgeusia (Gr 2) 
 
Headache 
 
 Headache (Gr 2) 
PSYCHIATRIC DISORDERS 
  
 
Insomnia 
 
  
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS 
  
 
Cough 
 
 Cough (Gr 2) 
 
Dyspnea 
 
 Dyspnea (Gr 2) 
 
 
Pneumonitis 
  
 
Respiratory, thoracic and 
mediastinal disorders - Other 
(oropharyngeal pain) 
 
  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS 
  
Pruritus 
 
 
 Pruritus (Gr 2) 
Rash maculo-papular 
 
 
 Rash maculo-papular (Gr 2) 
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision.  The current version can be obtained by contacting 
PIO@CTEP.NCI.NIH.GOV.  Your name, the name of the investigator, the protocol and the agent should 
be included in the e-mail. 
 
 
Adverse events reported on MLN0128 (TAK228) trials, but for which there is insufficient evidence 
to suggest that there was a reasonable possibility that MLN0128 (TAK228) caused the adverse 
event: 
 
CARDIAC DISORDERS - Heart failure; Pericardial effusion; Sinus tachycardia 
EYE DISORDERS - Blurred vision; Eye disorders - Other (visual acuity reduced); Eye pain; 
Photophobia 
GASTROINTESTINAL DISORDERS - Dyspepsia; Dysphagia; Esophagitis; Gastroesophageal reflux 
disease; Gastrointestinal disorders - Other (intestinal obstruction); Oral pain; Pancreatitis; Small intestinal 
obstruction; Small intestinal perforation; Toothache 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - Chills; Gait 
disturbance; Non-cardiac chest pain; Pain 
HEPATOBILIARY DISORDERS - Gallbladder obstruction 
IMMUNE SYSTEM DISORDERS - Allergic reaction 
INFECTIONS AND INFESTATIONS - Kidney infection; Lung infection; Sepsis; Skin infection; 
Upper respiratory infection 
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - Fall; Tracheal obstruction 

Alliance A091304 
Version Date: 04/03/2019 
61 
Update #09 
INVESTIGATIONS - Alanine aminotransferase increased; Aspartate aminotransferase increased; Blood 
bilirubin increased; Cholesterol high; Lymphocyte count decreased; Neutrophil count decreased; White 
blood cell decreased 
METABOLISM AND NUTRITION DISORDERS - Hypercalcemia; Hypertriglyceridemia; 
Hypoalbuminemia; Hypocalcemia; Hyponatremia; Metabolism and nutrition disorders - Other (vitamin D 
deficiency) 
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - Flank pain; Generalized 
muscle weakness; Musculoskeletal and connective tissue disorder - Other (muscle spasms); Myalgia 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) - 
Treatment related secondary malignancy 
NERVOUS SYSTEM DISORDERS - Intracranial hemorrhage; Nervous system disorders - Other 
(carotid artery occlusion); Tremor 
PSYCHIATRIC DISORDERS - Anxiety; Confusion; Depression; Personality change 
RENAL AND URINARY DISORDERS - Acute kidney injury; Hematuria; Urinary tract pain 
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - Bronchopulmonary 
hemorrhage; Epistaxis; Hypoxia; Nasal congestion; Pleural effusion; Pneumothorax; Postnasal drip; 
Productive cough 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Dry skin; Hyperhidrosis; Rash acneiform; 
Urticaria 
VASCULAR DISORDERS - Flushing; Hypotension; Thromboembolic event 
 
 
Note: MLN0128 (TAK228) in combination with other agents could cause an exacerbation of any adverse 
event currently known to be caused by the other agent, or the combination may result in events never 
previously associated with either agent. 

Alliance A091304 
Version Date: 04/03/2019 
62 
Update #09 
10.0 DRUG INFORMATION  
10.1 
Pazopanib (Commercial; IND Exempt)  
Procurement 
Commercial supplies. Pharmacies or clinics shall obtain supplies from normal commercial 
supply chain or wholesaler. 
Formulation 
Commercially available for oral administration as:  
Tablets: 200 mg 
Preparation, Storage and Stability 
Refer to package insert for complete dispensing instructions. Store tablets at room temperature 
between 20ºC and 25ºC (68ºF and 77ºF); excursions permitted between 15ºC and 30ºC (59ºF 
and 86ºF). 
Administration 
Refer to the treatment section for specific administration instructions. The manufacturer 
recommends pazopanib be administered on an empty stomach, 1 hour before or 2 hours after a 
meal. Do not crush tablet (rate of absorption may be increased; may affect systemic exposure). 
Drug Interactions 
Cytochrome P450 Effect: Pazopanib is metabolized principally by CYP3A4 with minor 
contributions from CYP1A2 and CYP3A4.  Therefore, inhibitors and inducers of CYP3A4 may 
alter the metabolism of pazopanib.   
CYP3A4 Inhibitors and Inducers:  Coadministration of pazopanib with strong inhibitors of 
CYP3A4 (e.g., ketoconazole, ritonavir, clarithromycin) increases pazopanib concentrations and 
should be avoided.  Grapefruit juice should be avoided as it inhibits CYP3A4 activity and may 
also increase plasma concentrations of pazopanib. CYP3A4 inducers such as rifampin may 
decrease plasma pazopanib concentrations. Pazopanib should not be used if chronic use of strong 
CYP3A4 inducers cannot be avoided.   
Transporter Inhibitors:  In vitro studies suggested that pazopanib is a substrate of P-glycoprotein 
and breast cancer resistance protein (BCRP).  Therefore, absorption and subsequent elimination 
of pazopanib may be influence by products that affect P-glycoprotein and BCRP.  Concomitant 
treatment with strong inhibitors of P-glycoprotein and BCRP should be avoided.   
CYP Substrates:  Results from drug-drug interaction trials conducted in cancer patients suggest 
that pazopanib is a weak inhibitor of CYP3A4, CYP2C8, and CYP2D6 in vivo, but had no effect 
on CYP1A2, CYP2C9, or CYP2C19.   Concomitant use of pazopanib with agents with narrow 
therapeutic windows that are metabolized by CYP3A4, CYP2D6, or CYP2C8 is not 
recommended.  Coadministration may result in inhibition of the metabolism of these products 
and create the potential for serious adverse events. 
Concomitant use of pazopanib and simvastatin increases the incidence of ALT elevations.  If a 
patient receiving concomitant simvastatin develops ALT elevations, follow dosing guidelines 
for pazopanib or consider discontinuing simvastatin.  Insufficient data are available to assess the 
risk of concomitant administration of alternative statins and pazopanib. 
Concomitant administration of pazopanib with esomeprazole, a proton pump inhibitor, 
decreased the exposure of pazopanib by approximately 40% (AUC and Cmax).  Concomitant 
use of pazopanib with drugs that raise gastric pH should be avoided.  If such drugs are needed, 
short acting antacids should be considered in place of proton pump inhibitors and H2 receptor 

Alliance A091304 
Version Date: 04/03/2019 
63 
Update #09 
antagonists.  Separate antacid and pazopanib dosing by several hours to avoid a reduction in 
pazopanib exposure.   
Pazopanib should be used with caution in patients with a history of QT interval prolongation, in 
patients taking antiarrhythmics or other medications that may prolong QT interal, and those with 
relevant pre-existing cardiac disease.  Baseline and periodic monitoring of electrocardiograms 
and maintenance of electrolytes (e.g. calcium, magnesium, potassium) within the normal range 
should be performed. 
Pharmacokinetics 
Absorption and Bioavailability: Pazopanib is absorbed orally with median time to achieve 
peak concentration of 2 to 4 hours after the dose. Median absolute bioavailability is 21%.  
Systemic exposure to pazopanib is increased when administered with food.  Administration with 
a high-fat or low-fat meal results in an approximately 2-fold increase in AUC and Cmax.  
Pazopanib should be administered at least one hour before or 2 hours after a meal.  
Plasma protein binding: 99% 
Half-life elimination: 30.9 hours after administration of a single 800 mg dose 
Time to peak, plasma: 2-4 hours  
Excretion: Primarily via feces with renal elimination accounting for < 4% of the administered 
dose 
Metabolism: In vitro studies demonstrate pazopanib is metabolized by CYP3A4 with a minor 
contribution from CYP1A2 and CYP2C8.   
Adverse Events 
Consult the package insert for the most current and complete information. Important Safety 
Information including Boxed WARNING: Severe and fatal hepatotoxicity, manifested as 
increases in serum transaminases (ALT, AST) and bilirubin, has been observed in clinical 
trials. Monitor hepatic function and interrupt, reduce or discontinue dosing as 
recommended.   
Common known potential toxicities, > 10%:   
Cardiovascular: Hypertension, bradycardia, peripheral edema  
Central nervous system: Fatigue, headache, dizziness  
Dermatologic: Hair discoloration, skin rash, alopecia, palmar-plantar erythrodysesthesia, skin 
depigmentation  
Endocrine & metabolic: Hyperglycemia, hypophosphatemia, hyponatremia, increased thyroid-
stimulating hormone (TSH), hypomagnesemia, hypoglycemia, hyperkalemia 
Gastrointestinal: Diarrhea, nausea, weight loss, anorexia, vomiting, dysgeusia, increased serum 
lipase, abdominal pain, mucositis, stomatitis 
Hematologic: Leukopenia, lymphocytopenia, thrombocytopenia, neutropenia 
Hepatic:  Increased serum AST, increased serum ALT, increased serum bilirubin, decreased 
serum albumin, increased serum alkaline phosphatase 
Neuromuscular & skeletal: Musculoskeletal pain, myalgia, weakness 
Respiratory:  Dyspnea, cough 
Miscellaneous: Tumor pain 
Less common known potential toxicities, 1% - 10%:  
Cardiovascular: Chest pain, left ventricular systolic dysfunction, venous thrombosis, ischemic 
heart disease or myocardial infarction, prolonged QT interval on ECG, facial edema, transient 
ischemic attacks 
Central nervous system:  Insomnia, voice disorder, chills 

Alliance A091304 
Version Date: 04/03/2019 
64 
Update #09 
Dermatologic: Xeroderma, nail disease 
Endocrine & metabolic:  Hypothyroidism 
Gastrointestinal: Dyspepsia, oral hemorrhage, rectal hemorrhage 
Hematologic: Febrile neutropenia, pancytopenia, lymphopenia, anemia 
Opthalmic:  Blurred vision 
Renal: Proteinuria, hematuria 
Respiratory: Epistaxis, pneumothorax, hemoptysis, pulmonary embolism  
Rare, less than 1% (limited to important or life-threatening): 
Cardiac disease, cerebral hemorrhage, cerebrovascular accident, congestive heart failure, 
gastrointestinal fistula, gastrointestinal perforation (including fistulas), hemolytic-uremic 
syndrome, hepatotoxicity, hypertensive crisis, intracranial hemorrhage, nephrotic syndrome, 
pancreatitis, reversible posterior leukoencephalopathy syndrome (RPLS), thrombotic 
thrombocytopenic purpura, torsade de pointes 
Nursing Guidelines 
• 
Pazopanib should be taken without food (1 hour before or 2 hours after a meal). Should 
be taken whole with water and not broken or crushed. If a dose is missed, do not take if 
it is less than 12 hours until the next dose. 
• 
There are numerous drug to drug interactions between pazopanib and other agents 
metabolized through the P450 system.  Assess patient’s concomitant medications, 
including OTC and herbal products.   
• 
Hypertension is a commonly reported side effect. Monitor blood pressure closely per 
study guidelines. Administer antihypertensives as ordered by MD. 
• 
Inform patient of possible changes in hair color. 
• 
Gastrointestinal side effects are common (diarrhea, nausea, vomiting, loss of appetite). 
Treat symptomatically and assess for effectiveness. 
• 
Due to the similarity in nature of this agent to other VEGF inhibitors (bevacizumab, 
VEGF-trap, etc.) monitor for signs of bleeding, thrombosis and PE. Instruct patient to 
report any calf tenderness, shortness of breath, chest pain or bleeding immediately. 
• 
Cytopenias are common. Monitor CBC w/diff and instruct patient to report any unusual 
bruising or bleeding and/or signs of infection to study team. 
• 
Monitor LFT’s. Patients who have AST/ALT levels > 3x ULN and concurrent bilirubin 
>2X ULN should permanently discontinue pazopanib. Patients with AST/ALT levels as 
above and mild hyperbilirubinemia (with suspected or known Gibert’s syndrome) 
should be monitored weekly while continuing pazopanib. 
• 
Cardiac side effects (CHF, MI, chest pain, etc).  while rare can be serious and life 
threatening. Instruct patient to report any cardiac symptoms to study team immediately. 
• 
RPLS, CVA, and TIA are uncommon, but are life threatening. Instruct patient to report 
any neurological symptoms to the study team immediately. 
10.2 
MLN0128 (TAK-228) (Supplied) (INK128, NSC #768435, IND 121931); IND holder: 
CTEP 
Investigators ordering and/or dispensing supplied agents at any time for study treatment must 
be currently registered with PMB, DCTD, NCI. A registered investigator must co-sign for other 
non-registered personnel prescribing the supplied agents. 
 
 

Alliance A091304 
Version Date: 04/03/2019 
65 
Update #09 
Procurement 
MLN0128 (TAK-228) is an investigational agent supplied by the National Cancer Institute 
(NCI).  Millennium Pharmaceuticals, Inc. will supply MLN0128 (TAK-228) to the 
CTEP/DCTD/NCI and will be distributed by the Pharmaceutical Management Branch, 
CTEP/DCTD/NCI.    
Drug Ordering:   NCI supplied agents may be requested by the Principal Investigator (or their 
authorized designee) at each participating institution.  Pharmaceutical Management Branch 
(PMB) policy requires that agent be shipped directly to the institution where the patient is to be 
treated.  PMB does not permit the transfer of agents between institutions (unless prior approval 
from PMB is obtained.)  The CTEP assigned protocol number must be used for ordering all 
CTEP supplied investigational agents.  The responsible investigator at each participating 
institution must be registered with CTEP, DCTD through an annual submission of FDA form 
1572 (Statement of Investigator), Curriculum Vitae, Supplemental Investigator Data Form 
(IDF), and Financial Disclosure Form (FDF).  If there are several participating investigators at 
one institution, CTEP supplied investigational agents for the study should be ordered under the 
name of one lead investigator at that institution. 
Active CTEP-registered investigators and investigator-designated shipping designees and 
ordering designees can submit agent requests through the PMB Online Agent Order Processing 
(OAOP) application < https://eapps-ctep.nci.nih.gov/OAOP/pages/login.jspx >.  Access to 
OAOP requires the establishment of a CTEP Identity and Access Management (IAM) account 
< https://eapps-ctep.nci.nih.gov/iam/ > and the maintenance of an “active” account status and a 
“current” password.  For questions about drug orders, transfers, returns, or accountability, call 
(240) 276-6575 Monday through Friday between 8:30 am and 4:30 pm (ET) or email 
PMBAfterHours@mail.nih.gov anytime. 
Agent Inventory Records - The investigator, or a responsible party designated by the 
investigator, must maintain a careful record of the inventory and disposition of all agents 
received from DCTD using the NCI Oral Drug Accountability Record Form.  (See the NCI 
Investigator’s Handbook for Procedures for Drug Accountability and Storage.) 
Classification: 
mTOR inhibitor, TORC1/2  
CAS Registry Number: 
1224844 
Molecular Formula: 
C15H15N7O 
 
M.W.:  
309.3 
Approximate Solubility 
MLN0128 exhibits a pH-dependant aqueous solubility: at physiological pH the solubility is 
approximately 0.1 mg/mL and at or below pH 3 the solubility is greater than 15 mg/mL. 
Mode of Action: 
MLN0128 is a non-rapamycin analog mTOR (mechanistic target of rapamycin) kinase inhibitor.  
The mTOR kinase regulates cell growth, translational control, angiogenesis, and cell survival 
by integrating nutrient and hormonal signals.  The mTOR complex (TORC) is an intracellular 
point of convergence for a number of cellular signaling pathways.  ML0128 is a potent and 
selective adenosine tri-phosphate (ATP)-competitive inhibitor of mTOR complex 1 and 2 
(TORC1/2). 
Description:  
MLN0128 drug substance is a white to off-white, crystalline powder. 
How Supplied: 
MLN0128 is supplied by Millennium Pharmaceuticals, Inc. and distributed by the 
Pharmaceutical Management Branch, CTEP/DCTD/NCI as size 2 hard gelatin capsules in the 

Alliance A091304 
Version Date: 04/03/2019 
66 
Update #09 
following strength: 5 mg (gray opaque color).  The composition of the drug product consists of 
a blend of MLN0128 drug substance, microcrystalline cellulose, and magnesium stearate.  
Milled formulations will have a white label with a large watermark of the strength on the label.  
MLN0128 capsules are packaged in 30-count, 60-cc high-density polyethylene (HDPE), white, 
opaque, round, tamper- and child-resistant bottles.   
Storage: 
Capsules are to be stored in the original package between 15°C to 30°C.   
Route of Administration:  
MLN0128 (TAK-228) should be taken on an empty stomach at least 2 hours after food and do 
not eat or drink (except water) for at least one hour after taking MLN0128 (TAK-228). Do not 
chew, open or manipulate the capsule in any way prior to swallowing.  Each dose should be 
taken with 8 ounces (240 mL) of water. 
Potential Drug Interactions: 
Multiple human metabolizing enzymes are involved in the Phase I metabolism of MLN0128. 
When normalized for human liver content, the CYP isoforms CYP3A4, CYP2C9, and CYP2C19 
appear to contribute to MLN0128 metabolism.  MLN0128 displayed low potential (IC50 > 25 
μM) for inhibition of the major human CYP isoforms. 
Other pathways: 
MLN0128 (TAK-228) did not inhibit P-glycoprotein but does inhibit breast cancer 
resistance protein (BCRP) and organic cation transporter 1 and 2. 
Pharmacokinetics 
Absorption: MLN0128 (TAK-228) is rapidly absorbed with a Tmax of 1 to 4 hour post dosing. 
Preliminary assessment of doses versus exposure relationship suggests MLN0128 (TAK-228) 
exposures increase linearly with dose. Studies in rats suggest that feeding state did not affect 
the absorption and pharmacokinetic profile of MLN0128 (TAK-228). 
Distribution: Total body clearance is approximately 20 L/hour and does not appear to 
accumulate in plasma when dosed as frequently as once daily. MLN0128 (TAK-228) 
exposures also increase linearly with dose. MLN0128 (TAK-228) has the propensity to 
cross the blood-brain-barrier. MLN0128 (TAK-228) is 70.5% bound to human plasma proteins. 
Metabolism: Hepatic to M1 metabolite (inactive) via Cytochrome P450 CYP2C9 (35.1%), 
CYP2C19 (28%) and CYP3A4 (27.8%) 
Half-life elimination: Approximately 8 hours 
Excretion: Biliary excretion of MLN0128 (TAK-228) and M1 each represented less than 1% 
of the total MLN0128 (TAK-228) dose after administration of a single IV dose of 0.5 mg/kg 
MLN0128 (TAK-228) to rats. Urinary excretion of MLN0128 (TAK-228) and M1 represented 
less than 1% and 21%, respectively, of the total MLN0128 (TAK-228) dose. 
Patient Care Implications: 
Women of childbearing potential should use effective methods of contraception during and 
through 3 months after the last dose of MLN0128. 
Men should use effective methods of contraception and not donate sperm during and through 4 
months after the last dose of MLN0128. 
 
Adverse Events 
Refer to MLN0128 (TAK-228) CAEPR in Section 9.4.2. 

Alliance A091304 
Version Date: 04/03/2019 
67 
Update #09 
 
Nursing Guidelines 
• 
Hyperglycemia is common. Monitor glucose levels as outlined in protocol. Patients who 
are diabetic will need to be monitored closely. Patients who are not diabetic may require 
daily home glucose monitoring. Instruct patients on this technique and instruct patients 
to report high blood sugars to study team. 
• 
GI side effects include nausea, vomiting, diarrhea, constipation and abdominal pain. 
Treat symptomatically and monitor for effectiveness. 
• 
Anemia and lymphopenia have been seen. Monitor CBC w/diff and report low blood 
counts to provider. 
• 
Monitor electrolyte panel, as patients may experience low phosphorus, magnesium, and 
potassium levels. 
• 
Patients may experience taste alterations, dry mouth, and stomatitis. Treat 
symptomatically and monitor for effectiveness. 
• 
Warn patients they may experience flu-like symptoms, including pyrexia, asthenia, 
headache, back pain. 
• 
Instruct patients to report any rash or itching to study team. 
11.0 MEASUREMENT OF EFFECT 
Response and progression will be evaluated in this study using the new international criteria proposed 
by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1)[28].  
Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the short 
axis measurements in the case of lymph nodes are used in the RECIST guideline. 
11.1 
Schedule of Evaluations: 
For the purposes of this study, patients should be reevaluated every 8 weeks for 6 assessments 
followed by every 12 weeks thereafter. Patients initiating crossover will restart their scanning 
intervals as every 8 weeks from date of crossover and for 6 assessments, followed by every 12 
weeks thereafter. 
11.2 
Definitions of Measurable and Non-Measurable Disease 
11.2.1 Measurable Disease 
A non-nodal lesion is considered measurable if its longest diameter can be accurately 
measured as 2.0 cm with chest x-ray, or as ≥1.0 cm with CT scan, CT component of a 
PET/CT, or MRI.  
A superficial non-nodal lesion is measurable if its longest diameter is ≥ 1.0 cm in diameter 
as assessed using calipers (e.g. skin nodules) or imaging.  In the case of skin lesions, 
documentation by color photography, including a ruler to estimate the size of the lesion, is 
recommended. 
A malignant lymph node is considered measurable if its short axis is >1.5 cm when assessed 
by CT scan (CT scan slice thickness recommended to be no greater than 5 mm).   
Tumor lesions in a previously irradiated area are considered measurable disease under the 
following conditions: They are at least 1.0 cm in diameter and have grown by at least 0.5 
cm (or 25%, whichever represents the smaller value) from the measured post-radiation 
nadir. 

Alliance A091304 
Version Date: 04/03/2019 
68 
Update #09 
11.2.2 Non-Measurable Disease 
All other lesions (or sites of disease) are considered non-measurable disease, including 
pathological nodes (those with a short axis ≥ 1.0 to < 1.5 cm).  Bone lesions, leptomeningeal 
disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory 
breast disease, and abdominal masses (not followed by CT or MRI), are considered as non-
measurable as well. 
Note: ‘Cystic lesions’ thought to represent cystic metastases can be considered as 
measurable lesions, if they meet the definition of measurability described above. However, 
if non-cystic lesions are present in the same patient, these are preferred for selection as target 
lesions.  In addition, lymph nodes that have a short axis < 1.0 cm are considered non-
pathological (i.e., normal) and should not be recorded or followed. 
11.3 
Guidelines for Evaluation of Measurable Disease 
11.3.1 Measurement Methods:   
• 
All measurements should be recorded in metric notation (i.e., decimal fractions of 
centimeters) using a ruler or calipers. 
• 
The same method of assessment and the same technique must be used to characterize 
each identified and reported lesion at baseline and during follow-up. For patients having 
only lesions measuring at least 1 cm to less than 2 cm must use CT imaging for both 
pre- and post-treatment tumor assessments.   
• 
Imaging-based evaluation is preferred to evaluation by clinical examination when both 
methods have been used at the same evaluation to assess the antitumor effect of a 
treatment.  
11.3.2 Acceptable Modalities for Measurable Disease: 
• 
Conventional CT and MRI:  This guideline has defined measurability of lesions on 
CT scan based on the assumption that CT slice thickness is 5 mm or less. If CT scans 
have slice thickness greater than 5 mm, the minimum size for a measurable lesion should 
be twice the slice thickness. 
As with CT, if an MRI is performed, the technical specifications of the scanning 
sequences used should be optimized for the evaluation of the type and site of disease.  
The lesions should be measured on the same pulse sequence.  Ideally, the same type of 
scanner should be used and the image acquisition protocol should be followed as closely 
as possible to prior scans.  Body scans should be performed with breath-hold scanning 
techniques, if possible. 
• 
PET-CT:  If the site can document that the CT performed as part of a PET-CT is of 
identical diagnostic quality to a diagnostic CT (with IV and oral contrast), then the CT 
portion of the PET-CT can be used for RECIST measurements and can be used 
interchangeably with conventional CT in accurately measuring cancer lesions over time.   
• 
Chest X-ray:  Lesions on chest x-ray are acceptable as measurable lesions when they 
are clearly defined and surrounded by aerated lung.  However, CT scans are preferable. 
• 
Physical Examination:  For superficial non-nodal lesions, physical examination is 
acceptable, but imaging is preferable, if both can be done. In the case of skin lesions, 
documentation by color photography, including a ruler to estimate the size of the lesion, 
is recommended. 
• 
FDG-PET:  FDG-PET scanning is allowed to complement CT scanning in assessment 
of progressive disease [PD] and particularly possible 'new' disease.  A ‘positive’ FDG-

Alliance A091304 
Version Date: 04/03/2019 
69 
Update #09 
PET scanned lesion is defined as one which is FDG avid with an update greater than 
twice that of the surrounding tissue on the attenuation corrected image; otherwise, an 
FDG-PET scanned lesion is considered ‘negative.’  New lesions on the basis of FDG-
PET imaging can be identified according to the following algorithm: 
a. Negative FDG-PET at baseline with a positive FDG-PET at follow-up is a sign of 
PD based on a new lesion. 
b. No FDG-PET at baseline and a positive FDG-PET at follow-up:   
1) If the positive FDG-PET at follow-up corresponds to a new site of disease 
confirmed by CT, this is PD.   
2) If the positive FDG-PET at follow-up is not confirmed as a new site of disease 
on CT at the same evaluation, additional follow-up CT scans (i.e., additional 
follow-up scans at least 4 weeks later) are needed to determine if there is truly 
progression occurring at that site. In this situation, the date of PD will be the 
date of the initial abnormal PDG-PET scan.   
3) If the positive FDG-PET at follow-up corresponds to a pre-existing site of 
disease on CT that is not progressing on the basis of the anatomic images, it is 
not classified as PD. 
11.3.3 Measurement at Follow-up Evaluation:   
• 
The cytological confirmation of the neoplastic origin of any effusion that appears or 
worsens during treatment when the measurable tumor has met criteria for response or 
stable disease is mandatory to differentiate between response or stable disease (an 
effusion may be a side effect of the treatment) and progressive disease. 
• 
Cytologic and histologic techniques can be used to differentiate between PR and CR in 
rare cases (e.g., residual lesions in tumor types such as germ cell tumors, where known 
residual benign tumors can remain.) 
11.4 
Measurement of Treatment/Intervention Effect 
11.4.1 Target Lesions & Target Lymph Nodes 
• 
Measurable lesions (as defined in Section 11.2.1) up to a maximum of 5, representative 
of all involved organs, should be identified as “Target Lesions” and recorded and 
measured at baseline.  These lesions can be non-nodal or nodal (as defined in 11.2.1), 
where no more than 2 lesions are from the same organ and no more than 2 malignant 
nodal lesions are selected.  
Note: If fewer than 5 target lesions and target lymph nodes are identified (as there often 
will be), there is no reason to perform additional studies beyond those specified in the 
protocol to discover new lesions.   
• 
Target lesions and target lymph nodes should be selected on the basis of their size, be 
representative of all involved sites of disease, but in addition should be those that lend 
themselves to reproducible repeated measurements.  It may be the case that, on occasion, 
the largest lesion (or malignant lymph node) does not lend itself to reproducible 
measurements in which circumstance the next largest lesion (or malignant lymph node) 
which can be measured reproducibly should be selected.   
• 
Baseline Sum of Dimensions (BSD):  A sum of the longest diameter for all target 
lesions plus the sum of the short axis of all the target lymph nodes will be calculated 
and reported as the baseline sum of dimensions (BSD).  The BSD will be used as 

Alliance A091304 
Version Date: 04/03/2019 
70 
Update #09 
reference to further characterize any objective tumor response in the measurable 
dimension of the disease.   
• 
Post-Baseline Sum of the Dimensions (PBSD):  A sum of the longest diameter for all 
target lesions plus the sum of the short axis of all the target lymph nodes will be 
calculated and reported as the post-baseline sum of dimensions (PBSD).  If the 
radiologist is able to provide an actual measure for the target lesion (or target lymph 
node), that should be recorded, even if it is below 0.5 cm.  If the target lesion (or target 
lymph node) is believed to be present and is faintly seen but too small to measure, a 
default value of 0.5 cm should be assigned.  If it is the opinion of the radiologist that the 
target lesion or target lymph node has likely disappeared, the measurement should be 
recorded as 0 cm. 
• 
The minimum sum of the dimensions (MSD) is the minimum of the BSD and the 
PBSD. 
11.4.2 Non-Target Lesions & Non-Target Lymph Nodes 
Non-measurable sites of disease (Section 11.2.2) are classified as non- target lesions or non-
target lymph nodes and should also be recorded at baseline.  These lesions and lymph nodes 
should be followed in accord with 11.4.3.3. 
11.4.3 Response Criteria 
11.4.3.1 All target lesions and target lymph nodes followed by CT/MRI/PET-CT/Chest X-
ray/physical examination must be measured on re-evaluation at evaluation times 
specified in Section 11.1.  Specifically, a change in objective status to either a PR or 
CR cannot be done without re-measuring target lesions and target lymph nodes.  
Note: Non-target lesions and non-target lymph nodes should be evaluated at each 
assessment, especially in the case of first response or confirmation of response.  In 
selected circumstances, certain non-target organs may be evaluated less frequently.  
For example, bone scans may need to be repeated only when complete response is 
identified in target disease or when progression in bone is suspected. 
11.4.3.2 Evaluation of Target Lesions 
• 
Complete Response (CR): All of the following must be true: 
a. Disappearance of all target lesions. 
b. Each target lymph node must have reduction in short axis to < 1.0 cm. 
• 
Partial Response (PR): At least a 30% decrease in PBSD (sum of the longest 
diameter for all target lesions plus the sum of the short axis of all the target lymph 
nodes at current evaluation) taking as reference the BSD (see Section 11.4.1). 
• 
Progression (PD): At least one of the following must be true: 
a. At least one new malignant lesion, which also includes any lymph node that 
was normal at baseline (< 1.0 cm short axis) and increased to ≥ 1.0 cm short 
axis during follow-up.  
b. At least a 20% increase in PBSD (sum of the longest diameter for all target 
lesions plus the sum of the short axis of all the target lymph nodes at current 
evaluation) taking as reference the MSD (Section 11.4.1).  In addition, the 
PBSD must also demonstrate an absolute increase of at least 0.5 cm from the 
MSD.  

Alliance A091304 
Version Date: 04/03/2019 
71 
Update #09 
c. See Section 11.3.2 for details in regards to the requirements for PD via FDG-
PET imaging. 
• 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR, nor sufficient 
increase to qualify for PD taking as reference the MSD. 
11.4.3.3 Evaluation of Non-Target Lesions & Non-target Lymph Nodes 
• 
Complete Response (CR): 
All of the following must be true: 
a. Disappearance of all non-target lesions.  
b. Each non-target lymph node must have a reduction in short axis to <1.0 cm. 
• 
Non-CR/Non-PD: Persistence of one or more non-target lesions or non-target 
lymph nodes. 
• 
Progression (PD): At least one of the following must be true: 
a. At least one new malignant lesion, which also includes any lymph node that 
was normal at baseline (< 1.0 cm short axis) and increased to ≥ 1.0 cm short 
axis during follow-up.   
b. Unequivocal progression of existing non-target lesions and non-target lymph 
nodes.  (NOTE:  Unequivocal progression should not normally trump target 
lesion and target lymph node status.  It must be representative of overall 
disease status change.)  
c. See Section 11.3.2 for details in regards to the requirements for PD via FDG-
PET imaging. 
11.4.4 Overall Objective Status 
The overall objective status for an evaluation is determined by combining the patient’s status 
on target lesions, target lymph nodes, non-target lesions, non-target lymph nodes, and new 
disease as defined in the following tables:  
 
For Patients with Measurable Disease:  
 
Target Lesions & 
Target Lymph Nodes 
Non-Target Lesions & 
Non-Target Lymph 
Nodes 
New  
Sites of Disease 
Overall Objective 
Status 
CR 
CR 
No 
CR 
CR 
Non-CR/Non-PD 
No 
PR 
PR 
CR 
Non-CR/Non-PD 
No 
PR 
CR/PR 
Not All Evaluated* 
No 
PR 
SD 
CR 
Non-CR/Non-PD 
Not All Evaluated* 
No 
SD 
Not all Evaluated 
CR 
Non-CR/Non-PD 
Not All Evaluated* 
No 
Not Evaluated 
(NE) 
PD 
Unequivocal PD 
CR 
Non-CR/Non-PD 
Not All Evaluated* 
Yes or No 
PD 

Alliance A091304 
Version Date: 04/03/2019 
72 
Update #09 
Target Lesions & 
Target Lymph Nodes 
Non-Target Lesions & 
Non-Target Lymph 
Nodes 
New  
Sites of Disease 
Overall Objective 
Status 
CR/PR/SD/PD/Not all 
Evaluated 
Unequivocal PD 
Yes or No 
PD 
CR/PR/SD/PD/Not all 
Evaluated 
CR 
Non-CR/Non-PD 
Not All Evaluated* 
Yes 
PD 
* 
See Section 11.4.3.1 
 
11.4.5 Symptomatic Deterioration: Patients with global deterioration of health status requiring 
discontinuation of treatment without objective evidence of disease progression at that time, 
and not either related to study treatment or other medical conditions, should be reported as 
PD due to “symptomatic deterioration.”  Every effort should be made to document the 
objective progression even after discontinuation of treatment due to symptomatic 
deterioration. 
11.5 
Definitions of analysis variables 
Formal definitions of variables used in analyses can be found in the Statistical Considerations 
section of the protocol. 
12.0 END OF TREATMENT/INTERVENTION 
12.1 
Duration of Treatment  
12.1.1 CR, PR, or SD: Patients who are in CR, PR or SD will continue on therapy until progression 
of disease, excessive toxicity requiring the patient to come off of treatment, or the patient 
withdraws from treatment. After treatment is discontinued, patients will be followed per the 
study calendar in Section 5.0. Patients receiving pazopanib may re-register and receive 
MLN0128 (TAK-228) following PD (see section 12.1.2). All follow-up and tests continue, 
as if the patient was initially randomized to receive MLN0128 (TAK-228). 
12.1.2 Disease Progressio:  
Upon Progression on Pazopanib: Patients may re-register and receive MLN0128 (TAK-
228). All follow-up and tests continue, as if the patient was initially randomized to receive 
MLN0128 (TAK-228). 
Upon progression on MLN0128 (TAK-228) Remove from protocol therapy any patient 
with disease progression. Document details, including tumor measurements, on data forms. 
After disease progression, patients should be followed for survival per the study calendar 
(Section 5.0).  
12.1.3 Discontinuation of study agent: If the patient discontinues their initial treatment 
assignment to either pazopanib or MLN0128 (TAK-228) for reasons other than disease 
progression or withdrawal of consent, and within 15 months of randomization, will continue 
following the Study Calendar (Section 5.0) for disease assessments. 

Alliance A091304 
Version Date: 04/03/2019 
73 
Update #09 
12.2 
Managing ineligible patients and registered patients who never receive protocol 
intervention  
Definition of ineligible patients: A study participant who is registered to the trial but does not 
meet all of the eligibility criteria is deemed to be ineligible. Patients who are deemed ineligible 
may continue protocol treatment, provided the treating physician, study chair, and executive 
officer agree there are no safety concerns if the patient continues protocol treatment. All scans, 
tests, and data submission are to continue as if the patient were eligible. Notification of the local 
IRB may be necessary per local IRB policies. 
Study participants who are registered to the trial but never receive study intervention (for a 
reason other than because they were deemed ineligible) must still complete follow-up 
requirements as specified below. Baseline, on-study, endpoint (e.g., relapse or progression), off 
treatment, and survival data submission required. 
The organization holding the IND will also be notified if a patient is found to  be ineligible upon 
audit or after the patient has already received several cycles of therapy.  
12.3 
Extraordinary Medical Circumstances 
If, at any time the constraints of this protocol are detrimental to the patient's health and/or the 
patient no longer wishes to continue protocol therapy, protocol therapy shall be discontinued. In 
this event: 
• 
Document the reason(s) for discontinuation of therapy on data forms. 
• 
Follow the patient for protocol endpoints as required by the Study Calendar. 

Alliance A091304 
Version Date: 04/03/2019 
74 
Update #09 
13.0 STATISTICAL CONSIDERATIONS AND METHODOLOGY 
13.1 
Study Design 
This study has two components, specifically 1) phase I dose seeking and 2) an unblinded 
randomized phase II study for patients having locally advanced/unresectable or metastatic 
sarcoma having failed prior treatments.  All patients will be pre-registered to undergo a central 
pathology review to confirm eligibility and to properly assign patients to their respective 
histologically defined cohort.  
Update # 05 (Dose Modification for Pazopanib Arm):  On August 4th, 2017, this trial was 
suspended due to AE assocated with the pazopanib arm and based on the requirements of the 
DSMB Toxicity Stopping Rule.  Data was reviewed, together with available treatment and AE 
data.  The DSMB was notified of the situation.  Upon a review of updated data and discussion 
with CTEP and the Alliance A091304 Study Team, Alliance Group Statistician, Alliance 
Experimental Therapeutics & Rare Tumor Committee Chair, the decision was made to continue 
the trial with a dosing scheme clower representing clinical practice.  The impact on the study 
design was discussed and considered not only the expected rate of the control arm (pazopanib), 
but also the evaluability of 25 patients currently enrolled (13-MLN0128 arm; 12-pazopanib).  
The consensus reached was to replace those 25 patients already enrolled and for the 
determination of the Primary Endpoint, while summarizing and including/excluding the data 
from those patients in the appropriate Secondary Endpoints.  The study design would not change, 
in consideration of the hazard ratio to detect, as well as the PFS rate assumed for the control arm 
(pazopanib).  To these ends, at the time of the analysis and for all sections that follow, we will 
reference such patients in this section as the following: 
• Analysis Group 1:  Patients enrolled to the phase II component, up through August 4th, 
2017. 
• Analysis Group 2:  Patients enrolled to the phase II component, after August 4th, 2017 
13.1.1 Phase I 
The primary goal of the phase I component is to evaluate the maximum tolerable dose 
(MTD) of MLN0128 (TAK-228).  There will be no restriction on patient enrollment based 
on histologically defined cohorts. Patients enrolled onto the phase I component and treated 
at the maximum tolerable dose will not be allowed to enroll onto the phase II component, 
due to the randomization aspect of the phase II component which could potentially assign 
the patient to receive the opposite treatment (control arm, pazopanib) and result in non-
concurrent randomization of patients and impact efficacy analysis. 
13.1.2 Phase II 
The primary goal of the phase II component is to evaluate differences in the progression-
free survival (PFS) of patients treated with either pazopanib (control arm) or MLN0128 
(TAK-228) (experimental arm).  The expected PFS rate within the control arm (pazopanib) 
is 4.6 months[24].  Only patients enrolled after determining the MTD will be allowed to 
enroll onto this component of the study. In order to achieve meaningful numbers in a few 
specific subtypes for which there is strong preclinical and clinical rationale, we have limited 
enrollment to the following histologically defined cohorts: 
• 
HISTOLOGIC COHORT 1: Undifferentiated Pleomorphic Sarcomas (UPS) 
including Malignant Fibrous Histiocytoma, Myxofibrosarcoma, High Grade 
Sarcoma NOS 
• 
HISTOLOGIC COHORT 2: Leiomyosarcomas (Uterine and Extra-Uterine) 

Alliance A091304 
Version Date: 04/03/2019 
75 
Update #09 
• 
HISTOLOGIC COHORT 3: Other Sarcomas [Malignant Peripheral Nerve Sheath 
Tumor (MPNST)]. 
During the Phase II, patients will undergo a central pathology review to confirm eligibility 
as well as to properly assign patients to their respective histologically defined cohort.  
Histologic Cohort 3 will be restricted to enrolling 25 patients in the Phase II component of 
the study and for Arms 5 and 6 due to the re-start of enrollment (Update #05). 
Patients will be randomized in 1:1 scheme and using the stratification factors specified 
within this protocol (Section 4.8).  Patients randomized to the pazopanib arm will have the 
opportunity to receive MLN0128 (TAK-228) upon disease progression.  
13.2 
Statistical Design and Analysis for the Primary Endpoint (Phase I) 
13.2.1 Primary Endpoint 
The primary endpoint is to determine the MTD of single agent MLN0128 (TAK-228), using 
the standard “cohorts of 3” or “3+3” design.  Patients will be considered evaluable upon 
completion of Cycle 1 of treatment and adverse assessment.   
13.2.2 MTD Definition and Determination 
Three patients will be treated at each dose level and observed for a minimum of 28 days (i.e. 
one full cycle) before new patients are treated. Doses will not be escalated in any individual 
patient. 
MTD Definition: MTD is defined as the dose level below the lowest dose that induces dose-
limiting toxicity (DLT) in at least one-third of patients (at least 2 of a maximum of 6 new 
patients). A total of 6 patients treated at the MTD will be sufficient to identify common 
toxicities at the MTD. For instance, those toxicities with an incidence of at least 25% will 
be observed with a probability of at least 82% [1 - (1-0.25)6]. 
Refer to Section 7 for definition of dose-limiting toxicity (DLT). The following steps will 
be used to determine the MTD.  Doses may not be escalated within a patient. 
• 
Step 1: The first cohort of three patients will be treated at the starting dose level 0.  
• 
Step 2: Each patient is observed for at least 28 days from the start of treatment and 
to assess toxicity. 
• 
If DLT is not seen in any of the 3 patients, 3 new patients will be accrued and treated at 
the next higher dose level. If DLT is seen in 2 or 3 of 3 patients treated at a given dose 
level, then the next 3 patients will be treated at the next lower dose level, if only 3 
patients were enrolled and treated at this lower dose level.  
• 
If DLT is seen in 1 of 3 patients treated at a given dose level, up to 3 additional patients 
will be enrolled and treated at the same dose level. If DLT is seen in at least one of these 
additional three patients (≥2 of 6), the MTD will have been exceeded, and further 
accrual will cease to this cohort and the phase II component will be considered to 
activate, following discussions with Disease Committee Leadership, CTEP, and the 
Study Team.  If dose-limiting toxicity (DLT) is not seen in any of the three additional 
patients, 3 new patients will be accrued and treated at the next higher dose level (ie, 
return to Step 1 and repeat this process).  
• 
After enrolling 6 patients on a specific dose level, if DLT is observed in at least 2 of 6 
patients, then the MTD will have been exceeded and defined as the previous dose unless 
only 3 patients were treated at the lower dose level. In that case, 3 additional patients 
will be treated at this lower dose level such that a total of 6 patients are treated at the 
MTD to more fully assess the toxicities associated with the MTD. 

Alliance A091304 
Version Date: 04/03/2019 
76 
Update #09 
• 
Evaluability:  If a patient fails to complete the initial course of therapy (defined as drug 
administration and weeks observation) for reasons other than dose-limiting toxicity 
defined adverse events, the patient will be regarded as uninformative in regard to the 
primary study goal and an additional patient will be treated at the current dose level; 
however, all toxicity information will be utilized in the analysis. 
13.2.3 Operating Characteristics:  
The following table gives the probability of dose escalation at a single dose level as a 
function of the true probability of DLT at that level using the Cohorts 3+3 design described 
in Section 13.2.2. 
True Rate of DLT (%) 
Probability of Dose Escalation 
10 
.91 
20 
.71 
30 
.49 
40 
.31 
50 
.17 
 
13.3 
Statistical Design and Analysis for the Primary Endpoint (Phase II) 
13.3.1 Primary Endpoint 
The primary endpoint of this study is progression-free survival.  An event will be defined as 
either disease progression or death (in cases where patients have died without evidence of 
disease progression).  Patients will be censored at their most recent disease assessment in 
cases where they are either lost to follow-up or remain alive without progressive disease.  
We will perform the analysis as ITT (intention to treat) where patients deemed ineligible 
due to histology will be excluded.   
NOTE: Patients erolled to Analysis Group 2 (see Section 13.1) will be used in the 
determination of the Primary Endpoint. 
13.3.2  Statistical Design 
We consider a median PFS of at least 7 months for patients treated with MLN0128 (TAK-
228) as clinically promising (Ha: PFS of MLN0128 (TAK-228) arm is superior to that of 
the pazopanib arm), relative to expected median PFS of 4.6 months associated with 
pazopanib (Ho: PFS for the MLN0128 (TAK-228) arm is at best, equivalent to that of the 
pazopanib arm). This corresponds to observing a hazard ratio of 0.66 (MLN0128 (TAK-
228) arm : pazopanib arm). Our goal is to show superiority and we will therefore be 
performing a 1-sided statistical tests with an overall alpha level targeted for 0.15.  To test 
these hypotheses, we will enroll a total of 98 patients and perform 2 statistical tests. Here, 
we will have one planned interim analysis with the possibility of stopping for “futility” only 
and then the final efficacy analysis. We will be using a Lan deMets spending function family 
for both alpha and beta, with O’Brien-Fleming stopping boundaries [25, 26].  We expect 
accrual to be 10 patients per month and require 15 months follow-up for all patients. The 
study design and calculations were performed using EaST v6. 
 
 
 
 

Alliance A091304 
Version Date: 04/03/2019 
77 
Update #09 
13.3.3 Study Operating Characteristics  
There is an 80% chance of detecting a HR (MLN0128 (TAK-228):pazopanib) less than 1.0 
with an attained significance level of 0.15, under the assumptions of the design parameters 
described in Sections 13.3.2 and 13.3.4. Based on 50,000 simulations, the probability of 
stopping early due to futility under the alternative hypotheses (HR=0.66) is 8.2% and the 
probability of rejecting for futility under the null hypotheses (HR=1) is 49.9%.  
13.3.4 Analysis Plan 
 
There will be two analyses performed for the primary endpoint. 
• 
Futility Analysis:  At the time we have reached 47 PFS events (53% of the 89 
events required for the final efficacy analysis), we will conduct an interim analysis 
for “futility” (non-binding) only. If the p-value associated with a stratified Log-
Rank test statistic is greater than 0.49989 (corresponding to a HR of 0.9992), we 
will stop the study due to evidence that MLN0128 (TAK-228) is no better than 
pazopanib and in terms of improving PFS. More specifically, the decision is based 
P, the cumulative probability from a Chi-square distribution (1 degree of freedom, 
assuming 1-sided test) of being less than the calculated stratified Log-Rank test 
statistic.  If P is greater than 0.049989, we will stop the study for futility.  
• 
Efficacy Analysis & Final Decision Rule:  At the time we have reached 89 PFS 
events, we will perform the “efficacy” analysis.  If the p-value associated with a 
stratified Log-Rank test statistic is less than 0.15, we will conclude that MLN0128 
(TAK-228) has improved the median PFS from 4.6 months (with pazopanib) to 7 
months. 
13.4 
Sample Size, Accrual Time, and Study Duration (Phase I and II) 
It is expected that we will enroll 10 patients, per month, based on accrual to A091102.  
Specifically, A091102 enrolled an 8-9 patients per month when similar cohorts were actively 
enrolling.  This study will further be open to enrollment, NCTN-wide, which was not the case 
for much of the accrual period for A091102.  
13.4.1 Phase I 
A maximum of three dose levels will be evaluated. Assuming that each dose level requires 
6 patients, plus an extra patient at each dose level to account for patients deemed as non-
evaluable (excluding the patients who are screen failures by histology in the pre-registration 
period), implies that we will require a maximum of 21 patients. Using a similar argument 
for the minimum number of patients (ie, 3 per dose level and only 2 levels) implies that we 
will require a minimum of 7 patients to fully evaluate the phase I component. We assume 
that it will take a maximum of 30 days after the last patient enrolled on the dose level, to 
confirm presence or absence of DLTs. Conservatively, we anticipate that the MTD could be 
identified within 9 months of study activation. We anticipate that 24 pre-registered patients 
(includes screen failures by histology in the pre-registration period plus patients deemed 
non-evaluable who were registered) will yield 7-21 patients who proceed to the phase I 
component of the study.  
13.4.2 Phase II 
Accrual will be limited to a maximum of 25 patients for Histologic Cohort 3 and to improve the 
opportunity to have meaningful conclusions for Histologic Cohort specific sub-analyses.  The 
study design requires 98 patients; however, we will enroll to a maximum of 103 patients to 
account for patients who are deemed ineligible after registration and randomization (i.e. 

Alliance A091304 
Version Date: 04/03/2019 
78 
Update #09 
inclusive of the addition 5% for patients deemed non-evaluable by eligibility criteria 3.3.1 and 
3.3.2). 
This study will include a pre-registration step to perform a central pathology review and to 
determine patient eligibility and proper classification of a histologically defined cohort. Based 
on current screen failure rates, we anticipate that there will be 114 pre-registered patients 
(includes 10% screen failures by histology in the pre-registration period), yielding the required 
103 randomized patients. 
Protocol Update #05:  We will replace the initial 25 patients randomized onto the phase II 
portion prior to August 4th, 2017 (ie, Analysis Group 1) and will not change the original 
estimates of the number of pre-registered paitents (114) and randomized patients (103). 
Protocol Update #07: The total number of pre-registered patients to Analysis Group 2 is 
increased to 140 (versus 114), after observing an unexpectedly high screen failure rate due to 
eligibility reasons beyond improper histology. This increase does not impact the sample size 
required for the study design. 
Protocol Update #08: The total number of pre-registered patients to Analysis Group 2 is 
increased to 170 (versus 140), after observing a 2nd increase in the observed failure rate due to 
eligibility reasons beyond improper histology. This increase does not impact the sample size 
required for the study design. 
13.4.3 Overall Maximum Accrual and Duration 
As of Update #05, final and expected enrollment numbers appear in the table below. 
 
Enrollment by Phase, as of the  
Temporary Suspension on 8/4/2017 & Protocol Update #08 
 
 
Phase I 
 
Phase II 
Through 8/4/2017 
(Analysis Group 1) 
Phase II 
After 8/4/2017 
(Analysis Group 2) 
Status on 8/4/2017 
Closed 
Closed 
To complete 
Pre-registrations 
12 
34 
170a,b 
Registrations/Randomizations 
9 
25c 
103 
Maximum Number of  
Pre-registrations, by Phase 
12 
204b 
MaximumNumber of 
Registrations/Randomizations, 
by Phase 
 
9 
 
128 
Total Number of Study  
Pre-registrations 
216b 
Total Number of Study 
Registrations/Randomizations 
137 
a) For Cohort 3 (Phase II, only) : We anticipate pre-registering a maximum of 25 cases 
to Analysis Group 2, with the expection that 10-15% may not be able to proceed 

Alliance A091304 
Version Date: 04/03/2019 
79 
Update #09 
due to improper histology, as well as a few pre-registered patients being allowed to 
complete enrollment (i.e., randomization). 
b) Update #08: increased from 140 to 170 patients (pre-registered Analysis Group 2), 
174 to 204 patients (pre-registrations by Phase), and 186 to 216 (total number of 
study pre-registrations). 
c) 12 were randomized to MLN0128;12 to pazaopanib. 
As of Update #05 (Dose Modification Impacting Study Population & Re-activation of Phase 
II for Analysis Group 2), the phase I component had been permanently closed to enrollent 
and 25 patients enrolled to the phase II component (now called Analysis Group 2) will be 
excluded from the evaluation of the primary endpoint.  Ten (10) months will be required to 
pre-register 114 patients, yielding the 103 patients randoimized to the trial.  Fifteen (15) 
months of follow-up are required, beyond the randomization of the last patient. Therefore, 
we estimate that upon re-activation of the phase II component, the results can be reported 
within a total of 2.6 years (i.e. 1 year for pre-registration, an additional 15 months for 
maturity/cleaning, and 6 months for analysis and publication). This acknowledges that the 
re-activation of Alliance A091401 may briefly impact enrollment onto this trial. Enrollment 
was rapid on A091401 and approximately 50-60 patients are required within the overlapping 
histologic cohorts. 
As of Update #08 (Re-activation, expanding total number of pre-registered patients): We 
expect to add an additional 1-2 months to the pre-enrollment phase for the increase in the 
number of pre-registrations.  That is, we expect the reporting of the final study results to 
occur 1-2 months within the activation of this update (3.1 years after the original activation 
of Analysis Cohort 2). 
13.5  Primary Endpoint Completion Time Estimation (For clinicaltrials.gov reporting) 
At study activation, this study will have been registered within the “ClincialTrials.gov” web site. 
The Primary and Secondary Endpoints (ie, “Outcome Measures”) along with other required 
information for this study will be reported on ClinicalTrials.gov.  
As of Update #08 (Expansion of total number of pre-registered cases required for Analysis 
Group 2):  For purposes of timing of the Results Reporting, the initial estimated completion date 
for the Primary Endpoint of this study is 3.1 years after the phase II component of this study 
reactivates to accrual and to fulfill the analysis of the primary endpoint within Analysis Group 
2. The definition of “Primary Endpoint Completion Date” (PECD) for this study is the time the 
last patient registered onto the phase II component has been followed for at least 15 months. 
13.6 
Supplementary Analysis Plans (Phase I and II) 
NOTE: All eligible patients having initiated treatment will be considered evaluable for these 
endpoints and according to their initial treatment assignments. Patients participating in the phase 
I portion of the trial will be analyzed separately from those enrolled to the phase II component.  
Unless otherwise specified, all patients randomized to the MLN0128 arms (ie, 1 and 5) will be 
combined; whereas, patients treated on the initial pazopanib arm (Arm 2) will be analyzed 
separately from those initiating treatment at the reduced dose (ie, Arm 6). 
13.6.1 Adverse Events: 
Patients will be evaluated for adverse events using the NCI Common Toxicity Criteria for 
Adverse Events version 4.0. All patients having at least one post-baseline assessment of 
adverse events are included in this analysis. Adverse events will be summarized by Dose 
Cohorts and treatment arm. Summary statistics (e.g., mean, median, standard deviation) and 
frequency tables will be used to describe the distributions of adverse events.  Rates of 

Alliance A091304 
Version Date: 04/03/2019 
80 
Update #09 
adverse events occurring in the MLN0128 (TAK-228) arm will be compared to the 
pazopanib arm with chi-squared tests (or suitable alternative) used for comparisons where 
applicable. Adverse event analyses will separate events associated with the original 
treatment assignments from those having occurred after crossing over to receive MLN0128 
(TAK-228) at disease progression.  
13.6.2 Tumor Response 
The frequencies and rates of tumor response categories (CR, PR, SD, and PD, and too 
early/not evaluated) will be summarized by Dose Cohort and treatment arm, and Fisher’s 
Exact test or applicable statistical tests will be used to compare the association of objective 
response rate (ORR, a tumor response of either CR or PR) and treatment.  
13.6.3 Duration of Response 
This will be defined as the time between each patient’s best tumor response and progression 
(or date of last disease assessment for patients who die without progression or are lost to 
follow-up) will be analyzed using Kaplan-Meier methodology [27].  This endpoint will be 
summarized by Dose Cohort for the phase I component. 
 
13.6.4 Clinical Benefit Rate (CBR) 
CBR is defined the number of patients having either CR, PR, or stable disease for at least 6 
months after starting treatment. Analyses will be similar to that performed for tumor 
response. This endpoint will be summarized by Dose Cohort for the phase I component. 
13.6.5 Time-to-Progression (TTP) & Survival (OS)   
TTP is defined as the time between randomization and disease progression. Patients will be 
censored at the date of their most recent disease assessment if they have died without 
evidence of progressive disease or are lost to follow up. OS is defined at the time between 
randomization and death due to any cause (or last contact for surviving patients and those 
lost to follow-up). Kaplan-Meier methodology will be used to estimate the distribution of 
TTP and OS. This endpoint will be summarized by Dose Cohort for the phase I component. 
13.6.6 Exploratory Endpoints  
13.6.6.1 Cross-Over Patients (Phase II, Only) 
We anticipate a total of 42 of the 56 (75%) patients treated on the pazopanib arm (Arm 
6) will cross over to receive MLN0128 (TAK-228) (Arm 3) at the time of disease 
progression. PFS and secondary endpoints will be evaluated in patients who cross over 
from pazopanib to MLN0128 (TAK-228) at the time of disease progression (with the 
exception of comparing PFS across two arms).   The date used for the calculations of 
duration of response, TTP, PFS, and OS will be the date the patient initiated MLN0128 
(TAK-228) (versus re-registration date). We note these analyses will be exploratory in 
nature. We may additionally include patients enrolled to pazopanib and part of Analysis 
Group 1, as it is specific to crossover treatment, only. 
13.6.6.2 Cohort-Specific Evaluation of 4-month CBR (Phase II, Analysis Group 2 Only) 
Due to the historical incidence of the subtypes defined for this study, we expect that 
Histologic Cohort 1 (Undifferentiated Pleomorphic Sarcoma) and Histologic Cohort 2 
(Leiomyosarcoma) will comprise 75-80% of patients enrolled onto the trial providing an 
opportunity to perform a meaningful cohort-specific analysis of CBR. To facilitate this 

Alliance A091304 
Version Date: 04/03/2019 
81 
Update #09 
exploratory analysis, we will limit Histologic Cohort 3 (i.e., Malignant Peripheral Nerve 
Sheath Tumors and Synovial Sarcomas) to maximum of 25 patients, leaving 88 patients 
to be enrolled to the other two histologic cohorts. This endpoint is powered for 
comparison across the two arms; therefore, we will restrict the patient population to 
Analysis Group 2.  Specifically, there will be 22 patients within each of Histologic 
Cohorts 1 and 2 who have been randomized to receive MLN0128 (TAK-228).  We expect 
a 12 week PFS rate of 40% which translates to a 4-month PFS rate of approximately 
30%.   A 29% CBR was observed in our recent study (A091103: Phase II Study of the 
Angiopoitein-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma.  We 
would consider MLN0128 (TAK-228) has having an early signal of improving CBR in 
a histologic cohort if we achieve a CBR of at least 45%. A minimum of 20 patients yields 
82% power using a 1-sided test and at 0.15 level of significance to detect a 4 month CBR 
of 45% if the true 4 month CBR is at most 25%, within a histologic cohort.  We further 
note that Histologic Cohort 3 is comprised of very rare sarcoma subtypes (estimated 
numbers <500 cases diagnosed in the United States each year) and were included due to 
the strength of the preclinical data and outcomes will be exploratory and hypothesis 
generating/confirming.  Only 12-13 patients from Histologic Cohort 3 randomized to 
receive MLN0128 (TAK-228), yielding 70% at 0.15 level of significance under the same 
assumptions specified for Histologic Cohorts 1 and 2.  Nonetheless, the results of these 
exploratory analyses may lead to discussions with leadership and CTEP as to the value 
of expanding enrollment to best address other endpoints within any of the Histologic 
Cohorts. 
13.6.6.3 Tissue Specimens for Banking (Phase I & Phase II) – Please see Section 14.0. 
13.7 
Study Monitoring 
During the Phase I component, toxicity monitoring calls will be held every other week (see 
Section 7.1.1). The principle investigator(s) and the study statistician will review the study at 
least twice a year to identify accrual, adverse event, and any endpoint problems that might be 
developing. The Alliance Data Safety Monitoring Board (DSMB) is responsible for reviewing 
accrual and safety data for this trial at least twice a year, based on reports provided by the 
Alliance Statistical Office. 
13.7.1 Adverse Event Stopping Rule   
13.7.1.1 Phase I 
Given the nature of the study design and close monitoring of adverse events for 
determining the MTD, an adverse event stopping rule will not be defined in this section 
for this portion of the study. 
13.7.1.2 Phase II 
The stopping rules specified below are based on the knowledge available at study 
development. We note that the Adverse Event Stopping Rule may be adjusted in the event 
of either (1) the study re-opening to accrual or (2) at any time during the conduct of the trial 
and in consideration of newly acquired information regarding the adverse event profile of 
the treatment(s) under investigation. The study team may choose to suspend accrual because 
of unexpected adverse event profiles that have not crossed the specified rule below. In such 
cases, the study team will consult with the Alliance DSMB and applicable entities (eg, 
CTEP/NCI) in terms of proceeding with the study. 
Initial Arm Assignment: As of Update #05 and applicable to Arms 5 and 6 - Accrual will 
be temporarily suspended to this study if at any time we observe events considered at least 

Alliance A091304 
Version Date: 04/03/2019 
82 
Update #09 
possibly related to study treatment (i.e. an adverse event with attribute specified as 
“possible”, “probable”, or “definite”) on a study arm that satisfy either of the following: 
• 
an excessive death rate, defined as 1% or higher mortality attributed to study drug, 
or 
• 
if 3 or more patients in the first 15 patients in the experimental arm (or 30% when 
accrual is greater than 15 patients in the arm) experience a grade 3 or higher adverse 
event. 
• 
if 3 or more patients in the first 15 patients in the control arm (or 30% when accrual 
is greater than 15 patients in the arm) experience a grade 3 or higher adverse event 
fron an unanticipated toxicty. Please refer to the most up to date version of the 
toxicity profile table of “anticipated” toxicities in section 9.4.1. 
We note that we will review grade 4 and 5 adverse events deemed “unrelated” or “unlikely 
to be related”, to verify their attribution and to monitor the emergence of a previously 
unrecognized treatment-related adverse event. 
Crossover Treatment: 
In patients receiving MLN0128 (TAK-228) after crossover from pazopanib on the phase II 
component of the study: Accrual will be temporarily suspended to this study if at any time 
we observe events considered at least possibly related to study treatment (i.e. an adverse 
event with attribute specified as “possible”, “probable”, or “definite”) on a study arm that 
satisfy either of the following: 
- 
an excessive death rate, defined as 1% or higher mortality attributed to study drug, or 
- 
if 3 or more patients in the first 15 patients in the arm (or 30% when accrual is greater 
than 15 patients in the arm) treated patients experience a grade 3 or higher adverse event. 
We will review grade 4 and 5 adverse events deemed “unrelated” or “unlikely to be related”, 
to verify their attribution and to monitor the emergence of a previously unrecognized 
treatment-related adverse event. 
13.7.2  Accrual Monitoring Stopping Rule  
Phase I 
Given the expected accrual rate is around 2 patients per month, it is expected that the study 
will take around .75 year to fully accrue.  We plan to monitor the accrual continually and if 
we only end up accruing 3 patients by the start of 3rd quarter, we will consider stopping the 
trial for slow accrual. 
 
Phase II (Analysis Group 2 only, as of Update #05) 
Given the expected accrual rate is around 10 patients per month, it is expected that the study 
will take around 10 months to pre-register a sufficient number of patients to randomize a 
total of 103 patients to Analysis Group 2.  We plan to monitor the accrual continually and 
if we only end up accruing 12 patients by the start of 3rd quarter, we will consider stopping 
the trial for slow accrual. 
13.8  Study Reporting  
This study will be monitored by the Alliance Data Safety Monitoring Board (DSMB), an NCI-
approved functioning body. Reports containing efficacy, adverse event, and administrative 
information will be provided to the DSMB every six months as per NCI guidelines. 

Alliance A091304 
Version Date: 04/03/2019 
83 
Update #09 
This study will be monitored by the Clinical Data Update System (CDUS) version 2.0. A full 
(i.e. Complete) report containing cumulative CDUS data will be submitted quarterly to CTEP 
by electronic means. Reporting time points are: January 31, April 30, July 31, and October 31. 
This study will be monitored by the Food and Drug Administration due to the Investigational 
New Drug (IND) status of the agent. An IND report will be produced and submitted to the 
Regulatory Affairs Coordinator within 60 days of the anniversary date that the IND went into 
effect.  
Results Reporting on ClinicalTrials.gov: At study activation, this study will have been registered 
within the “ClincialTrails.gov” web site. The Primary and Secondary Endpoints (ie, “Outcome 
Measures”) along with other required information for this study will be reported on 
ClinicalTrials.gov. See Section 13.4 for further details. 
13.9 
Descriptive Factors 
• 
Dose Cohorts (Phase I Component, Only): Level 0 vs Level -1 vs Level -2. 
• 
Study Component:  Phase I vs Phase II 
• 
Histologic Cohort (Phase I & Phase II Components): 1 vs 2 vs 3 
13.10 Inclusion of Women and Minorities 
This study will be available to all eligible patients, regardless of race, gender, or ethnic origin. 
There is no information currently available regarding differential effects of this regimen in 
subsets defined by race, gender, or ethnicity, and there is no reason to expect such differences 
to exist. Therefore, although the planned analysis will, as always, look for differences in 
treatment effect based on racial and gender groupings, the sample size is not increased in order 
to provide additional power for subset analyses. Expected sizes of racial by gender subsets for 
patients randomized to this study are shown in the following table. 
 
 

Alliance A091304 
Version Date: 04/03/2019 
84 
Update #09 
 
Accrual Targets (as of Protocol Update #05) 
Racial Categories 
Ethnic Categories 
Total 
Not Hispanic or 
Latino 
Hispanic or Latino 
Female 
Male 
Female 
Male 
American Indian/ Alaska Native 
3 
4 
0 
0 
7 
Asian 
3 
1 
0 
0 
4 
Native Hawaiian or Other Pacific Islander 
0 
0 
0 
0 
0 
Black or African American 
4 
4 
0 
0 
8 
White 
51 
57 
5 
5 
118 
More Than One Race 
0 
0 
0 
0 
0 
Total 
61 
66 
5 
5 
137 
 
Ethnic 
Categories: 
Hispanic or Latino – a person of Cuban, Mexican, Puerto Rico, South or Central 
American, or other Spanish culture or origin, regardless of race. The term “Spanish 
origin” can also be used in addition to “Hispanic or Latino.” 
Not Hispanic or Latino 
Racial 
Categories: 
American Indian or Alaskan Native – a person having origins in any of the original 
peoples of North, Central, or South America, and who maintains tribal affiliations or 
community attachment. 
Asian – a person having origins in any of the original peoples of the Far East, 
Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, 
India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and 
Vietnam. (Note: Individuals from the Philippine Islands have been recorded as Pacific 
Islanders in previous data collection strategies.)  
Black or African American – a person having origins in any of the black racial 
groups of Africa. Terms such as “Haitian” or “Negro” can be used in addition to 
“Black or African American.” 
Native Hawaiian or other Pacific Islander – a person having origins in any of the 
original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. 
White – a person having origins in any of the original peoples of Europe, the Middle 
East, or North Africa. 
 
 
 

Alliance A091304 
Version Date: 04/03/2019 
85 
Update #09 
 
14.0 CORRELATIVE AND COMPANION STUDIES  
Tumor samples collected for banking will be used for future studies. This tissue collection must be 
offered to all patients enrolled on Alliance A091304 (although patients may opt to not participate). 
This tissue collection does not require separate IRB approval.  
14.1 
Tissue Specimens for Banking 
For this study, we will store tissue specimens for which we do not have a defined plan at this time. 
See section 6.2 for details of tissue submission. This tissue will only be stored for patients who opt 
in for participation. A potential utility of these specimens would be the following: 
14.1.1 Background 
Emerging preclinical data, as outlined in Section 1.3 have supported the notion that 
PI3K/Akt/mTOR signaling axis is upregulated in multiple sarcoma subtypes. MLN-0128 is 
a potent inhibitor of both TORC1 and TORC2, with potent antitumor activity in preclinical 
models of sarcoma as well as breast adenocarcinoma, multiple myeloma, and renal cell 
carcinoma. More work is required to understand whether the baseline activity of this 
signaling pathway will correlate with benefit to inhibition of this pathway. This could be 
explored by IHC analysis of baseline paraffin-embedded tissue specimens of various 
sarcoma subtypes. 
14.1.2 Objectives 
1) The potential to explore the baseline activity of the PI3K/Akt/mTOR signaling pathway 
in undifferentiated pleomorphic sarcomas, leiomyosarcomas, and other sarcomas. 
2) The potential to explore the relationship between baseline activity of the 
PI3K/Akt/mTOR pathway and clinical benefit with MLN-0128 and/or pazopanib. 
14.1.3 Methods 
Activity of the PI3K/Akt/mTOR pathway could be analyzed via immunohistochemistry 
performed on unstained slides obtained at baseline for the following targets, which include 
but are not limited to: PTEN, phosphorylated (p)-Akt-Ser473, p-Akt-Thr308, TORC1, 
TORC2, Rictor, Raptor, p-rS6, and p-4EBP1. 
IHC would be semiquantified into categories (e.g. 0, 1+, 2+, 3+) and correlations with 
clinical outcomes such as response rate, PFS, and OS. Standard statistical methods 
appropriate for categorical data analysis, logistic regression, Kaplan-Meier methodology, 
and Cox Proportional Hazards models will be used.   A formal statistical analysis plan will 
be developed based on the final list of scientifically relevant correlatives and approved prior 
to sample processing, by the appropriate entities. 
As of Update #05, consideration will be given to the appropriate study population associated 
with the timing of the re-actiavation of the study to the phase II component of the trial and 
due to the change in dose scheme for the pazopanib arm.  Any compairisons should include 
concurrently enrolled patients associated with the primary endpoint of the trial; however, a 
subset of analyses may include all patients depending on arm assignment.   These details 
will be agreed upon and at the time of designing the formal Statistical Analysis Plan for 
analyses associated with biospecimens. 
 

Alliance A091304 
Version Date: 04/03/2019 
86 
Update #09 
15.0 GENERAL REGULATORY CONSIDERATIONS AND CREDENTIALING 
There are no credentialing requirements for A091304. 
 
 
 
 

Alliance A091304 
Version Date: 04/03/2019 
87 
Update #09 
16.0 REFERENCES 
1. 
Jemal, A., et al., Cancer statistics, 2010. CA Cancer J Clin. 60(5): p. 277-300. 
2. 
Wibmer, C., et al., Increasing incidence rates of soft tissue sarcomas? A population-based 
epidemiologic study and literature review. Ann Oncol. 21(5): p. 1106-11. 
3. 
Lorigan, P., et al., Phase III trial of two investigational schedules of ifosfamide compared with 
standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European 
Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. 
J Clin Oncol, 2007. 25(21): p. 3144-50. 
4. 
Borden, E.C., et al., Soft tissue sarcomas of adults: state of the translational science. Clin Cancer 
Res, 2003. 9(6): p. 1941-56. 
5. 
Helman, L.J. and P. Meltzer, Mechanisms of sarcoma development. Nat Rev Cancer, 2003. 3(9): 
p. 685-94. 
6. 
Taylor, B.S., et al., Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer, 
2011. 
7. 
Barretina, J., et al., Subtype-specific genomic alterations define new targets for soft-tissue 
sarcoma therapy. Nat Genet, 2010. 
8. 
Ohanna, M., et al., Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for 
cell cycle and size control. Nat Cell Biol, 2005. 7(3): p. 286-94. 
9. 
Chawla Sp Fau - Staddon, A.P., et al., Phase II study of the mammalian target of rapamycin 
inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. (1527-7755 
(Electronic)). 
10. 
Chawla, S.P., et al., Survival results with AP23573, a novel mTOR inhibitor, in patients with 
advanced soft tissue or bone sarcomas: update of the phase II trial. J Clin Oncol, 2007 ASCO 
Annual Meeting Procedings Part I. 25(18S (June 20 Supplement) 1007). 
11. 
Cao, L., et al., Addiction to elevated insulin-like growth factor I receptor and initial modulation of 
the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. 
Cancer Res, 2008. 68(19): p. 8039-48. 
12. 
Rodrik-Outmezguine, V.S., et al., mTOR kinase inhibition causes feedback-dependent biphasic 
regulation of AKT signaling. Cancer Discov, 2011. 1(3): p. 248-59. 
13. 
O'Reilly, K.E., et al., mTOR inhibition induces upstream receptor tyrosine kinase signaling and 
activates Akt. Cancer Res, 2006. 66(3): p. 1500-8. 
14. 
Baird, K., et al., Gene expression profiling of human sarcomas: insights into sarcoma biology. 
Cancer Res, 2005. 65(20): p. 9226-35. 
15. 
Olmos, D., et al., Biological rationale and current clinical experience with anti-insulin-like 
growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench 
to the bedside. Cancer J, 2010. 16(3): p. 183-94. 
16. 
Prieur, A., et al., EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream 
oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 
3. Mol Cell Biol, 2004. 24(16): p. 7275-83. 

Alliance A091304 
Version Date: 04/03/2019 
88 
Update #09 
17. 
Tap, W.D., et al., AMG479 in relapsed or refractory Ewing's family tumors or desmoplastic small 
round cell tumors (DSRCT): Phase II results. J Clin Oncol, 2010 ASCO Annual Meeting 
Procedings. 28(15s). 
18. 
Pappo, A.S., et al., Activity of R1507, a monoclonal antibody to the insulin-like growth factor 
receptor (IGF1R), in patients with recurrent or refractory Ewing's sarcoma family of tumors: 
Results of a phase II SARC study. J Clin Oncol, 2006 ASCO Annual Meeting Procedings 2010. 
28(15s). 
19. 
Chawla, S.P., et al., Updated results of a phase II trial of AP23573, a novel mTOR inhibitor in 
patients with advanced soft tissue or bone sarcomas. J Clin Oncol, 2006 ASCO Annual Meeting 
Procedings Part I. 24(18S (June 20 Supplement) 9505). 
20. 
Schwartz, G.K., et al., Cixutumumab and temsirolimus for patients with bone and soft-tissue 
sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol, 2013. 14(4): p. 371-82. 
21. 
Hsieh, A.C., et al., The translational landscape of mTOR signalling steers cancer initiation and 
metastasis. Nature, 2012. 485(7396): p. 55-61. 
22. 
Garcia-Garcia, C., et al., Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in 
Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy. Clin Cancer Res, 2012. 
18(9): p. 2603-12. 
23. 
Tan, A.D., P.J. Novotny, and e. al., A patient-level meta-analytic investigation of the prognostic 
significance of baseline quality of life (QOL) for overall survival (OS) among 3,704 patients 
participating in 24 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer 
Center (MC) oncology clinical trials. J Clin Oncol, 2008. 26 (20 suppl): p. 9515. 
24. 
van der Graaf, W.T.A., et al., Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a 
randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 2012. 379(9829): p. 
1879-1886. 
25. 
Lan, K.K. and D.L. DeMets, Changing frequency of interim analysis in sequential monitoring. 
Biometrics, 1989. 45(3): p. 1017-20. 
26. 
O'Brien, P.C. and T.R. Fleming, A multiple testing procedure for clinical trials. Biometrics, 1979. 
35(3): p. 549-56. 
27. 
Kaplan, E. and P. Meier, Nonparametric estimation for incomplete observations. J Am Stat 
Assoc, 1958. 53: p. 457-481. 
28.  
Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised RECIST 
guideline (version 1.1). Eur J Cancer, 2009. 45(2): p. 228-47. 

Alliance A091304 
Version Date: 04/03/2019 
89 
Update #09 
APPENDIX I 
REGISTRATION FATIGUE/UNISCALE ASSESSMENTS 
 
 
Registration Fatigue/Uniscale Assessments 
 
At patient registration, this form is to be administered by a nurse/CRA, completed by the patient, 
and entered into Medidata Rave at the time of registration. 
 
If needed, this appendix can be adapted to use as a source document.  A booklet containing this 
assessment does not exist – please do not order this booklet. 
 
 
 
 
How would you describe: 
 
your level of fatigue, on the average in the past week including today? 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
No 
Fatigue 
 
 
 
 
 
 
 
 
 
Fatigue 
as bad  
as it can be 
 
your overall quality of life in the past week including today? 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
As bad as 
it can be 
 
 
 
 
 
 
 
 
 
As good as 
it can be 
 
 

Version Date: 04/03/2019 
90 
Update #09 
 
APPENDIX II MEDICATION DIARIES 
PATIENT MEDICATION DIARY –MLN0128 (TAK-228) 
 
Today’s date ______________________________ 
Agent:MLN0128 (TAK-228) 
Patient Name__________________ (initials acceptable) Patient Study ID ________ 
 
INSTRUCTIONS TO THE PATIENT: 
1. 
Complete one form for each week-period while you take MLN0128 (TAK-228). 
2. 
MLN0128 (TAK-228) should be taken on an empty stomach at least 2 hours after food and do not 
eat or drink (except water) for at least one hour after taking MLN0128 (TAK-228). The capsules 
should be swallowed whole and must not be crushed or broken. Drink at least 20 ounces of fluids 
per day to avoid dehydration.  
3. 
Record the date, day of weekly dose, the number of capsules you took, and when you took them. 
Record doses as soon as you take them; do not batch entries together at a later time. 
4. 
If you have any comments or notice any side effects, please record them in the Comments column. 
If you make a mistake while you write, please cross it out with one line, put your initials next to it, 
and then write the corrected information next to your initials.  Example: 10:30 am SB 9:30 am 
5.    If you miss a dose of MLN0128 (TAK-228), you should take it as soon as you remember, as long as 
it falls within 24 hours of the time you normally take your dose.  
6. 
Please return this form to your physician when you go for your next appointment. 
 
Week 
 
Date 
# of capsules taken 
Comments 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
 
Physician’s Office will complete this section: 
 
How many days this cycle were 0 tablets taken? __________ 
How many days this cycle was only 1 tablet taken?________ 
How many days this cycle were 2 tablets taken?__________ 
How many days this cycle were 3 tablets taken?__________ 
How many days this cycle were 4 tablets taken?__________ 
How many days this cycle were 5 tablets taken?__________ 
How many days this cycle were 6 tablets taken?__________ 
How many days this cycle were > 6 tablets taken?________ 
 
1. Total number of capsules taken this month (each size) 
_________________________________________ 
 
2. Physician/Nurse/Data Manager’s Signature 
_________________________________________________ 
 
Patient’s signature 
______________________________________________________________________________

Version Date: 04/03/2019 
91 
Update #09 
 
 
PATIENT MEDICATION DIARY – Pazopanib 
 
Today’s date ______________________________ 
Agent: Pazopanib 
Patient Name__________________ (initials acceptable) Patient Study ID ________ 
 
INSTRUCTIONS TO THE PATIENT: 
1. 
Complete one form for each 4 week-period while you take pazopanib. 
2. 
Pazopanib should be taken orally without food at least 1 hour before OR 2 hours after a 
meal. The tablets should be swallowed whole and must not be crushed or broken.  
3. 
Record the date, the number of tablets you took, and when you took them. Record doses as soon as 
you take them; do not batch entries together at a later time. 
4. 
If you have any comments or notice any side effects, please record them in the Comments column. 
If you make a mistake while you write, please cross it out with one line, put your initials next to it, 
and then write the corrected information next to your initials.  Example: 10:30 am SB 9:30 am 
5.    If you miss a dose of pazopanib, you should take it as soon as you remember, but only if there are 
12 or more hours remaining before the next dose. If the dose is due in less than 12 hours, skip the 
missed dose and take the next dose as scheduled. 
6. 
If vomiting occurs after taking pazopanib, do not take a replacement dose on that day. Resume 
drug the next day. 
7. 
Please return this form to your physician when you go for your next appointment. 
 
Day 
 
Date 
Time of daily 
doses (am/pm) 
# of tablets taken 
Comments 
1 
 
 
 
 
 
2 
 
 
 
 
 
3 
 
 
 
 
 
4 
 
 
 
 
 
5 
 
 
 
 
 
6 
 
 
 
 
 
7 
 
 
 
 
 
8 
 
 
 
 
 
9 
 
 
 
 
 
10 
 
 
 
 
 
11 
 
 
 
 
 
12 
 
 
 
 
 
13 
 
 
 
 
 
14 
 
 
 
 
 
15 
 
 
 
 
 
16 
 
 
 
 
 
17 
 
 
 
 
 
18 
 
 
 
 
 
19 
 
 
 
 
 
20 
 
 
 
 
 

Alliance A091304 
Version Date: 04/03/2019 
92 
Update #09 
 
Day 
 
Date 
Time of daily 
doses (am/pm) 
# of capsules taken 
Comments 
21 
 
 
 
 
 
22 
 
 
 
 
 
23 
 
 
 
 
 
24 
 
 
 
 
 
25 
 
 
 
 
 
26 
 
 
 
 
 
27 
 
 
 
 
 
28 
 
 
 
 
 
Only If Needed 
29 
 
 
 
 
 
30 
 
 
 
 
 
31 
 
 
 
 
 
32 
 
 
 
 
 
33 
 
 
 
 
 
34 
 
 
 
 
 
35 
 
 
 
 
 
 
Physician’s Office will complete this section: 
 
How many days this cycle were 0 tablets taken?______________ 
How many days this cycle was only 1 tablet taken?___________ 
How many days this cycle were 2 tablets taken?______________ 
How many days this cycle were 3 tablets taken?______________ 
How many days this cycle were 4 tablets taken?______________ 
How many days this cycle were > 4 tablets taken?____________ 
 
For Cycles 1 and 2, only:  Was escalation attempted during cycle (yes vs no)?  _____ 
        If yes, provide date (mm/dd/yyyy)   ___________________ 
 
3. Total number of tablets taken this month _________________________________________ 
 
4. Physician/Nurse/Data Manager’s Signature 
_________________________________________________ 
 
Patient’s signature 
______________________________________________________________________________ 
 
 

Version Date: 04/03/2019 
93 
Update #09 
 
APPENDIX III  CRADA 
 
The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/are provided to the NCI under a 
Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical Company(ies) (hereinafter 
referred to as “Collaborator(s)”) and the NCI Division of Cancer Treatment and Diagnosis.  Therefore, 
the following obligations/guidelines, in addition to the provisions in the “Intellectual Property Option to 
Collaborator”  
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm) contained within the terms of 
award, apply to the use of the Agent(s) in this study: 
 
1. Agent(s) may not be used for any purpose outside the scope of this protocol, nor can Agent(s) be 
transferred or licensed to any party not participating in the clinical study.  Collaborator(s) data for 
Agent(s) are confidential and proprietary to Collaborator(s) and shall be maintained as such by the 
investigators.  The protocol documents for studies utilizing Agents contain confidential information 
and should not be shared or distributed without the permission of the NCI.  If a copy of this protocol 
is requested by a patient or patient’s family member participating on the study, the individual should 
sign a confidentiality agreement.  A suitable model agreement can be downloaded from: 
http://ctep.cancer.gov. 
 
2. For a clinical protocol where there is an investigational Agent used in combination with (an)other 
Agent(s), each the subject of different Collaborative Agreements, the access to and use of data by 
each Collaborator shall be as follows (data pertaining to such combination use shall hereinafter be 
referred to as "Multi-Party Data”): 
 
a. NCI will provide all Collaborators with prior written notice regarding the existence and nature of 
any agreements governing their collaboration with NCI, the design of the proposed combination 
protocol, and the existence of any obligations that would tend to restrict NCI's participation in the 
proposed combination protocol. 
 
b. Each Collaborator shall agree to permit use of the Multi-Party Data from the clinical trial by any 
other Collaborator solely to the extent necessary to allow said other Collaborator to develop, 
obtain regulatory approval or commercialize its own Agent. 
 
c. Any Collaborator having the right to use the Multi-Party Data from these trials must agree in 
writing prior to the commencement of the trials that it will use the Multi-Party Data solely for 
development, regulatory approval, and commercialization of its own Agent. 
 
3. Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement will be 
made available to Collaborator(s), the NCI, and the FDA, as appropriate and unless additional 
disclosure is required by law or court order as described in the IP Option to Collaborator 
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm).  Additionally, all Clinical 
Data and Results and Raw Data will be collected, used and disclosed consistent with all applicable 
federal statutes and regulations for the protection of human subjects, including, if applicable, the 
Standards for Privacy of Individually Identifiable Health Information set forth in 45 C.F.R. Part 164. 
 
4. When a Collaborator wishes to initiate a data request, the request should first be sent to the NCI, who 
will then notify the appropriate investigators (Group Chair for Cooperative Group studies, or PI for 
other studies) of Collaborator's wish to contact them. 
 

Alliance A091304 
Version Date: 04/03/2019 
94 
Update #09 
5. Any data provided to Collaborator(s) for Phase 3 studies must be in accordance with the guidelines 
and policies of the responsible Data Monitoring Committee (DMC), if there is a DMC for this clinical 
trial. 
 
6. Any manuscripts reporting the results of this clinical trial must be provided to CTEP by the Group 
office for Cooperative Group studies or by the principal investigator for non-Cooperative Group 
studies for immediate delivery to Collaborator(s) for advisory review and comment prior to 
submission for publication.  Collaborator(s) will have 30 days from the date of receipt for review.  
Collaborator shall have the right to request that publication be delayed for up to an additional 30 days 
in order to ensure that Collaborator’s confidential and proprietary data, in addition to 
Collaborator(s)’s intellectual property rights, are protected.  Copies of abstracts must be provided to 
CTEP for forwarding to Collaborator(s) for courtesy review as soon as possible and preferably at least 
three (3) days prior to submission, but in any case, prior to presentation at the meeting or publication 
in the proceedings.  Press releases and other media presentations must also be forwarded to CTEP 
prior to release.  Copies of any manuscript, abstract and/or press release/ media presentation should 
be sent to: 
 
Email:  ncicteppubs@mail.nih.gov 
 
The Regulatory Affairs Branch will then distribute them to Collaborator(s).  No publication, manuscript 
or other form of public disclosure shall contain any of Collaborator’s confidential/ proprietary 
information.

Version Date: 04/03/2019 
95 
Update #09 
 
APPENDIX IV: PATIENT DRUG INFORMATION HANDOUT AND WALLET CARD 
 
Information for Patients, Their Caregivers and Non-Study Healthcare Team on Possible Interactions 
with Other Drugs and Herbal Supplements  
 
The patient ____________________________ is enrolled on a clinical trial using the experimental study 
drug, MLN0128 (TAK-228).  This clinical trial is sponsored by the National Cancer Institute.  This form is 
addressed to the patient, but includes important information for others who care for this patient.  
 
These are the things that you as a healthcare provider need to know: 
  
MLN0128 (TAK-228) interacts with a certain specific enzyme in your liver.  
 
•  The enzyme in question is CYP3A4 and MLN0128 (TAK-228) is broken down by this enzyme and 
may be affected by other drugs that inhibit or induce this enzyme. 
 
To the patient: Take this paper with you to your medical appointments and keep the attached 
information card in your wallet.   
 
MLN0128 (TAK-228) may interact with other drugs which can cause side effects. For this reason, it is very 
important to tell your study doctors of any medicines you are taking before you enroll onto this clinical 
trial.  It is also very important to tell your doctors if you stop taking any regular medicines, or if you start 
taking a new medicine while you take part in this study.  When you talk about your current medications 
with your doctors, include medicine you buy without a prescription (over-the-counter remedy), or any 
herbal supplements such as St. John’s Wort.  It is helpful to bring your medication bottles or an updated 
medication list with you. 
 
Many health care providers can write prescriptions.  You must tell all of your health care providers (doctors, 
physician assistants, nurse practitioners, pharmacists) you are taking part in a clinical trial.  
 
These are the things that you and they need to know:  
 
MLN0128 (TAK-228) must be used very carefully with other medicines that use certain liver enzymes.  
Before you enroll onto the clinical trial, your study doctor will work with your regular health care providers 
to review any medicines and herbal supplements that are considered strong inducers/inhibitors of CYP3A4. 
 
• Please be very careful!  Over-the-counter drugs (including herbal supplements) may contain 
ingredients that could interact with your study drug.  Speak to your doctors or pharmacist to 
determine if there could be any side effects.  
Your regular health care provider should check a frequently updated medical reference or call your study 
doctor before prescribing any new medicine or discontinuing any medicine.  Your study doctor’s name is 
_____________________________________ and he or she can be contacted at ____________________.

Version Date: 04/03/2019 
96 
Update #09 
 
STUDY DRUG INFORMATION WALLET 
CARD   
You are enrolled on a clinical trial using the 
experimental study drug MLN0128 (TAK-228).  
This clinical trial is sponsored by the NCI. 
MLN0128 (TAK-228) may interact with drugs 
that are processed by your liver.  Because of this, 
it is very important to: 
➢ Tell your doctors if you stop taking any 
medicines or if you start taking any new 
medicines.  
➢ Tell all of your health care providers (doctors, 
physician assistants, nurse practitioners, or 
pharmacists) that you are taking part in a clinical 
trial. 
➢ Check with your doctor or pharmacist whenever 
you need to use an over-the-counter medicine or 
herbal supplement. 
 
MLN0128 (TAK-228) interacts with a specific 
liver enzyme called CYP3A4, and must be used 
very carefully with other medicines that interact 
with this enzyme.  
➢ Before you enroll onto the clinical trial, your 
study doctor will work with your regular health 
care providers to review any medicines  and 
herbal supplements that are considered strong 
inducers/inhibitors or substrates of CYP3A4  
➢ Before prescribing new medicines, your regular 
health care providers should go to a frequently-
updated medical reference for a list of drugs to 
avoid, or contact your study doctor.   
➢ Your study doctor’s name is 
_____________________________ and can be 
contacted at 
_________________________________.